Ethynylbenzene derivatives

ABSTRACT

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R 1 , R 2 , R 3 , R 101 , L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of U.S. Provisional Application Ser. No.61/379,935, filed Sep. 3, 2010, which is incorporated by referenceherein in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with government support under NIH/NIAID R01AI055588 grant entitled “Structural and Biochemical Studies of LpxCInhibition.” The government has certain rights.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to ethynylbenzene derivatives, and in particular,to such compounds that inhibitUDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC),and to methods of using such compounds to treat Gram-negative bacterialinfections.

2. Description of the Related Art

Antimicrobial resistance is increasing and becoming alarmingly common.This problem is compounded when bacterial strains are resistant tomultiple antibacterials. There clearly is a need for new antibacterials,particularly antibacterials with novel mechanisms of action.

The gene lpxC encodes the enzymeuridyldiphospho-3-O—(R-hydroxydecanoyl)-N-acetylglucosamine deacetylase(LpxC). This enzyme is involved in the synthesis of lipid A, the lipidmoiety of lipopolysaccharide, which is an essential component of allGram-negative bacteria. Commercially useful LpxC inhibitors would needto both inhibit the enzymatic activity of LpxC from a variety ofbacteria and defeat the resistance mechanisms of Gram-negative bacteria.

SUMMARY OF THE INVENTION

In a broad aspect, the disclosure encompasses the compounds of formulaI, shown below, pharmaceutical compositions containing those compoundsand methods of using such compounds to treat and/or prevent bacterialinfections.

Thus, one aspect (embodiment 1) of the disclosure provides compounds offormula I:

or a pharmaceutically acceptable salt thereof, wherein

-   Q, Y, D, and X independently represent CH or nitrogen, provided that    at least two of Q, Y, D, and X are CH;-   each R is independently hydrogen, or C₁-C₆ alkyl, or two R groups    form ═O;-   R₁ is —C(R₅)═C(R₄)(R₅), —C≡C—R₄, aryl optionally substituted with    R₆, heteroaryl optionally substituted with R₆, or heterocyclyl    optionally substituted with R₆;-   R₂ is —CH(R₉)(R₁₀), or heterocyclyl optionally substituted with one    or more R₁₀;-   R₃ is hydrogen or C₁-C₆ alkyl;    -   or R₂ and R₃ together with the nitrogen to which they are        attached form heterocyclyl ring optionally substituted with one        or more R₁₀;-   R₄ is C₁-C₆ alkyl optionally substituted with R₇, aryl optionally    substituted with R₈, heteroaryl optionally substituted with R₈, or    heterocyclyl optionally substituted with R₈;-   each R₅ is independently hydrogen, or C₁-C₆ alkyl;-   each R₆ is independently selected from the group consisting of    halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy;-   each R₇ is independently selected from the group consisting of    halogen, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆    alkoxy, and C₁-C₆ haloalkoxy;-   each R₈ is independently selected from the group consisting of    halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH,    —S(C₁-C₆ alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl),    amino(C₁-C₆ alkyl), —CH₂—NH(C₁-C₆ alkyl), —CH₂—N(C₁-C₆ alkyl)₂,    —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH, —CONH—NH₂,    —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆    alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl),    —NHC(═NH)NH₂, —NH—S(O)₀₋₂—(C₁-C₆ alkyl), —NH—S(O)₀₋₂-aryl,    —NH—S(O)₀₋₂-heteroaryl, aryl(C₁-C₆ alkyl), heteroaryl(C₁-C₆ alkyl),    heterocyclyl(C₁-C₆ alkyl), —CH₂—NHCONH₂, —CH₂—NHCONH(C₁-C₆ alkyl),    and —CH₂—OCO(C₁-C₆ alkyl);-   R₉ is hydrogen, C₁-C₆ alkyl, aryl, aryl(C₁-C₆ alkyl), heteroaryl,    heteroaryl(C₁-C₆ alkyl), heterocyclyl, or heterocyclyl(C₁-C₆ alkyl),    wherein each alkyl, aryl, heteroaryl, or heterocyclyl moiety is    optionally substituted with one or more R₁₁;-   R₁₀ is independently selected from the group consisting of halogen,    —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, oxo, —CONH₂,    —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH, —CONH—NH₂, —CO₂H,    and —CO₂(C₁-C₆ alkyl);-   each R₁₁ is independently selected from the group consisting of    halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH,    —S(C₁-C₆ alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl),    amino(C₁-C₆ alkyl), —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂,    —CONH—OH, —CONH—NH₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —OCO(C₁-C₆    alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂,    —NHCONH(C₁-C₆ alkyl), —NHC(═NH)NH₂, —NH—S(O)₀₋₂—(C₁-C₆ alkyl),    —NH—S(O)₀₋₂-aryl, and —NH—S(O)₀₋₂-heteroaryl;    provided that when R₁ is phenylethaynyl, aminophenylethynyl, or    pyridinylethynyl, two R groups form oxo, and R₃ is hydrogen, then R₂    is not 3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl,    3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl),    3-amino-1-(hydroxyamino)-1-oxopropan-2-yl,    3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl).

The disclosure also provides synthetic intermediates that are useful inmaking the compounds of formula I.

The disclosure also provides methods of preparing compounds of thedisclosure and the intermediates used in those methods.

The disclosure also provides pharmaceutical compositions comprising acompound of formula I or a pharmaceutically acceptable salt thereof andat least one pharmaceutically acceptable carrier, solvent, adjuvant ordiluent.

The disclosure also provides methods for inhibitingUDP-3-O—(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC),and methods of treating Gram-negative bacterial infections.

The disclosure further provides a compound or pharmaceutical compositionthereof in a kit with instructions for using the compound orcomposition.

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, the disclosure provides compounds of formula Iwherein R groups form ═O, i.e., an oxo group (Embodiment 2).

In another embodiment based on formula I, R₁ is —C≡C—R₄. (Embodiment 3)Other embodiments are those where R₁ is —C≡C—R₄, and R₄ is aryloptionally substituted with R₈, or heteroaryl optionally substitutedwith R₈. (Embodiment 4)

In still other embodiments based on formula I, R₄ is aryl optionallysubstituted with R₈, and R₈ is selected from the group consisting ofhalogen, —NO₂, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆alkoxy, and C₁-C₆ haloalkoxy. (Embodiment 5)

In another embodiments based on formula I, R₄ is heteroaryl optionallysubstituted with R₈, and R₈ is selected from the group consisting ofhalogen, —NO₂, C₁-C₆ alkyl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂,—NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, and C₁-C₆haloalkoxy. (Embodiment 6) In embodiment 7, R₄ is thienyl, imidazolyl,triazolyl, tetrazolyl, pyrazolyl), isoxazolyl, oxazolyl, isothiazolyl,thiazolyl, or furanyl, each substituted with R₈, and R₈ is selected fromthe group consisting of halogen, —NO₂, C₁-C₆ alkyl, C₁-C₆ alkyl, C₁-C₆haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy,and C₁-C₆ haloalkoxy.

In another embodiment based on formula I, the compound may berepresented by the formula:

In still other embodiments based on formula I, R₈ is selected from thegroup consisting of is halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl,—NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆haloalkoxy, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆alkyl), —CH₂—NH(C₁-C₆ alkyl), —CH₂—N(C₁-C₆ alkyl)₂, —CONH₂, —CON(C₁-C₆alkyl), —CON(C₁-C₆ alkyl)₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —OCO(C₁-C₆alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆alkyl), —NH—S(O)₀₋₂—(C₁-C₆ alkyl), —NH—S(O)₀₋₂-aryl,—NH—S(O)₀₋₂-heteroaryl, aryl(C₁-C₆ alkyl), heteroaryl(C₁-C₆ alkyl),heterocyclyl(C₁-C₆ alkyl), —CH₂—NHCONH₂, —CH₂—NHCONH(C₁-C₆ alkyl), and—CH₂—OCO(C₁-C₆ alkyl). (Embodiment 9)

In embodiment 10, which is based on formula I, R₈ is selected from thegroup consisting of is halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂,—NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, hydroxy(C₁-C₆alkyl), amino(C₁-C₆ alkyl), —CH₂—NH(C₁-C₆ alkyl), —CH₂—N(C₁-C₆ alkyl)₂,—CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —COH, —CO₂H, —NHCO(C₁-C₆alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —NH—S(O)₀₋₂—(C₁-C₆ alkyl),heteroaryl(C₁-C₆ alkyl), heterocyclyl(C₁-C₆ alkyl), —CH₂—NHCONH₂, and—CH₂—NHCONH(C₁-C₆ alkyl).

Embodiment 11, which is based on formula I, provides compounds whereinR₈ is selected from the group consisting of is halogen, —CN, C₁-C₆alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH,C₁-C₆ alkoxy, —CONH₂, —COH, —CO₂H, —NHCO(C₁-C₆ alkyl), —NHCONH₂,—NHCONH(C₁-C₆ alkyl), and —NH—S(O)₀₋₂—(C₁-C₆ alkyl).

In embodiment 12, which is based on formula I, R₈ is selected from thegroup consisting of is —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂,—NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), and—NH—S(O)₀₋₂—(C₁-C₆ alkyl).

In other embodiment, which is based on formula I, R₈ is selected fromthe group consisting of is hydroxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl),—CH₂—NH(C₁-C₆ alkyl), —CH₂—N(C₁-C₆ alkyl)₂, heteroaryl(C₁-C₆ alkyl),heterocyclyl(C₁-C₆ alkyl), —CH₂—NHCONH₂, and —CH₂—NHCONH(C₁-C₆ alkyl).(Embodiment 13)

In embodiment 14, which is based on formula I, R₈ is selected from thegroup consisting of is amino(C₁-C₆ alkyl), —CH₂—NH(C₁-C₆ alkyl),—CH₂—N(C₁-C₆ alkyl)₂, —CH₂—NHCONH₂, and —CH₂—NHCONH(C₁-C₆ alkyl). Inembodiment 13, R₈ is selected from the group consisting of ishydroxy(C₁-C₆ alkyl), heteroaryl(C₁-C₆ alkyl), and heterocyclyl(C₁-C₆alkyl).

In embodiment 15, which is based on formula I, the compound may berepresented by the formula:

Embodiment 16 based on formula I provides compounds of formula:

Embodiment 17 which is based on formula I, provides compounds offormula:

Embodiment 18 which is based on formula I, provides compounds offormula:

In embodiment 19 which is based on formula I, I, the compound may berepresented by the formula:

In one embodiment of embodiment 19, halogen is —F, and in otherembodiment of embodiment 19, halogen is —Cl.

In embodiment 20 which is based on formula I, the compound may berepresented by the formula:

In embodiment 20-a which is based on formula I, the compound may berepresented by the formula:

In embodiment 20-b which is based on formula I, the compound may berepresented by the formula:

In embodiment 21 based on formula I, the compound may be represented bythe formula:

In embodiment 21-a, the trifluoromethyl group is at the para position ofthe R₁ phenyl group, and in embodiment 21-b, the trifluoromethyl groupis at the meta position of the R₁ phenyl group. Thus, in embodiment 21-abased on formula I, the compound may be represented by the formula:

Thus, in embodiment 21-b based on formula I, the compound may berepresented by the formula:

In embodiment 22 based on formula I, the compound may be represented bythe formula:

In embodiment 22-a, the hydroxy group is at the para position of the R₁phenyl group, and in embodiment 21-b, the hydroxy group is at the metaposition of the R₁ phenyl group.

In embodiment 22-c, the methoxy group is at the para position of the R₁phenyl group, and in embodiment 22-d, the methoxy group is at the metaposition of the R₁ phenyl group.

In embodiment 23 based on formula I, the compound may be represented bythe formula:

In embodiment 23-a, the urea group is at the para position of the R₁phenyl group, and in embodiment 23-b, the urea group is at the metaposition of the R₁ phenyl group.

In embodiment 23-c, the methylurea group is at the para position of theR₁ phenyl group, and in embodiment 23-d, the methylurea group is at themeta position of the R₁ phenyl group.

In embodiment 23-e, the acetamide group is at the para position of theR₁ phenyl group, and in embodiment 23-f, the acetamide group is at themeta position of the R₁ phenyl group.

In embodiment 23-g, the methylsulfonamide group is at the para positionof the R₁ phenyl group, and in embodiment 23-h, the methylsulfonamidegroup is at the meta position of the R₁ phenyl group.

In embodiment 24 based on formula I, the compound may be represented bythe formula:

In embodiment 24-a, the carboxylic acid group is at the para position ofthe R₁ phenyl group, and in embodiment 24-b, the carboxylic group is atthe meta position of the R₁ phenyl group.

In embodiment 24-c, the formyl group is at the para position of the R₁phenyl group, and in embodiment 24-d, the formyl group is at the metaposition of the R₁ phenyl group.

In embodiment 24-e, the carbamoyl group is at the para position of theR₁ phenyl group, and in embodiment 24-f, the carbamoyl group is at themeta position of the R₁ phenyl group.

In embodiment 25 based on formula I, the compound may be represented bythe formula:

wherein R₂₇ is —OH, —NH₂, —N(C₁-C₆ alkyl)₂, or —NHCONH₂.

In embodiment 25-a, the R₂₇-methyl group is at the para position of theR₁ phenyl group, and in embodiment 25-b, the R₂₇-methyl group is at themeta position of the R₁ phenyl group.

In embodiment 26 based on formula I, the compound may be represented bythe formula:

wherein R₂₇ is aryl, heteroaryl, or heterocyclyl.

In embodiment 26-a, the R₂₇-methyl group is at the para position of theR₁ phenyl group, and in embodiment 26-b, the R₂₇-methyl group is at themeta position of the R₁ phenyl group.

Another embodiment of the invention, i.e., Embodiment A, encompassescompounds of any of embodiments 1-26 where:

-   R₂ is —CH(R₉)(R₁₀);-   R₃ is hydrogen;-   R₉ is C₁-C₆ alkyl, aryl(C₁-C₆ alkyl), or heteroaryl(C₁-C₆ alkyl),    wherein each alkyl, aryl, or heteroaryl moiety is optionally    substituted with one or more R₁₁;-   R₁₀ is —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —CO₂H, or —CO₂(C₁-C₆ alkyl); and-   each R₁₁ is independently selected from the group consisting of    halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH,    —S(C₁-C₆ alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl),    amino(C₁-C₆ alkyl), —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂,    —CONH—OH, —CONH—NH₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —OCO(C₁-C₆    alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂,    —NHCONH(C₁-C₆ alkyl), —NHC(═NH)NH₂, —NH—S(O)₀₋₂—(C₁-C₆ alkyl),    —NH—S(O)₀₋₂-aryl, and —NH—S(O)₀₋₂-heteroaryl.

Particular embodiments based on formula I include those of EmbodimentA-1, i.e., compounds of Embodiment A wherein

-   R₉ is aryl(C₁-C₆ alkyl), or heteroaryl(C₁-C₆ alkyl), wherein each    alkyl, aryl, or heteroaryl moiety is optionally substituted with one    or more R₁₁; and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆    alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl)

Particular embodiments based on formula I include those of EmbodimentA-2, i.e., compounds of Embodiment A-1 wherein

-   R₉ is aryl(C₁-C₂ alkyl), or heteroaryl(C₁-C₂ alkyl), wherein each    alkyl, aryl, or heteroaryl moiety is optionally substituted with one    or more R₁₁; and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆    alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-3, i.e., compounds of Embodiment A-2 wherein

-   R₉ is benzyl, optionally substituted on either the ring portion or    the methylene with one or more R₁₁; and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆    alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-4, i.e., compounds of Embodiment A-3 wherein

-   R₂ is —CH(R₉)(R₁₀);-   R₉ is benzyl, optionally substituted on either the ring portion or    the methylene with one or more R₁₁;-   R₁₀ is —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —CO₂H, or —CO₂(C₁-C₆ alkyl); and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆    alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-5, i.e., compounds of Embodiment A-4 where R₂ is of formula:

wherein

-   R₁₀ is —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —CO₂H, or —CO₂(C₁-C₆ alkyl);-   R₂₁ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl),    —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl);-   R₂₂ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl),    —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl); and-   R₂₃ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and amino(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-6, i.e., compounds of Embodiment A-5 where:

-   R₁₀ is —CONH—OH, —CONH—NH₂, or —CO₂H; and-   R₂₁ is —NH₂ or —OH;-   R₂₂ is selected from the group consisting of hydrogen, C₁-C₆ alkyl,    C₁-C₆ haloalkyl, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and    amino(C₁-C₆ alkyl); and-   R₂₃ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and amino(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-7, i.e., compounds of Embodiment A-5 where:

-   R₁₀ is —CONH—OH; and-   R₂₁ is —OH;-   R₂₂ is hydrogen or C₁-C₆ alkyl; and-   R₂₃ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and amino(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-8, i.e., compounds of Embodiment A-1 where

-   R₉ is heteroaryl(C₁-C₂ alkyl) optionally substituted with one or    more R₁₁; and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆    alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-9, i.e., compounds of Embodiment A-8 wherein the heteroaryl isselected from the group consisting of pyrrolyl, imidazolyl, triazolyl,pyrazolyl, tetrazolyl, furyl, oxazolyl, pyridinyl, pyrazinyl,pyrimidinyl, pyridazinyl, triazinyl, benzimidazolyl, indazolyl, indolyl,and quinolinyl, each of which is optionally substituted with one or moreR₁₁.

Particular embodiments based on formula I include those of EmbodimentA-10, i.e., compounds of Embodiment A-9 wherein the heteroaryl isselected from the group consisting of pyrrolyl, imidazolyl, triazolyl,pyridinyl, benzimidazolyl, indazolyl, and indolyl, each of which isoptionally substituted with one or more R₁₁.

Particular embodiments based on formula I include those of EmbodimentA-11, i.e., compounds of Embodiments A-9 or A-10, wherein

-   R₂ is —CH(R₉)(R₁₀);-   R₉ is heteroaryl(C₁-C₂ alkyl) optionally substituted with one or    more R₁₁;-   R₁₀ is —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —CO₂H, or —CO₂(C₁-C₆ alkyl); and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆    alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-12, i.e., compounds of Embodiment A-11, wherein R₂ is of formula:

wherein

-   the heteroaryl is optionally substituted with one or more R₂₃;-   R₁₀ is —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —CO₂H, or —CO₂(C₁-C₆ alkyl);-   R₂₁ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl),    —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl);-   R₂₂ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl),    —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),    —NHCONH₂, and —NHCONH(C₁-C₆ alkyl); and-   R₂₃ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and amino(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-13, i.e., compounds of Embodiment A-12 wherein

-   R₁₀ is —CONH—OH, —CONH—NH₂, or —CO₂H; and-   R₂₁ is hydrogen, —NH₂, or —OH;-   R₂₂ is selected from the group consisting of hydrogen, C₁-C₆ alkyl,    C₁-C₆ haloalkyl, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and    amino(C₁-C₆ alkyl); and-   R₂₃ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and amino(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-14, i.e., compounds of Embodiment A-13 wherein

-   R₁₀ is —CONH—OH; and-   R₂₁ is —OH;-   R₂₂ is hydrogen or C₁-C₆ alkyl; and-   R₂₃ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and amino(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-15, i.e., compounds of Embodiment A wherein

-   R₉ is C₁-C₆ alkyl, optionally substituted with one or more R₁₁; and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆    alkyl), —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —NHC(═NH)NH₂, —OCO(C₁-C₆    alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂, and    —NHCONH(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-16, i.e., compounds of Embodiment A-15 wherein

-   R₂ is —CH(R₉)(R₁₀);-   R₉ is C₁-C₆ alkyl, optionally substituted with one or more R₁₁;-   R₁₀ is —CONH—OH, —CONH—NH₂, or —CO₂H; and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆    alkyl), —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —NHC(═NH)NH₂, —OCO(C₁-C₆    alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂, and    —NHCONH(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-17, i.e., compounds of Embodiment A-16 wherein

-   R₂ is —CH(R₉)(R₁₀);-   R₉ is C₁-C₄ alkyl, optionally substituted with one or more R₁₁;-   R₁₀ is —CONH—OH; and-   each R₁₁ is independently selected from the group consisting of    halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆    alkyl), —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —NHC(═NH)NH₂, —OCO(C₁-C₆    alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂, and    —NHCONH(C₁-C₆ alkyl)

Particular embodiments based on formula I include those of EmbodimentA-18, i.e., compounds of any of embodiments 1-26 where

-   R₂ is heterocyclyl optionally substituted with one or more R₁₀;-   R₃ is hydrogen; and-   R₁₀ is halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂,    —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆    haloalkoxy, oxo, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂,    —CONH—OH, —CONH—NH₂, —CO₂H, and —CO₂(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-19, i.e., compounds of Embodiment A-18 wherein the heterocyclyl ringis 4- to 7-member ring containing 1 or 2 hetero atoms selected fromnitrogen, oxygen, and sulfur, and the ring may be saturated or partiallyunsaturated, and optionally substituted with one or more R₁₀.

Particular embodiments based on formula I include those of EmbodimentA-20, i.e., compounds of Embodiment A-19 wherein, wherein theheterocyclyl ring is selected from the group consisting of azetidinyl,pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperazinyl,homopiperidinyl, diazepanyl, imidazolidinyl,2,3-dihydro-1H-imidazol-4-yl, 1,4,5,6-tetrahydropyrazin-2-yl,2,3,4,7-tetrahydro-1H-1,4-diazepin-1-yl, 1,4,5,6-tetrahydropyridin-3-yl,4,5-dihydro-1H-pyrrol-3-yl, and 3,4-dihydro-2H-1,4-oxazin-6-yl, each ofwhich is optionally substituted with one or more R₁₀.

Particular embodiments based on formula I include those of EmbodimentA-21, i.e., compounds of Embodiment A-20 wherein

-   R₂ is heterocyclyl optionally substituted with one or more R₁₀,    wherein the heterocyclyl ring is selected from the group consisting    of azetidinyl, pyrrolidinyl, and piperidinyl;-   R₃ is hydrogen; and-   R₁₀ is halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, oxo,    —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH, —CONH—NH₂,    —CO₂H, and —CO₂(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-22, i.e., compounds of Embodiment A-21 wherein R₂ is heterocyclyloptionally substituted with one or more R₁₀, wherein the heterocyclylring is selected from the group consisting of azetidinyl, pyrrolidinyl,and piperidinyl; and

-   R₁₀ is —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, and oxo.

Particular embodiments of Formula I include those of Embodiment A-23,i.e., compounds of any of embodiments 1-26 where

-   R₂ and R₃ together with the nitrogen to which they are attached form    heterocyclyl ring optionally substituted with one or more R₁₀;-   R₁₀ is halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂,    —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆    haloalkoxy, oxo, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂,    —CONH—OH, —CONH—NH₂, —CO₂H, and —CO₂(C₁-C₆ alkyl).

Particular embodiments based on formula I include those of EmbodimentA-24, i.e., compounds of Embodiment A-23 wherein the heterocyclyl ringis 4- to 7-member ring containing 1 or 2 hetero atoms selected fromnitrogen, oxygen, and sulfur, and the ring may be saturated or partiallyunsaturated, and optionally substituted with one or more R₁₀.

Particular embodiments based on formula I include those of EmbodimentA-25, i.e., compounds of Embodiment A-24 wherein the heterocyclyl ringis selected from the group consisting of azetidinyl, pyrrolidinyl,piperidinyl, piperazinyl, morpholinyl, homopiperazinyl, homopiperidinyl,diazepanyl, imidazolidinyl, 2,3-dihydro-1H-imidazol-4-yl,1,4,5,6-tetrahydropyrazin-2-yl, 2,3,4,7-tetrahydro-1H-1,4-diazepin-1-yl,1,4,5,6-tetrahydropyridin-3-yl, 4,5-dihydro-1H-pyrrol-3-yl, and3,4-dihydro-2H-1,4-oxazin-6-yl, each of which is optionally substitutedwith one or more R₁₀.

Particular embodiments based on formula I include those of EmbodimentA-26, i.e., compounds of Embodiment A-25 wherein the heterocyclyl ringis selected from the group consisting of azetidinyl, pyrrolidinyl, andpiperidinyl, each of which is optionally substituted with one or moreR₁₀.

Other embodiments based on formula I include those of Embodiment A-27,i.e., compounds of any of embodiments 1-26 where R₂ is of formula:

-   R₂₄ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl),    —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —OCO(C₁-C₆    alkyl), and —NHCO(C₁-C₆ alkoxy);-   R₂₅ is selected from the group consisting of hydrogen, halogen,    C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆    alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl),    hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and amino(C₁-C₆ alkyl);-   R₂₆ is C₁-C₆ haloalkyl; and-   R₁₀ is —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —CO₂H, or —CO₂(C₁-C₆ alkyl).

Embodiment A-28 includes compounds of embodiment A-27, wherein R₂₆ is C₁haloalkyl. Embodiment A-29 includes compounds of embodiment A-28 whereinR₂₆ is —CH₂F, —CHF₂, or —CF₃. Embodiment A-30 includes compounds ofembodiment A-29 where R₂₆ is —CHF₂. Embodiment A-29-a includes compoundsof embodiment A-29 where R₂₆ is —CH₂F and Embodiment A-29-b includescompounds of embodiment A-29 where R₂₆ is —CF₃.

Particular embodiments based on formula I include those of EmbodimentA-31, i.e., compounds of embodiment A-27 to A-30 wherein R₂₅ ishydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl.

Other embodiments based on formula I include those of Embodiment A-32,i.e., compounds of Embodiment A-31 wherein R₂₅ is hydrogen or C₁-C₆alkyl. Embodiment A-33 includes compounds of embodiment A-32 where R₂₅is hydrogen. Embodiment A-34 includes compounds of embodiment A-32 whereR₂₅ is C₁-C₆ alkyl. Embodiment A-35 includes compounds of embodimentA-34 where R₂₅ is methyl.

Particular embodiments based on formula I include those of EmbodimentA-36, i.e., compounds of embodiment A-27 where R₂₅ is methyl, and R₂₆ is—CHF₂.

Other particular embodiments based on formula I include those ofEmbodiment A-37, i.e., compounds of embodiment A-27 where R₂₅ ishydrogen, and R₂₆ is —CHF₂.

Some embodiments based on formula I include those of Embodiment A-38,i.e., compounds of embodiment A-27 to A-37 where R₂₄ is selected fromthe group consisting of —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH,C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl), —NHCO(C₁-C₆alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —OCO(C₁-C₆ alkyl), and—NHCO(C₁-C₆ alkoxy). Embodiment A-39 includes compounds of embodimentA-38 where R₂₄ is selected from the group consisting of —NH₂, —NH(C₁-C₆alkyl), —N(C₁-C₆ alkyl)₂, —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆alkyl), and —NHCO(C₁-C₆ alkoxy).

Embodiment A-40 includes compounds of embodiment A-39 where R₂₄ is —NH₂.Embodiment A-41 includes compounds of embodiment A-39 where R₂₄ is—NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), or —NHCO(C₁-C₆alkoxy). Embodiment A-42 includes the compounds of embodiment A-39 whereR₂₄ is —OH or C₁-C₆ alkoxy. Embodiment A-43 includes compounds ofembodiment A-32 where R₂₄ is —OH.

Some embodiments based on formula I include those of Embodiment A-44,i.e., compounds of embodiment A-27 to A-43 where R₁₀ is —CONH—OH,—CONH—NH₂, or —CO₂H. Embodiment A-45 includes compounds of embodimentA-44 wherein R₁₀ is —CONH—OH.

Particular embodiments of Formula I include those of Embodiment A-44,i.e., compounds of embodiment A-27 to A-45 where R₃ is hydrogen.

In another embodiment (Embodiment B), the invention provides compoundsof the formula II:

and pharmaceutically acceptable salts thereof, wherein

-   Z represents a heterocyclyl ring containing 4-8 members, where the    ring may contain, in addition to the nitrogen attached to the phenyl    group, 1 or 2 additional hetero atoms selected from nitrogen,    oxygen, and sulfur, and the ring may be saturated or partially    unsaturated;-   R₁ is —C(R₅)═C(R₄)(R₅), —C≡C—R₄, aryl optionally substituted with    R₆, heteroaryl optionally substituted with R₆, or heterocyclyl    optionally substituted with R₆;    -   R₄ is C₁-C₆ alkyl optionally substituted with R₇, aryl        optionally substituted with R₈, heteroaryl optionally        substituted with R₈, or heterocyclyl optionally substituted with        R₈;    -   each R₅ is independently hydrogen, or C₁-C₆ alkyl;    -   each R₆ is independently selected from the group consisting of        halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂,        —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, and C₁-C₆        haloalkoxy;    -   each R₇ is independently selected from the group consisting of        halogen, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆        alkoxy, and C₁-C₆ haloalkoxy;    -   each R₈ is independently selected from the group consisting of        halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂,        —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆        haloalkoxy, —SH, —S(C₁-C₆ alkyl), oxo, hydroxy(C₁-C₆ alkyl),        alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl), —CH₂—NH(C₁-C₆ alkyl),        —CH₂—N(C₁-C₆ alkyl)₂, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆        alkyl)₂, —CONH—OH, —CONH—NH₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl),        —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl),        —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —NHC(═NH)NH₂, —NH—S(O)₀₋₂—(C₁-C₆        alkyl), —NH—S(O)₀₋₂-aryl, —NH—S(O)₀₋₂-heteroaryl, aryl(C₁-C₆        alkyl), heteroaryl(C₁-C₆ alkyl), heterocyclyl(C₁-C₆ alkyl),        —CH₂—NHCONH₂, —CH₂—NHCONH(C₁-C₆ alkyl), and —CH₂—OCO(C₁-C₆        alkyl);-   R₁₀₁ is independently selected from the group consisting of R₁₁₂ and    NR₁₁₂R₁₁₃,    -   where R₁₁₂ and R₁₁₃ independently represent hydrogen, halogen,        C₁-C₆ alkyl, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, or C₁-C₆ alkyl        substituted with up to three groups selected from hydroxyl,        —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,        —CONH—NH₂, —CO₂H, —CO₂(C₁-C₆ alkyl), and R₁₁₅,        -   where R₁₁₅ represents phenyl or naphthyl, or a 5- or            6-membered heteroaryl group optionally fused to benzo, where            R₁₁₅ is optionally substituted with up to three groups            selected from halogen, hydroxyl, C₁-C₆ alkyl, C₁-C₆ alkoxy,            C₁-C₃ haloalkyl, nitro, cyano, —(CH₂)_(m)NR₂₁₅R₂₁₆,            C(O)NR₂₁₅R₂₁₆, and NR₂₁₅R₂₁₆, where m is 1, 2, 3, or 4, and            R₂₁₅ and R₂₁₆ independently represent hydrogen, C₁-C₆ alkyl,            hydroxyl(C₁-C₆)alkyl, and amino(C₁-C₆)alkyl.

Particular embodiments based on Formula II include those of EmbodimentB-1, i.e., compounds of Embodiment B wherein R₁ is —C≡C—R₄, and R₄ isaryl optionally substituted with up to three of R₈, or heteroaryloptionally substituted with up to three of R₈,

-   where each R₈ is independently selected from the group consisting of    halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy.

Particular embodiments based on Formula II include those of EmbodimentB-2, i.e., compounds of Embodiment B or B-1 wherein Z is pyrrolidinyl,piperidinyl, piperazinyl, morpholinyl, homopiperazinyl, homopiperidinyl,diazepanyl, imidazolidinyl, 2,3-dihydro-1H-imidazol-4-yl,1,4,5,6-tetrahydropyrazin-2-yl, 2,3,4,7-tetrahydro-1H-1,4-diazepin-1-yl,1,4,5,6-tetrahydropyridin-3-yl, 4,5-dihydro-1H-pyrrol-3-yl, or3,4-dihydro-2H-1,4-oxazin-6-yl.

Particular embodiments based on Formula II include those of EmbodimentB-3, i.e., compounds of Embodiment B, B-1, or B-2 where R₁₀₁ isNR₁₁₂HR₁₁₃, and

-   -   R₁₁₂ represents hydrogen or C₁-C₆ alkyl;    -   R₁₁₃ represents C₁-C₆ alkyl substituted with up to three groups        selected from hydroxyl, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆        alkyl)₂, —CONH—OH, —CONH—NH₂, —CO₂H, and —CO₂(C₁-C₆ alkyl).

Particular embodiments based on Formula II include those of EmbodimentB-4, i.e., compounds of Embodiment B or B-1 through B-3 where R₁₀₁represents a group of the formula:

where

-   -   R₂₂₀ is hydroxy, sulfhydryl, amino, or C₁-C₂ alkylamino;    -   R₂₂₁ is C₁-C₆ alkyl or C₁-C₆ haloalkyl;    -   R₂₂₂ is hydrogen or phenyl optionally substituted with        —(CH₂)_(m)NR₂₁₅R₂₁₆;    -   m is 1, 2, 3, or 4; and n is 0 or 1.

Particular embodiments based on Formula II include those of EmbodimentB-5, i.e., compounds of Embodiment B or B-1 through B-4 where R₂₂₀ ishydroxyl or amino; R₂₂₁ is methyl or ethyl; and R₂₂₂ is hydrogen orphenyl optionally substituted with —(CH₂)_(m)NR₂₁₅R₂₁₆, where R₂₁₅ ishydrogen, m is 1 or 2; and R₂₁₆ is aminomethyl or methylaminomethyl.

Particular embodiments based on Formula II include those of EmbodimentB-6, i.e., compounds of Embodiment B or B-1 through B-5 where Z ispiperazin-1-yl or piperidin-1-yl, each of which is attached to thephenyl carrying the acetylenyl group in a position para to theacetylenyl group.

Particular embodiments based on Formula II include those of EmbodimentB-7, i.e., compounds of Embodiment B or B-1 through B-6 where in theC(O)R₁₀₁ group is attached to Z in the 4-position based on the point ofattachment of Z to the phenyl carrying the acetylenyl group.

In another embodiment (Embodiment C), the invention provides compoundsof the formula III:

or a pharmaceutically acceptable salt thereof, wherein

-   each R is independently hydrogen, or C₁-C₆ alkyl, or two R groups    form ═O;-   L is —O—C(R₅)(R₅)—C≡C— or —C≡C—C(R₅)(R₅)—O—;-   R₁ is C₁-C₆ alkyl optionally substituted with R₇, aryl optionally    substituted with R₈, heteroaryl optionally substituted with R₈, or    heterocyclyl optionally substituted with R₈;-   R₂ is —CH(R₉)(R₁₀), or heterocyclyl optionally substituted with one    or more R₁₀;-   R₃ is hydrogen or C₁-C₆ alkyl;    -   or R₂ and R₃ together with the nitrogen to which they are        attached form heterocyclyl ring optionally substituted with one        or more R₁₀;-   each R₅ is independently hydrogen, or C₁-C₆ alkyl;-   each R₇ is independently selected from the group consisting of    halogen, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆    alkoxy, and C₁-C₆ haloalkoxy;-   each R₈ is independently selected from the group consisting of    halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy;-   R₉ is hydrogen, C₁-C₆ alkyl, aryl, aryl(C₁-C₆ alkyl), heteroaryl,    heteroaryl(C₁-C₆ alkyl), heterocyclyl, or heterocyclyl(C₁-C₆ alkyl),    wherein each alkyl, aryl, heteroaryl, or heterocyclyl moiety is    optionally substituted with one or more R₁₁;-   R₁₀ is independently selected from the group consisting of halogen,    —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl),    —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, oxo, —CONH₂,    —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH, —CONH—NH₂, —CO₂H,    and —CO₂(C₁-C₆ alkyl); and-   each R₁₁ is independently selected from the group consisting of    halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH,    —S(C₁-C₆ alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl),    amino(C₁-C₆ alkyl), —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂,    —CONH—OH, —CONH—NH₂, —CO₂H, —CO₂(C₁-C₆ alkyl), —NHCONH₂,    —NHC(═NH)NH₂, —NH—S(O)₀₋₂—(C₁-C₆ alkyl), —NH—S(O)₀₋₂-aryl, and    —NH—S(O)₀₋₂-heteroaryl.

Particular embodiments based on Formula III include those of EmbodimentC-1, i.e., compounds of Embodiment C where two R groups form ═O.

Particular embodiments based on Formula III include those of EmbodimentC-2, i.e., compounds of Embodiment C or C-1 where

-   L is —O—C(R₅)(R₅)—C≡C—;-   R₁ is C₁-C₆ alkyl optionally substituted with R₇, aryl optionally    substituted with R₈, heteroaryl optionally substituted with R₈, or    heterocyclyl optionally substituted with R₈;

Other particular embodiments based on Formula III include those ofEmbodiment C-3, i.e., compounds of Embodiment C-2 which have theformula:

Particular embodiments based on Formula III include those of EmbodimentC-4, i.e., compounds of Embodiment C or C-1 through C-3 wherein R₁ isaryl optionally substituted with R₈, where R₈ is selected from the groupconsisting of halogen, —NO₂, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂,—OH, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy.

Particular embodiments based on Formula III include those of EmbodimentC-5, i.e., compounds of Embodiment C-4 where R₁ is phenyl optionallysubstituted halogen, —NO₂, —NH₂, —OH, C₁-C₆ alkoxy, and C₁-C₆haloalkoxy.

Particular embodiments based on Formula III include those of EmbodimentC-6, i.e., compounds of Embodiments C4 or C5 wherein

-   L is —C≡C—C(R₆)(R₆)—O—;-   R₁ is C₁-C₆ alkyl optionally substituted with R₇, aryl optionally    substituted with R₈, heteroaryl optionally substituted with R₈, or    heterocyclyl optionally substituted with R₈;

Particular embodiments based on Formula III include those of EmbodimentC-7, i.e., compounds of Embodiment C-6 where the compound is of formula:

Particular embodiments based on Formula III include those of EmbodimentC-8, i.e., compounds of Embodiment C-6 or C-7 wherein R₁ is aryloptionally substituted with R₈, where R₈ is selected from the groupconsisting of halogen, —NO₂, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂,—OH, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy.

Particular embodiments based on Formula III include those of EmbodimentC-9, i.e., compounds of Embodiment C-8, wherein R₁ is phenyl optionallysubstituted halogen, —NO₂, —NH₂, —OH, C₁-C₆ alkoxy, and C₁-C₆haloalkoxy.

Particular embodiments based on Formula III include those of EmbodimentC-10, i.e., compounds of any Embodiment C or C-1 through C-9 wherein

-   R₂ is —CH(R₉)(R₁₀);-   R₃ is hydrogen;-   R₉ is C₁-C₆ alkyl, aryl(C₁-C₆ alkyl), or heteroaryl(C₁-C₆ alkyl),    wherein each alkyl, aryl, or heteroaryl moiety is optionally    substituted with one or more R₁₁;-   R₁₀ is —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH,    —CONH—NH₂, —CO₂H, or —CO₂(C₁-C₆ alkyl); and-   each R₁₁ is independently selected from the group consisting of    halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆    alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH,    —S(C₁-C₆ alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl),    amino(C₁-C₆ alkyl), —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂,    —CONH—OH, —CONH—NH₂, —CO₂H, —CO₂(C₁-C₆ alkyl), —NHCONH₂,    —NHC(═NH)NH₂, —NH—S(O)₀₋₂—(C₁-C₆ alkyl), —NH—S(O)₀₋₂-aryl, and    —NH—S(O)₀₋₂-heteroaryl.

Particular embodiments based on Formula III include those of EmbodimentC-10, i.e., compounds of any Embodiment C or C-1 through C-9 wherein

-   R₂ is heterocyclyl optionally substituted with one or more R₁₀;-   R₃ is hydrogen; and-   R₁₀ is halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂,    —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆    haloalkoxy, oxo, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂,    —CONH—OH, —CONH—NH₂, —CO₂H, and —CO₂(C₁-C₆ alkyl).

Therapeutics Applications

The invention provides methods of treating Gram-negative bacterialinfections, the method comprising administering to a subject in need ofsuch treatment an effective amount of one or more compounds of theinvention Particular Gram-negative bacteria are Pseudomonas aeruginosa,Stenotrophomonas maltophilia, Burkholderia cepacia, Alcaligenesxylosoxidans, Acinetobacter, Enterobacteriaceae, Haemophilus, Neisseriaspecies, Francisella tularensis, Yersinia pestis, Burkholderiapseudomallei, Burkholderia mallei, Rickettsia prowazekii, Coxiellaburnetti, Campylobacter jejuni, Shigella, Moraxella catarrhalis, andChlamydia trachomatis. In one embodiment, the Gram-negative bacteria isNeisseria gonorrhoeae. In another embodiment, the Gram-negative bacteriais Acinetobacter Baumannii.

Specific enterobacteriaceae is selected from the group consisting ofSerratia, Proteus, Klebsiella, Enterobacter, Citrobacter, Salmonella,Providencia, Morganella, Cedecea, Edwardsiella, Escherichia coli,Enterobacter cloacae, and Enterobacter aerogenes.

In another aspect, the invention provides methods for inhibiting adeacetylase enzyme in Gram-negative bacteria, the method comprisingcontacting the bacteria with an effective amount of one or morecompounds of the invention. A specific deacetylase enzyme is LpxC.

Pharmaceutical Compositions

In another aspect, the present disclosure provides compositionscomprising one or more of compounds as described above with respect toformula I and an appropriate carrier, excipient or diluent. The exactnature of the carrier, excipient or diluent will depend upon the desireduse for the composition, and may range from being suitable or acceptablefor veterinary uses to being suitable or acceptable for human use. Thecomposition may optionally include one or more additional compounds.

When used to treat or prevent such diseases, the compounds describedherein may be administered singly, as mixtures of one or more compoundsor in mixture or combination with other agents useful for treating suchdiseases and/or the symptoms associated with such diseases. Thecompounds may also be administered in mixture or in combination withagents useful to treat other disorders or maladies, such as steroids,membrane stabilizers, 5LO inhibitors, leukotriene synthesis and receptorinhibitors, inhibitors of IgE isotype switching or IgE synthesis, IgGisotype switching or IgG synthesis, β-agonists, tryptase inhibitors,aspirin, COX inhibitors, methotrexate, anti-TNF drugs, retuxin, PD4inhibitors, p38 inhibitors, PDE4 inhibitors, and antihistamines, to namea few. The compounds may be administered in the form of compounds perse, or as pharmaceutical compositions comprising a compound.

Pharmaceutical compositions comprising the compound(s) may bemanufactured by means of conventional mixing, dissolving, granulating,dragee-making levigating, emulsifying, encapsulating, entrapping orlyophilization processes. The compositions may be formulated inconventional manner using one or more physiologically acceptablecarriers, diluents, excipients or auxiliaries which facilitateprocessing of the compounds into preparations which can be usedpharmaceutically.

The compounds may be formulated in the pharmaceutical composition perse, or in the form of a hydrate, solvate, N-oxide or pharmaceuticallyacceptable salt, as previously described. Typically, such salts are moresoluble in aqueous solutions than the corresponding free acids andbases, but salts having lower solubility than the corresponding freeacids and bases may also be formed.

Pharmaceutical compositions may take a form suitable for virtually anymode of administration, including, for example, topical, ocular, oral,buccal, systemic, nasal, injection, transdermal, rectal, vaginal, etc.,or a form suitable for administration by inhalation or insufflation.

For topical administration, the compound(s) may be formulated assolutions, gels, ointments, creams, suspensions, etc. as are well-knownin the art. Systemic formulations include those designed foradministration by injection, e.g., subcutaneous, intravenous,intramuscular, intrathecal or intraperitoneal injection, as well asthose designed for transdermal, transmucosal oral or pulmonaryadministration.

Useful injectable preparations include sterile suspensions, solutions oremulsions of the active compound(s) in aqueous or oily vehicles. Thecompositions may also contain formulating agents, such as suspending,stabilizing and/or dispersing agent. The formulations for injection maybe presented in unit dosage form, e.g., in ampules or in multidosecontainers, and may contain added preservatives. Alternatively, theinjectable formulation may be provided in powder form for reconstitutionwith a suitable vehicle, including but not limited to sterile pyrogenfree water, buffer, dextrose solution, etc., before use. To this end,the active compound(s) may be dried by any art-known technique, such aslyophilization, and reconstituted prior to use.

For transmucosal administration, penetrants appropriate to the barrierto be permeated are used in the formulation. Such penetrants are knownin the art.

For oral administration, the pharmaceutical compositions may take theform of, for example, lozenges, tablets or capsules prepared byconventional means with pharmaceutically acceptable excipients such asbinding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidoneor hydroxypropyl methylcellulose); fillers (e.g., lactose,microcrystalline cellulose or calcium hydrogen phosphate); lubricants(e.g., magnesium stearate, talc or silica); disintegrants (e.g., potatostarch or sodium starch glycolate); or wetting agents (e.g., sodiumlauryl sulfate). The tablets may be coated by methods well known in theart with, for example, sugars, films or enteric coatings.

Liquid preparations for oral administration may take the form of, forexample, elixirs, solutions, syrups or suspensions, or they may bepresented as a dry product for constitution with water or other suitablevehicle before use. Such liquid preparations may be prepared byconventional means with pharmaceutically acceptable additives such assuspending agents (e.g., sorbitol syrup, cellulose derivatives orhydrogenated edible fats); emulsifying agents (e.g., lecithin oracacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethylalcohol, Cremophore™ or fractionated vegetable oils); and preservatives(e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). Thepreparations may also contain buffer salts, preservatives, flavoring,coloring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to givecontrolled release of the compound, as is well known.

For buccal administration, the compositions may take the form of tabletsor lozenges formulated in conventional manner.

For rectal and vaginal routes of administration, the compound(s) may beformulated as solutions (for retention enemas) suppositories orointments containing conventional suppository bases such as cocoa butteror other glycerides.

For nasal administration or administration by inhalation orinsufflation, the compound(s) can be conveniently delivered in the formof an aerosol spray from pressurized packs or a nebulizer with the useof a suitable propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, fluorocarbons, carbondioxide or other suitable gas. In the case of a pressurized aerosol, thedosage unit may be determined by providing a valve to deliver a meteredamount. Capsules and cartridges for use in an inhaler or insufflator(for example capsules and cartridges comprised of gelatin) may beformulated containing a powder mix of the compound and a suitable powderbase such as lactose or starch.

For ocular administration, the compound(s) may be formulated as asolution, emulsion, suspension, etc. suitable for administration to theeye. A variety of vehicles suitable for administering compounds to theeye are known in the art.

For prolonged delivery, the compound(s) can be formulated as a depotpreparation for administration by implantation or intramuscularinjection. The compound(s) may be formulated with suitable polymeric orhydrophobic materials (e.g., as an emulsion in an acceptable oil) or ionexchange resins, or as sparingly soluble derivatives, e.g., as asparingly soluble salt. Alternatively, transdermal delivery systemsmanufactured as an adhesive disc or patch which slowly releases thecompound(s) for percutaneous absorption may be used. To this end,permeation enhancers may be used to facilitate transdermal penetrationof the compound(s).

Alternatively, other pharmaceutical delivery systems may be employed.Liposomes and emulsions are well-known examples of delivery vehiclesthat may be used to deliver compound(s). Certain organic solvents suchas dimethylsulfoxide (DMSO) may also be employed, although usually atthe cost of greater toxicity.

The pharmaceutical compositions may, if desired, be presented in a packor dispenser device which may contain one or more unit dosage formscontaining the compound(s). The pack may, for example, comprise metal orplastic foil, such as a blister pack. The pack or dispenser device maybe accompanied by instructions for administration.

The compound(s) described herein, or compositions thereof, willgenerally be used in an amount effective to achieve the intended result,for example in an amount effective to treat or prevent the particulardisease being treated. By therapeutic benefit is meant eradication oramelioration of the underlying disorder being treated and/or eradicationor amelioration of one or more of the symptoms associated with theunderlying disorder such that the patient reports an improvement infeeling or condition, notwithstanding that the patient may still beafflicted with the underlying disorder. Therapeutic benefit alsogenerally includes halting or slowing the progression of the disease,regardless of whether improvement is realized.

The amount of compound(s) administered will depend upon a variety offactors, including, for example, the particular indication beingtreated, the mode of administration, whether the desired benefit isprophylactic or therapeutic, the severity of the indication beingtreated and the age and weight of the patient, the bioavailability ofthe particular compound(s) the conversation rate and efficiency intoactive drug compound under the selected route of administration, etc.

Determination of an effective dosage of compound(s) for a particular useand mode of administration is well within the capabilities of thoseskilled in the art. Effective dosages may be estimated initially from invitro activity and metabolism assays. For example, an initial dosage ofcompound for use in animals may be formulated to achieve a circulatingblood or serum concentration of the metabolite active compound that isat or above an IC₅₀ of the particular compound as measured in as invitro assay. Calculating dosages to achieve such circulating blood orserum concentrations taking into account the bioavailability of theparticular compound via the desired route of administration is wellwithin the capabilities of skilled artisans. Initial dosages of compoundcan also be estimated from in vivo data, such as animal models. Animalmodels useful for testing the efficacy of the active metabolites totreat or prevent the various diseases described above are well-known inthe art. Animal models suitable for testing the bioavailability and/ormetabolism of compounds into active metabolites are also well-known.Ordinarily skilled artisans can routinely adapt such information todetermine dosages of particular compounds suitable for humanadministration.

Dosage amounts will typically be in the range of from about 0.0001mg/kg/day, 0.001 mg/kg/day or 0.01 mg/kg/day to about 100 mg/kg/day, butmay be higher or lower, depending upon, among other factors, theactivity of the active metabolite compound, the bioavailability of thecompound, its metabolism kinetics and other pharmacokinetic properties,the mode of administration and various other factors, discussed above.Dosage amount and interval may be adjusted individually to provideplasma levels of the compound(s) and/or active metabolite compound(s)which are sufficient to maintain therapeutic or prophylactic effect. Forexample, the compounds may be administered once per week, several timesper week (e.g., every other day), once per day or multiple times perday, depending upon, among other things, the mode of administration, thespecific indication being treated and the judgment of the prescribingphysician. In cases of local administration or selective uptake, such aslocal topical administration, the effective local concentration ofcompound(s) and/or active metabolite compound(s) may not be related toplasma concentration. Skilled artisans will be able to optimizeeffective local dosages without undue experimentation.

DEFINITIONS

The following terms and expressions used herein have the indicatedmeanings.

Terms used herein may be preceded and/or followed by a single dash, “-”,or a double dash, “═”, to indicate the bond order of the bond betweenthe named substituent and its parent moiety; a single dash indicates asingle bond and a double dash indicates a double bond. In the absence ofa single or double dash it is understood that a single bond is formedbetween the substituent and its parent moiety; further, substituents areintended to be read “left to right” unless a dash indicates otherwise.For example, C₁-C₆alkoxycarbonyloxy and —OC(O)C₁-C₆alkyl indicate thesame functionality; similarly arylalkyl and -alkylaryl indicate the samefunctionality.

The term “alkenyl” as used herein, means a straight or branched chainhydrocarbon containing from 2 to 10 carbons, unless otherwise specified,and containing at least one carbon-carbon double bond. Representativeexamples of alkenyl include, but are not limited to, ethenyl,2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl,2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl, and3,7-dimethylocta-2,6-dienyl.

The term “alkoxy” as used herein, means an alkyl group, as definedherein, appended to the parent molecular moiety through an oxygen atom.Representative examples of alkoxy include, but are not limited to,methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, andhexyloxy.

The term “alkyl” as used herein, means a straight or branched chainhydrocarbon containing from 1 to 10 carbon atoms unless otherwisespecified. Representative examples of alkyl include, but are not limitedto, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl,tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl,2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, andn-decyl. When an “alkyl” group is a linking group between two othermoieties, then it may also be a straight or branched chain; examplesinclude, but are not limited to —CH₂—, —CH₂CH₂—, —CH₂CH₂CHC(CH₃)—,—CH₂CH(CH₂CH₃)CH₂—.

The term “alkylene” refers to a bivalent alkyl group. An “alkylenechain” is a polymethylene group, i.e., —(CH₂)_(n)—, wherein n is apositive integer, preferably from one to six, from one to four, from oneto three, from one to two, or from two to three. A substituted alkylenechain is a polymethylene group in which one or more methylene hydrogenatoms is replaced with a substituent. Suitable substituents includethose described below for a substituted aliphatic group. An alkylenechain also may be substituted at one or more positions with an aliphaticgroup or a substituted aliphatic group.

The term “alkynyl” as used herein, means a straight or branched chainhydrocarbon group containing from 2 to 10 carbon atoms and containing atleast one carbon-carbon triple bond. Representative examples of alkynylinclude, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl,3-butynyl, 2-pentynyl, and 1-butynyl.

The term “aryl,” as used herein, means a phenyl (i.e., monocyclic aryl),or a bicyclic ring system containing at least one phenyl ring or anaromatic bicyclic ring containing only carbon atoms in the aromaticbicyclic ring system. The bicyclic aryl can be azulenyl, naphthyl, or aphenyl fused to a monocyclic cycloalkyl, a monocyclic cycloalkenyl, or amonocyclic heterocyclyl. The bicyclic aryl is attached to the parentmolecular moiety through any carbon atom contained within the phenylportion of the bicyclic system, or any carbon atom with the napthyl orazulenyl ring. The fused monocyclic cycloalkyl or monocyclicheterocyclyl portions of the bicyclic aryl are optionally substitutedwith one or two oxo and/or thia groups. Representative examples of thebicyclic aryls include, but are not limited to, azulenyl, naphthyl,dihydroinden-1-yl, dihydroinden-2-yl, dihydroinden-3-yl,dihydroinden-4-yl, 2,3-dihydroindol-4-yl, 2,3-dihydroindol-5-yl,2,3-dihydroindol-6-yl, 2,3-dihydroindol-7-yl, inden-1-yl, inden-2-yl,inden-3-yl, inden-4-yl, dihydronaphthalen-2-yl, dihydronaphthalen-3-yl,dihydronaphthalen-4-yl, dihydronaphthalen-1-yl,5,6,7,8-tetrahydronaphthalen-1-yl, 5,6,7,8-tetrahydronaphthalen-2-yl,2,3-dihydrobenzofuran-4-yl, 2,3-dihydrobenzofuran-5-yl,2,3-dihydrobenzofuran-6-yl, 2,3-dihydrobenzofuran-7-yl,benzo[d][1,3]dioxol-4-yl, benzo[d][1,3]dioxol-5-yl,2H-chromen-2-on-5-yl, 2H-chromen-2-on-6-yl, 2H-chromen-2-on-7-yl,2H-chromen-2-on-8-yl, isoindoline-1,3-dion-4-yl,isoindoline-1,3-dion-5-yl, inden-1-on-4-yl, inden-1-on-5-yl,inden-1-on-6-yl, inden-1-on-7-yl, 2,3-dihydrobenzo[b][1,4]dioxan-5-yl,2,3-dihydrobenzo[b][1,4]dioxan-6-yl,2H-benzo[b][1,4]oxazin3(4H)-on-5-yl,2H-benzo[b][1,4]oxazin3(4H)-on-6-yl,2H-benzo[b][1,4]oxazin3(4H)-on-7-yl,2H-benzo[b][1,4]oxazin3(4H)-on-8-yl, benzo[d]oxazin-2(3H)-on-5-yl,benzo[d]oxazin-2(3H)-on-6-yl, benzo[d]oxazin-2(3H)-on-7-yl,benzo[d]oxazin-2(3H)-on-8-yl, quinazolin-4(3H)-on-5-yl,quinazolin-4(3H)-on-6-yl, quinazolin-4(3H)-on-7-yl,quinazolin-4(3H)-on-8-yl, quinoxalin-2(1H)-on-5-yl,quinoxalin-2(1H)-on-6-yl, quinoxalin-2(1H)-on-7-yl,quinoxalin-2(1H)-on-8-yl, benzo[d]thiazol-2(3H)-on-4-yl,benzo[d]thiazol-2(3H)-on-5-yl, benzo[d]thiazol-2(3H)-on-6-yl, and,benzo[d]thiazol-2(3H)-on-7-yl. In certain embodiments, the bicyclic arylis (i) naphthyl or (ii) a phenyl ring fused to either a 5 or 6 memberedmonocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, or a 5or 6 membered monocyclic heterocyclyl, wherein the fused cycloalkyl,cycloalkenyl, and heterocyclyl groups are optionally substituted withone or two groups which are independently oxo or thia.

An “aralkyl” or “arylalkyl” group comprises an aryl group covalentlyattached to an alkyl group, either of which independently is optionallysubstituted. Preferably, the aralkyl group is aryl(C₁-C₆)alkyl,including, without limitation, benzyl, phenethyl, and naphthyl methyl.

The terms “cyano” and “nitrile” as used herein, mean a —CN group.

The term “cycloalkyl” as used herein, means a monocyclic or a bicycliccycloalkyl ring system. Monocyclic ring systems are cyclic hydrocarbongroups containing from 3 to 8 carbon atoms, where such groups can besaturated or unsaturated, but not aromatic. In certain embodiments,cycloalkyl groups are fully saturated. Examples of monocycliccycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicycliccycloalkyl ring systems are bridged monocyclic rings or fused bicyclicrings. Bridged monocyclic rings contain a monocyclic cycloalkyl ringwhere two non-adjacent carbon atoms of the monocyclic ring are linked byan alkylene bridge of between one and three additional carbon atoms(i.e., a bridging group of the form —(CH₂)_(w)—, where w is 1, 2, or 3).Representative examples of bicyclic ring systems include, but are notlimited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane,bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, andbicyclo[4.2.1]nonane. Fused bicyclic cycloalkyl ring systems contain amonocyclic cycloalkyl ring fused to either a phenyl, a monocycliccycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or amonocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl isattached to the parent molecular moiety through any carbon atomcontained within the monocyclic cycloalkyl ring. Cycloalkyl groups areoptionally substituted with one or two groups which are independentlyoxo or thia. In certain embodiments, the fused bicyclic cycloalkyl is a5 or 6 membered monocyclic cycloalkyl ring fused to either a phenylring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 memberedmonocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a5 or 6 membered monocyclic heteroaryl, wherein the fused bicycliccycloalkyl is optionally substituted by one or two groups which areindependently oxo or thia.

The term “halo” or “halogen” as used herein, means —Cl, —Br, —I or —F.

The terms “haloaliphatic”, “haloalkyl”, “haloalkenyl” and “haloalkoxy”refer to an aliphatic, alkyl, alkenyl or alkoxy group, as the case maybe, which is substituted with one or more halogen atoms.

The term “heteroaryl,” as used herein, means a monocyclic heteroaryl ora bicyclic ring system containing at least one heteroaromatic ring. Themonocyclic heteroaryl can be a 5 or 6 membered ring. The 5 membered ringconsists of two double bonds and one, two, three or four nitrogen atomsand optionally one oxygen or sulfur atom. The 6 membered ring consistsof three double bonds and one, two, three or four nitrogen atoms. The 5or 6 membered heteroaryl is connected to the parent molecular moietythrough any carbon atom or any nitrogen atom contained within theheteroaryl. Representative examples of monocyclic heteroaryl include,but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl,oxadiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl,pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl,triazolyl, and triazinyl. The bicyclic heteroaryl consists of amonocyclic heteroaryl fused to a phenyl, a monocyclic cycloalkyl, amonocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclicheteroaryl. The fused cycloalkyl or heterocyclyl portion of the bicyclicheteroaryl group is optionally substituted with one or two groups whichare independently oxo or thia. When the bicyclic heteroaryl contains afused cycloalkyl, cycloalkenyl, or heterocyclyl ring, then the bicyclicheteroaryl group is connected to the parent molecular moiety through anycarbon or nitrogen atom contained within the monocyclic heteroarylportion of the bicyclic ring system. When the bicyclic heteroaryl is amonocyclic heteroaryl fused to a benzo ring, then the bicyclicheteroaryl group is connected to the parent molecular moiety through anycarbon atom or nitrogen atom within the bicyclic ring system.Representative examples of bicyclic heteroaryl include, but are notlimited to, benzimidazolyl, benzofuranyl, benzothienyl, benzoxadiazolyl,benzoxathiadiazolyl, benzothiazolyl, cinnolinyl,5,6-dihydroquinolin-2-yl, 5,6-dihydroisoquinolin-1-yl, furopyridinyl,indazolyl, indolyl, isoquinolinyl, naphthyridinyl, quinolinyl, purinyl,5,6,7,8-tetrahydroquinolin-2-yl, 5,6,7,8-tetrahydroquinolin-3-yl,5,6,7,8-tetrahydroquinolin-4-yl, 5,6,7,8-tetrahydroisoquinolin-1-yl,thienopyridinyl, 4,5,6,7-tetrahydrobenzo[c][1,2,5]oxadiazolyl, and6,7-dihydrobenzo[c][1,2,5]oxadiazol-4(5H)-onyl. In certain embodiments,the fused bicyclic heteroaryl is a 5 or 6 membered monocyclic heteroarylring fused to either a phenyl ring, a 5 or 6 membered monocycliccycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 memberedmonocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl,wherein the fused cycloalkyl, cycloalkenyl, and heterocyclyl groups areoptionally substituted with one or two groups which are independentlyoxo or thia.

The terms “heterocyclyl” and “heterocycloalkyl” as used herein, mean amonocyclic heterocycle or a bicyclic heterocycle. The monocyclicheterocycle is a 3, 4, 5, 6 or 7 membered ring containing at least oneheteroatom independently selected from the group consisting of O, N, andS where the ring is saturated or unsaturated, but not aromatic. The 3 or4 membered ring contains 1 heteroatom selected from the group consistingof O, N and S. The 5 membered ring can contain zero or one double bondand one, two or three heteroatoms selected from the group consisting ofO, N and S. The 6 or 7 membered ring contains zero, one or two doublebonds and one, two or three heteroatoms selected from the groupconsisting of O, N and S. The monocyclic heterocycle is connected to theparent molecular moiety through any carbon atom or any nitrogen atomcontained within the monocyclic heterocycle. Representative examples ofmonocyclic heterocycle include, but are not limited to, azetidinyl,azepanyl, aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl,1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl, imidazolidinyl,isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl,morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl,piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl,pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl,thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl,thiomorpholinyl, 1,1-dioxidothiomorpholinyl (thiomorpholine sulfone),thiopyranyl, and trithianyl. The bicyclic heterocycle is a monocyclicheterocycle fused to either a phenyl, a monocyclic cycloalkyl, amonocyclic cycloalkenyl, a monocyclic heterocycle, or a monocyclicheteroaryl. The bicyclic heterocycle is connected to the parentmolecular moiety through any carbon atom or any nitrogen atom containedwithin the monocyclic heterocycle portion of the bicyclic ring system.Representative examples of bicyclic heterocyclyls include, but are notlimited to, 2,3-dihydrobenzofuran-2-yl, 2,3-dihydrobenzofuran-3-yl,indolin-1-yl, indolin-2-yl, indolin-3-yl, 2,3-dihydrobenzothien-2-yl,decahydroquinolinyl, decahydroisoquinolinyl, octahydro-1H-indolyl, andoctahydrobenzofuranyl. Heterocyclyl groups are optionally substitutedwith one or two groups which are independently oxo or thia. In certainembodiments, the bicyclic heterocyclyl is a 5 or 6 membered monocyclicheterocyclyl ring fused to phenyl ring, a 5 or 6 membered monocycliccycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 memberedmonocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl,wherein the bicyclic heterocyclyl is optionally substituted by one ortwo groups which are independently oxo or thia.

The term “nitro” as used herein, means a —NO₂ group.

The term “oxo” as used herein means a ═O group.

The term “saturated” as used herein means the referenced chemicalstructure does not contain any multiple carbon-carbon bonds. Forexample, a saturated cycloalkyl group as defined herein includescyclohexyl, cyclopropyl, and the like.

The term “substituted”, as used herein, means that a hydrogen radical ofthe designated moiety is replaced with the radical of a specifiedsubstituent, provided that the substitution results in a stable orchemically feasible compound. The term “substitutable”, when used inreference to a designated atom, means that attached to the atom is ahydrogen radical, which can be replaced with the radical of a suitablesubstituent.

The phrase “one or more” substituents, as used herein, refers to anumber of substituents that equals from one to the maximum number ofsubstituents possible based on the number of available bonding sites,provided that the above conditions of stability and chemical feasibilityare met. Unless otherwise indicated, an optionally substituted group mayhave a substituent at each substitutable position of the group, and thesubstituents may be either the same or different. As used herein, theterm “independently selected” means that the same or different valuesmay be selected for multiple instances of a given variable in a singlecompound.

The term “thia” as used herein means a ═S group.

The term “unsaturated” as used herein means the referenced chemicalstructure contains at least one multiple carbon-carbon bond, but is notaromatic. For example, a unsaturated cycloalkyl group as defined hereinincludes cyclohexenyl, cyclopentenyl, cyclohexadienyl, and the like.

It will be apparent to one skilled in the art that certain compounds ofthis disclosure may exist in tautomeric forms, all such tautomeric formsof the compounds being within the scope of the disclosure. Unlessotherwise stated, structures depicted herein are also meant to includeall stereochemical forms of the structure; i.e., the R and Sconfigurations for each asymmetric center. Therefore, singlestereochemical isomers as well as enantiomeric and diastereomericmixtures of the present compounds are within the scope of thedisclosure. Both the R and the S stereochemical isomers, as well as allmixtures thereof, are included within the scope of the disclosure.

“Pharmaceutically acceptable” refers to those compounds, materials,compositions, and/or dosage forms which are, within the scope of soundmedical judgment, suitable for contact with the tissues of human beingsand animals without excessive toxicity, irritation, allergic response,or other problems or complications commensurate with a reasonablebenefit/risk ratio or which have otherwise been approved by the UnitedStates Food and Drug Administration as being acceptable for use inhumans or domestic animals.

“Pharmaceutically acceptable salt” refers to both acid and base additionsalts.

“Therapeutically effective amount” refers to that amount of a compoundwhich, when administered to a subject, is sufficient to effect treatmentfor a disease or disorder described herein. The amount of a compoundwhich constitutes a “therapeutically effective amount” will varydepending on the compound, the disorder and its severity, and the age ofthe subject to be treated, but can be determined routinely by one ofordinary skill in the art.

“Modulating” or “modulate” refers to the treating, prevention,suppression, enhancement or induction of a function, condition ordisorder. For example, it is believed that the compounds of the presentdisclosure can modulate atherosclerosis by stimulating the removal ofcholesterol from atherosclerotic lesions in a human.

“Treating” or “treatment” as used herein covers the treatment of adisease or disorder described herein, in a subject, preferably a human,and includes:

i. inhibiting a disease or disorder, i.e., arresting its development;

ii. relieving a disease or disorder, i.e., causing regression of thedisorder;

iii. slowing progression of the disorder; and/or

iv. inhibiting, relieving, ameliorating, or slowing progression of oneor more symptoms of the disease or disorder

“Subject” refers to a warm blooded animal such as a mammal, preferably ahuman, or a human child, which is afflicted with, or has the potentialto be afflicted with one or more diseases and disorders describedherein.

“EC₅₀” refers to a dosage, concentration or amount of a particular testcompound that elicits a dose-dependent response at 50% of maximalexpression of a particular response that is induced, provoked orpotentiated by the particular test compound.

“IC₅₀” refers to an amount, concentration or dosage of a particular testcompound that achieves a 50% inhibition of a maximal response in anassay that measures such response.

Methods of Preparation

The compounds of the present disclosure may be prepared by use of knownchemical reactions and procedures. Representative methods forsynthesizing compounds of the disclosure are presented below. It isunderstood that the nature of the substituents required for the desiredtarget compound often determines the preferred method of synthesis. Allvariable groups of these methods are as described in the genericdescription if they are not specifically defined below.

General Procedure

Those having skill in the art will recognize that the starting materialsand reaction conditions may be varied, the sequence of the reactionsaltered, and additional steps employed to produce compounds encompassedby the present disclosure, as demonstrated by the following examples.Many general references providing commonly known chemical syntheticschemes and conditions useful for synthesizing the disclosed compoundsare available (see, e.g., Smith and March, March's Advanced OrganicChemistry: Reactions, Mechanisms, and Structure, Fifth Edition,Wiley-Interscience, 2001; or Vogel, A Textbook of Practical OrganicChemistry, Including Qualitative Organic Analysis, Fourth Edition, NewYork: Longman, 1978).

Starting materials can be obtained from commercial sources or preparedby well-established literature methods known to those of ordinary skillin the art. The reactions are performed in a solvent appropriate to thereagents and materials employed and suitable for the transformationsbeing effected. It will be understood by those skilled in the art oforganic synthesis that the functionality present on the molecule shouldbe consistent with the transformations proposed. This will sometimesrequire a judgment to modify the order of the synthetic steps or toselect one particular process scheme over another in order to obtain adesired compound of the disclosure.

In some cases, protection of certain reactive functionalities may benecessary to achieve some of the above transformations. In general, theneed for such protecting groups as well as the conditions necessary toattach and remove such groups will be apparent to those skilled in theart of organic synthesis. An authoritative account describing the manyalternatives to the trained practitioner are J. F. W. McOmie,“Protective Groups in Organic Chemistry”, Plenum Press, London and NewYork 1973, in T. W. Greene and P. G. M. Wuts, “Protective Groups inOrganic Synthesis”, Third edition, Wiley, New York 1999, in “ThePeptides”; Volume 3 (editors: E. Gross and J. Meienhofer), AcademicPress, London and New York 1981, in “Methoden der organischen Chemie”,Houben-Weyl, 4.sup.th edition, Vol. 15/I, Georg Thieme Verlag, Stuttgart1974, in H.-D. Jakubke and H. Jescheit, “Aminosauren, Peptide,Proteine”, Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982,and/or in Jochen Lehmann, “Chemie der Kohlenhydrate: Monosaccharide andDerivate”, Georg Thieme Verlag, Stuttgart 1974. The protecting groupsmay be removed at a convenient subsequent stage using methods known fromthe art.

LC/MS analysis is conducted on an Agilent 1200 HPLC with a quadrupolemass analyzer. LC chromatography used an Agilent XDB-C18 column (4.6×50mm, 1.8 μm) with a water/acetonitrile (each with 0.2% (v/v) formic acid)gradient at a flow rate of 0.5 mL/min. HRMS analyses are performed atthe Duke MS Center. Thin-layer chromatography (TLC) is performed onSigma-Aldrich plates with a fluorescent indicator. Proton (¹H) andcarbon (¹³C) NMR spectra are recorded at 300 and 75 MHz, respectively,on a Varian Spectrometer. Chemistry shifts (δ) are reported in parts permillion (ppm) referenced to ¹H (TMS at 0.00), ¹³C (DMSO at 39.55, CDCl₃at 77.0, and CD₃OD at 49.0). Column chromatography is conducted usingeither silica gel (Silicycle 40-64 μm) or prepacked RediSep columns(Teledyne Isco Inc., Lincoln, Nebr.) on an Isco CombiFlash Rfinstrument. All moisture-sensitive reactions are carried out using drysolvents and under a slight pressure of ultra-pure quality argon.Glassware is dried in an oven at 140° C. for at least 12 h prior to use,and then assembled quickly while hot, sealed with rubber septa, andallowed to cool under a stream of argon. Reactions are stirredmagnetically using Teflon-coated magnetic stirring bars. Commerciallyavailable disposable syringes are used for transferring reagents andsolvents.

The disclosures of all articles and references mentioned in thisapplication, including patents, are incorporated herein by reference intheir entirety.

EXAMPLES

The preparation of the compounds of the disclosure is illustratedfurther by the following examples, which are not to be construed aslimiting the disclosure in scope or spirit to the specific proceduresand compounds described in them. In all cases, unless otherwisespecified, the column chromatography is performed using a silica gelsolid phase.

Example 1

2: To an oven-dried round bottom flask equipped with water cooled westcondenser and magnetic stir bar are added Methyl 4-iodobenzoate (10.48g, 40 mmol), bis triphenylphosphine) palladium (II) dichloride (1.404 g,2.0 mmol, 0.05 equiv) and copper (I) iodide (0.076 g, 4 mmol, 0.10equiv.). The vessel is then sealed with a rubber septum under argon andare added anhydrous THF (100 mL) and diisopropylethylamine (28 mL, 160mmol, 4 equiv). Finally, the (trimethylsily) acetylene (8 mL, 52 mmol,1.3 equiv) is added and the reaction mixture is heated by oil at 60 Cfor 22 h. The resulting dark solution is condensed to dryness with arotavapor, and the residue is treated with water (100 mL), extractedwith EtOAc (3×100 mL). The combined extracts are washed with water (50mL) and brine (anhydrous Na₂SO₄). The crude products are purified byflash chromatography (eluting with 50-60% DCM in hexane) to afford 2(7.9 g, 85.1%) yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 0.25 (s, 9H),3.90 (s, 3H), 7.51 (d, J=8.7 Hz, 2H), 7.96 (d, J=8.7 Hz, 2H); ¹³C NMR(75 MHz, CDCl₃) δ 0.06, 52.44, 79.90, 104.28, 127.98, 129.60, 129.90,132.09, 166.71; LC/MS m/s [M+Na]⁺ 255.1.

3: The silylatealkyne compound starting material (7.9 g, 34 mmol) isdissolved in anhydrous MeOH (150 mL), and then potassium carbonate(23.46 g, 170 mmol, 5 equiv) is added. The mixture is stirred for 3 hunder argon at room temperature. The mixture is added to water (150 mL)to quench the reaction. The mixture is extracted with diethyl ether(3×100 mL), and then the combined organic extracts are dried overanhydrous Na₂SO₄. The solvent is evaporated in vacuum to afford thecrude product, which is purified by chromatography (eluting with 25-30%DCM in hexane) to afford 3 (4.4 g, 80% yield) as brown solid. ¹H NMR(300 MHz, CDCl₃) δ 3.23 (s, 1H), 3.91 (s, 3H), 7.54 (d, J=8.7 Hz, 2H),7.98 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 52.20, 80.31, 83.01,126.96, 129.68, 130.34, 132.30, 166.63; LC/MS m/s [M+H]⁺ 161.2.

5: Copper (II) acetate (1.13 g, 6.2 mmol, 2 equiv) is added at roomtemperature and under stream of argon to a stirred solution of 3 (0.50g, 3.1 mmol) and 4-ethynylbenzenamin (2.64 g, 15.5 mmol, 5 equiv)dissolved in anhydrous pyridine (5 mL), and MeOH (5 mL), and the mixtureare stirred at room temperature for 24 h. The resulting blue solution iscondensed to dryness with a rotavapor, and the residue is treated withwater (50 mL), extracted with EtOAc (3×70 mL), and dried over anhydrousNa₂SO₄. The crude products are purified by flash chromatography (elutingwith 20-30% EtOAc in hexane) to afford 5 (0.30 g, 35% yield) as yellowsolid. ¹H NMR (300 MHz, DMSO-_(d6)) δ 3.83 (s, 3H), 5.85 (s, 2H), 6.54(d, J=8.1 Hz, 2H), 7.25 (d, J=8.4 Hz, 2H), 7.64 (d, J=8.1 Hz, 2H), 7.92(d, J=8.1 Hz, 2H); ¹³C NMR (75 Hz, DMSO-_(d6)) δ 53.04, 71.77, 78.29,80.49, 86.98, 105.73, 114.28, 126.74, 130.06, 130.32, 132.98, 134.76,151.64, 166.19; LC/MS m/s [M+H]⁺ 276.1.

6: A 3N solution of NaOH (10 mL) is added to stir solution of methylester (0.50 g, 1.82 mmol) in MeOH (100 mL) at room temperature. Thereaction solution is heated to reflux for 1 h. Then the reaction turnedclear. All of the starting material is gone by TLC. The reaction iscooled to room temperature and some MeOH is removed by evaporation underreduced pressure (50 mL). Water (20 mL) is added to the mixture. Conc.HCl is added dropwise to the stirred solution until acidic by pH paper(pH=2). The yellow precipitate that formed is collected by suctionfiltration. The solid is washed with water (2×20 mL) to give 6 (0.45 g,90% yield). ¹H NMR (300 MHz, DMSO-_(d6)) δ 6.95 (d, J=8.4 Hz, 2H), 7.45(d, J=8.4 Hz, 2H), 7.66 (d, J=8.4 Hz, 2H), 7.93 (d, J=8.4 Hz, 2H); ¹³CNMR (75 MHz, DMSO-_(d6)) δ 72.99, 77.22, 81.23, 85.02, 112.00, 118.79,125.80, 130.24, 131.93, 133.07, 134.64, 144.23, 167.19; LC/MS m/s [M+H]⁺262.1.

8: Benzl chloroformate (2.42 g, 14.2 mmol, 1.10 equiv) is added dropwiseto a stirred mixture of α-Amino-γ-butyrolactone hydroxybromide (2.35 g,12.9 mmol) in anhydrous THF (20 mL) under argon. The mixture is cooledto 0° C., triethylamino (2.61 g, 25.8 mmol, 2.00 equiv) is addeddropwise. The whole reaction mixture is stirred at 0° C. for 1 h, thenallowed to warm to room temperature with the stirring is continued for16 h. The resulting suspension solution is concentrated to dryness andthe residue is treated with water (50 mL). The mixture is acidified topH=3 with 3N HCl, and extracted with EtOAc (3×70 mL). The combinedorganic layers are washed with brine (50 mL), and dried (anhydrousNa₂SO₄). Evaporation of the solvent affords viscous oil, which ispurified by CombiFlash (eluting with EtOAc in hexane 0-40%) to give 8(2.638 g, 87% yield) as white solid. ¹H (300 MHz, CDCl₃) δ 2.12-2.21 (m,1H), 2.64-2.73 (m, 1H), 4.15-4.24 (m, 1H), 4.39 (t, J=17.4 Hz, 2H), 5.10(s, 2H), 5.51 (d, J=5.1 Hz, 1H), 7.26-7.73 (m, 5H); ¹³C (75 MHz, CDCl₃)δ 30.26, 50.66, 66.00, 67.53, 128.40, 128.55, 128.82, 136.17, 156.38,175.40; LC/MS m/s [M+H]⁺ 236.1.

9: A solution of sodium hydroxide (0.44 g, 11.1 mmol, 1.00 equiv) inanhydrous methanol (15 mL) is added to a stirred suspension of the 8(2.60 g, 11.1 mmol) in anhydrous methanol (10 mL). The whole mixture isstirred at room temperature under argon for 3 h. The resulting solutionis concentrated to dryness as a white solid. The carboxylate salt isdissolved in anhydrous dimethylformamide (20 mL) and benzyl bromide(1.90 g, 11.1 mmol, 1.00 equiv) is added. The mixture is stirred at roomtemperature under argon for 36 h, and then concentrated to dryness. Theresidue is treated with water (50 mL), extracted with ether (3×80 mL).The ether layers are washed with 1N HCl (50 mL), water (50 mL), brine(50 mL), and dried (anhydrous Na₂SO₄). Evaporation of the solventaffords a solid, which is purified by CombiFlash (eluting with EtOAc inhexane 0-40%) to give 9 (3.23 g, 85% yield) as white solid. ¹H (300 MHz,CDCl₃) δ 1.67-1.78 (m, 1H), 2.10-2.21 (m, 1H), 2.93 (t, J=12.0 Hz, 1H),3.58-3.75 (m, 2H), 4.55-4.62 (m, 1H), 5.11 (s, 2H), 5.18 (s, 2H), 5.79(d, J=7.8 Hz, 1H), 7.29-7.35 (m, 5H); ¹³C (75 MHz, CDCl₃) δ 35.75,51.61, 58.58, 67.52, 67.62, 128.41, 128.82, 128.89, 135.38, 136.28,157.04, 172.63; LC/MS m/s [M+H]⁺ 344.3.

10: Anhydrous dimethylsulphoxide (DMSO) (1.45 ml, 20.38 mmol, 2.20equiv) in dichloromethane (10 mL) is added dropwise to a stirredsolution of oxalylchloride (5.10 mL, 10.19 mmol, 1.10 equiv) at −78° C.under argon. The solution is stirred for 20 min, and then the alcohol(3.18 g, 9.26 mmol) in dichloromethane (15 mL) is added over 3 min. Theresulting slurry is stirred for 15 min and anhydrous triethylamine (6.45mL, 46.3 mmol, 5.00 equiv) is added. The mixture is stirred for anadditional 5 min at −78° C., then is allowed to warm to room temperaturefor 10 min. The whole mixture is concentrated to dryness, and theresidue is treated with water (50 mL), extracted with EtOAc (3×80 mL).The organic layers are washed with brine (50 mL), dried (anhydrousNa₂SO₄). Evaporation of the solvent affords the crude product, which ispurified by CombiFlash (eluting with EtOAc in hexane 0-30%) to give 10(2.76 g, 87%) as a white solid. ¹H (300 MHz, CDCl₃) δ 3.08 (q, J=54.9Hz, 2H), 4.67-4.73 (m, 1H), 5.10 (s, 2H), 5.21 (s, 2H), 5.78 (d, J=8.4Hz, 1H), 7.29-7.38 (m, 10H), 9.67 (s, 1H); ¹³C (75 MHz, CDCl₃) δ 45.99,49.38, 67.40, 67.91, 128.35, 128.54, 128.80, 128.88, 135.28, 136.28,156.19, 170.81, 199.43; LC/MS m/s [M+H]⁺ 342.3.

11: To a solution of 10 (2.74 g, 8.0 mmol) in anhydrous pyridine (10 mL)and methanol (10 mL) is added hydroxylamine hydrochloride (0.97 g, 14.0mmol, 1.75 equiv). The reaction mixture is stirred at room temperatureunder argon for 3 h, and then concentrated to dryness. The residue ispurified by CombiFlash (elution with EtOAc in hexane 0-30%) to give 11(2.78 g, 98% yield) as white solid. ¹H (300 MHz, CDCl₃) δ 2.69 (t,J=12.0 Hz, 1H), 2.87 (t, J=12.9 Hz, 1H), 4.62 (t, J=14.1 Hz, 1H), 5.10(d, J=2.4 Hz, 2H), 5.18 (d, J=3.6 Hz, 2H), 5.81 (d, J=8.1 Hz, 1H), 5.97(d, J=8.7 Hz, 1H), 6.76 (t, J=10.5 Hz, 1H), 7.27-7.34 (m, 10H); ¹³C (75MHz, CDCl₃) δ 28.42, 32.53, 51.950, 67.40, 67.82, 128.39, 128.61,128.79, 128.89, 135.30, 136.29, 147.24, 156.31, 171.56; LC/MS m/s [M+H]⁺357.4.

12: To a solution of a mixture of oximes 11 (1.81 g, 5.08 mmol) inanhydrous methanol (30 mL) is added NaBH₃CN (321 mg, 5.1 mmol, 1.00equiv) and the reaction mixture is stirred at room temperature underargon for 1.5 h. The pH of the solution during the period of thereaction is kept at 2-3 by addition of methanolic HCl (1N) solutionduring the period of the reaction. The reaction mixture is neutralizedwith 1N NaOH and concentrated to dryness. The residue is dilute by water(50 mL), extracted with CHCl₃ (3×80 mL), and dried (anhydrous Na₂SO₄).Evaporation of the solvent affords the crude product, which is purifiedby CombiFlash (eluting with MeOH in DCM 0-7%) to give 12 (440 mg, 35%yield) as white solid. ¹H (300 MHz, CD₃OD) δ 1.90-2.03 (m, 1H),2.36-2.47 (m, 1H), 3.47-3.58 (m, 2H), 4.258 (t, J=18.3 Hz, 1H), 5.08 (s,2H), 7.28-7.35 (m, 5H); ¹³C (75 MHz, CD₃OD) δ 23.97, 46.20, 50.19,66.51, 127.72, 127.85, 128.30, 136.95, 157.22, 168.18; LC/MS m/s [M+H]⁺251.1.

13: To a mixture of 30% HBr in acetic acid (0.78 mL) and trifluoroaceticacid (0.32 mL) is added pyrrolidone 12 (200 mg, 0.80 mmol), and themixture is stirred at room temperature for 70 min. Ether (50 mL) isadded to the reaction and the resulting precipitate is filtered off. Theprecipitate is dissolved in milliQ water (2 mL) and passed through acolumnfilled with Dowex 50W×4 (H⁺) (sigma) (10 g), eluting with milliQwater (200 mL), then 1N NH₃ solution (200 mL). The eluent isconcentrated in vacuum to give 13 (83 mg, 89% yield) as white solid. ¹H(300 MHz, D₂O) δ 1.71-1.81 (m, 1H), 2.28-2.32 (m, 1H), 3.37-3.41 (m,2H), 3.74 (t, J=16.5 Hz, 1H); ¹³C (75 MHz, D₂O) δ 22.32, 48.09, 49.91,163.03; LC/MS m/s [M+H]⁺ 117.1.

CPD-043: To a stirred of amine 13 (40 mg, 0.345 mmol) and acid (108 mg,0.414 mmol, 1.20 equiv) in anhydrous DMF (1.5 mL) is added EDC.HCl (79.1mg, 0.414 mmol, 1.20 equiv), and HOBt (55.9 mg, 0.414 mmol, 1.20 equiv)at room temperature. The mixture is cooled with an ice-bath to 0° C.,and the DIPEA (0.24 mL, 1.38 mmol, 4.0 equiv). The whole mixture isstirred under argon at 0° C. for 1 h, then allowed to warm to ambienttemperature with the stirring is continued for additional 36 h. Theresulting yellow solution is concentrated to dryness. The residue istreated with water (10 mL), extracted with EtOAc (3×50 mL). The organiclayers are washed with 1N NaOH (10 mL), brine (50 mL), and dried(anhydrous Na₂SO₄). Evaporation of the solvent affords the crudeproduct, which is purified by CombiFlash (eluting with MeOH in DCM0-10%) to give CPD-043,4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-2-oxopyrrolidin-3-yl)benzamide(43 mg, 35%) as yellow solid. ¹H (300 MHz, DMSO-_(d6)) δ 1.91-2.01 (m,1H), 2.27-2.36 (m, 1H), 3.42-3.47 (m, 2H), 4.53 (q, J=26.7 Hz, 2H), 5.84(s, 2H), 6.52 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.63 (d, J=8.4Hz, 2H), 7.85 (d, J=8.4 Hz, 2H), 8.92 (d, J=8.4 Hz, 1H), 9.81 (s, 1H);¹³C (75 MHz, DMSO-_(d6)) δ 24.18, 46.59, 48.97, 71.79, 77.36, 80.79,86.40, 105.78, 114.25, 124.84, 128.33, 130.19, 132.73, 134.72, 151.57,165.80, 167.33; LC/MS m/s [M+H]⁺ 360.2.

Example 2

CPD-044,(R)-4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-2-oxopyrrolidin-3-yl)benzamide

CPD-044: Following the procedure of CPD-043: ¹H (300 MHz, DMSO-_(d6)) δ1.91-2.01 (m, 1H), 2.27-2.36 (m, 1H), 3.42-3.47 (m, 2H), 4.53 (q, J=26.7Hz, 2H), 5.84 (s, 2H), 6.52 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H),7.63 (d, J=8.4 Hz, 2H), 7.85 (d, J=8.4 Hz, 2H), 8.92 (d, J=8.4 Hz, 1H),9.81 (s, 1H); ¹³C (75 MHz, DMSO-_(d6)) δ 24.18, 46.59, 48.97, 71.79,77.36, 80.79, 86.40, 105.78, 114.25, 124.84, 128.33, 130.19, 132.73,134.72, 151.57, 165.80, 167.33; LC/MS m/s [M+H]⁺ 360.2.

Example 3

Oxazolidinone 16. A suspension of L-Valine (7.0 g, 59.8 mmol) inanhydrous ethanol (400 mL) is treated with a solution of NaOH (2.5 g,59.8 mmol, 1.00 equiv) in H₂O (8 mL). The resultant mixture homogenizedwhile stirring at room temperature for 30 min. After evaporation of mostof the solvent in vacuo, the oily concentrate is diluted with pentane(300 mL). t-But CHO (8.61 mL, 74.34 mmol, 1.50 equiv) is then added andthe mixture heated at reflux under a Dean-Stark trap until H₂Ogeneration ceased (ca. 48 h). The mixture is cooled to room temperatureand concentrated in vacuo, affording a white powder, which is driedazeotropically with toluene (3×200 mL) and stored under vacuumovernight. A suspension of the dried salt in DCM (200 mL) is cooled to0° C., allyl chloroformate (9.40 mL, 89.7 mmol, 1.50 equiv) is added,and the slurry is stirred at 5 OC for 14 days. After dilution with H₂0(200 mL), DMAP (50 mg) is introduced to catalyze the hydrolysis ofexcess chloroformate. The mixture is stirred for 24 h and then extractedwith EtOAc (1 L). The organic layer is washed with I0% aqueousNaHSO₄(100 m mL), saturated aqueous NaHCO₃ (100 mL), and brine (200 mL each),dried over MgS04, and concentrated in vacuo. The crude product ispurified by CombiFlash (eluting with EtOAc in hexane 0-10%) to obtain 16as solid. 12.5 g (2 steps 78% yield).

Prenyloxazolidinone 18. A solution of oxazolidinone 16 (12.0 g, 44.6mmol) in anhydrous THF (150 mL) is cooled to −78° C., and 0.5 M KHMDS intoluene (107.0 mL, 53.52 mmol, 1.20 equiv) is added via a droppingsyringe at a rate that maintained an internal temperature of −70° C. Theresultant yellow solution is stirred for 15 min and then treateddropwise with I-bromo-3-methyl-2-butene (13.3 mL, 89.2 mmol, 2.00equiv), again maintaining an internal temperature no higher than −70° C.The reaction is stirred 30 min future at −78° C. and quenched at lowtemperature (−78° C.) with 10% aqueous NaHSO₄ (300 mL). Followingextraction with EtOAc (2×100 mL), the combined organic layers are washedwith 10% aqueous NaHSO₄ (2×200 mL), saturated aqueous NaHCO₃ (200 mL),and brine (200 mL), dried over Na₂SO₄, and concentrated in vacuo. Thecrude product is purified by CombiFlash (eluting with EtOAc in hexane0-10%) affords 18 (8.77 g, 58% yield) as colorless oil:

Alloc-Protected Amino Ester 20. A solution of oxazolidinone 18 (8.5 g,25.2 mmol) in a mixture of methanol (50 mL) and 1 N aqueous NaOH (50 mL)is heated at reflux for 18 h. The mixture is cooled to room temperatureand concentrated in vacuo, and the resultant mixture is acidified with10% aqueous NaHSO₄ to pH=1 and then extracted with EtOAc (3×50 mL). Thecombined organic phases are washed with H₂0 (50 mL) and brine (50 mL),dried over Na₂SO₄, and concentrated in vacuo. A solution of the cruderesidue in DMF (30.0 mL) is treated with anhydrous K₂CO₃ (6.88 g) andcooled to 0° C. Iodomethane (10.80 mL, 75.6 mmol, 3.00 equiv) is slowlyadded and the resultant yellow mixture stirred at 0° C. for 30 min andat room temperature for 30 min. The reaction mixture is quenched withH₂0 (30 mL) and extracted with ether (2×100 mL). The combined extractsare washed with H₂O (4×50 mL), saturated aqueous NaHCO₃ (50 mL), andbrine (50 mL), dried over Na₂SO₄, and concentrated in vacuo. The crudeproduct is purified by CombiFlash (eluting with EtOAc in hexane 0-10%)to give 20 as a colorless oil. (4.96 g, 70% yield).

Primary Amine 21. A mixture of alloc derivative 20 (4.90 g, 17.3 mmol),dimedone (12.13 g, 86.5 mmol, 5.00 equiv), and Pd(PPh₃)₄ (100 mg, 0.087mmol, 0.05 equiv) in THF (50 mL) is stirred at room temperature for 16h. Following dilution with ether (200 mL) and extraction with 1 N HCl(5×75 mL), the combined aqueous layers are made basic by addition ofsolid K₂CO₃, and additional base is added to facilitate extraction ofthe product. The resultant mixture is extracted with EtOAc (3×100 mL),and the combined organic layers are washed with saturated aqueous NaHCO₃(100 mL) and brine (100 mL), dried over Na₂SO₄, and concentrated invacuo. The crude product is purified by CombiFlash (eluting with EtOAcin hexane 0-20%) to obtain 21 as a colorless oil (3.30 g, 97% yield).

Boc Derivative 22. A solution of amine 21 (3.00 g, 15.0 mmol) anddi-tert-butyl dicarbonate (3.95 g, 18.1 mmol, 1.20 equiv) in THF (20 mL)is heated at reflux for 16 h and then allowed to cooled H₂O (30 mL) andDMAP (50 mg) are added to hydrolyze excess dicarbonate. After 30 min themixture is extracted with EtOAc (2×50 mL), and the combined organiclayers are washed with 10% aqueous NaHSO₄, saturated aqueous NaHCO₃ (50mL), and brine (2×25 mL), dried over MgSO₄, and concentrated in vacuo.The crude product is purified by CombiFlash (eluting with EtOAc in DCM0-10%) to give 22 (2.40 g, 53% yield) as clear colorless oil.

Aldehyde 23. A solution of 22 (1.00 g, 3.30 mmol) and sudan II (10 mg)in DCM (20 mL) is cooled to −78° C., and ozone is bubbled into thereaction until a red color disappeared (5 min). After excess ozone ispurged with argon, Dimethyl sulfide (1.0 mL, 1.33 mmol) is added and thesolution is allowed to warm to room temperature. After 2 h, the yellowsolution is concentrated in vacuo to give 23 as yellow oil. The productis going to next step without future purification.

Oxime 24: To a solution of 23 (0.90 g, 8.0 mmol) in anhydrous pyridine(10 mL) and ethanol (0.10 mL) is added hydroxylamine hydrochloride (0.80g, 9.9 mmol, 3.5 equiv). The reaction mixture is stirred at roomtemperature under argon for 3 h, and then concentrated to dryness. Theresidue is purified by CombiFlash (elution with MeOH in DCM 0-2%) togive 24 as yellow oil (0.90 g, 95.0% yield).

25: To a solution of a mixture of oximes 24 (0.300 g, 1.04 mmol) inanhydrous methanol (10 mL) is added NaBH₃CN (66 mg, 1.04 mmol, 1.00equiv) and the reaction mixture is stirred at room temperature underargon for 40 min. The pH of the solution during the period of thereaction is keep at 2-3 by addition of methanolic HCl (1N) solutionduring the period of the reaction. The reaction mixture is neutralizedwith 1N NaOH and concentrated to dryness. The residue is dilute by water(20 mL), extracted with CHCl₃ (3×80 mL), and dried (anhydrous Na₂SO₄).Evaporation of the solvent affords the crude product, which is purifiedby CombiFlash (eluting with MeOH in DCM 0-5%) to give 25 (245 mg, 91%yield) as colorless oil.

26: A solution of 25 (100 mg, 0.34 mg) in anhydrous Methanol (10 mL) isadded sodium methoxide in MeOH (0.11 mL, 0.41 mmol, 1.20 equiv, 25% inmethanol). The reaction mixture is stirred at reflux for 3 h underargon. Then the reaction mixture is condensed to dryness and dilutedwith water (20 mL). The residue is treated with 0.1 N HCl to pH 7,extracted with DCM (3×50 mL). The combined organic layers are washedbrine (30 mL), dried (anhydrous Na₂SO₄). The crude product is purifiedby CombiFlash (eluting with MeOH in DCM 0-5%) to give the 26 as whitsolid (90 mg, 93% yield).

27: To a solution of 26 in anhydrous DCM (4 mL) is added trifluoroaceticacid (1 mL) under argon at room temperature. The reaction mixture isstirred for 80 min. Then the solution is concentrated to dryness. Theresidue is dissolved in milliQ water (2 mL) and passed through acolumnfilled with Dowex 50W×4 (H⁺) (sigma) (10 g), eluting with milliQwater (200 mL), then 1N NH₃ solution (200 mL). The eluent isconcentrated in vacuum to give 27 (53.0 mg, 96% yield) as white solid.

CPD-048: To a stirred of 27 (40.0 mg, 0.25 mmol) and 6 (91.2 mg, 0.35mmol, 1.40 equiv, prepared as in Example 1) in anhydrous DMF (1.0 mL) isadded EDC.HCl (67.0 mg, 0.35 mmol, 1.40 equiv), HOBt (47.0 mg, 0.35mmol, 1.40 equiv) at room temperature. The mixture is cooled with anice-bath to 0° C., and the DIPEA (0.24 mL, 1.25 mmol, 5.0 equiv). Thewhole mixture is stirred under argon at 0° C. for 1 h, then allowed towarm to ambient temperature with the stirring is continued foradditional 20 h. The resulting yellow solution is concentrated todryness. The residue is treated with water (10 mL), extracted with EtOAc(3×50 mL). The organic layers are washed with 1N NaOH (10 mL), brine (50mL), and dried (anhydrous Na₂SO₄). Evaporation of the solvent affordsthe crude product, which is purified by CombiFlash (eluting with MeOH inDCM 0-10%) to give CPD-048 (48.1 mg, 40%) as yellow solid. ¹H NMR (300MHz, CDCl₃) δ 0.98 (d, J=6.6 Hz, 3H), 1.04 (d, J=6.9 Hz, 3H), 1.25 (s,1H), 1.81-1.95 (m, 1H), 1.95-2.04 (m, 1H), 2.26-2.35 (m, 1H), 3.61-3.68(m, 1H), 3.70-3.77 (m, 1H), 3.95 (br, s, 2H), 6.59 (d, J=8.7 Hz, 2H),7.33 (d, J=8.7 Hz, 2H), 758 (d, J=9.0 Hz, 2H), 8.03 (d, J=8.7 Hz, 2H);¹³C NMR (75 MHz, CDCl₃) δ 16.12, 17.86, 34.33, 44.99, 59.94, 71.93,78.81, 79.65, 85.41, 110.23, 114.82, 126.40, 128.80, 130.28, 132.65,134.49, 148.17, 163.36, 173.35; LC/MS m/s [M+H]⁺ 402.6.

Example 4

29: A solution of p-toluenesulfonyl chloride (74.36 g, 0.39 mol, 1.5equiv) in anhydrous pyridine (300 mL) is dropwise added3-methyl-3-oxetane-methanol (26.52 g, 0.26 mol) over 10 min at 0° C.under argon. After 5 min, the reaction mixture is allowed to warm toroom temperature with the stirring is continued for an additional 1.5 h.The mixture is then slowly added to a vigorously stirring mixture ofmilliQ water 800 mL and crushed ice 800 g for 30 min. Then the whiteprecipitate is collected on whatman filter #1 and washed with cold water(300 mL). The product is dried under high vacuum to obtain a white powerof oxetane tosylate 29 (47.88 g 72% yield). ¹H NMR (300 MHz, CDCl₃) δ1.28 (s, 3H), 2.43 (s, 3H), 4.08 (s, 2H), 4.29-4.35 (m, 2H), 7.34 (d,J=7.8 Hz, 2H), 7.78 (d, J=7.5 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 20.85,21.86, 39.45, 74.50, 79.13, 128.15, 130.22, 132.81, 145.34; LC/MS m/s[M+H]⁺ 164.9.

31: Cbz-L-Ser (29.60 g, 0.167 mol), 3-methyl-(3-tosylmethyl oxetane) 29(29.95 g, 0.125 mol), tetrabutylammonium iodide (2.30 g, 0.06 mol, 0.05equiv), TEA (14.04 g, 0.138 mol, 1.1 equiv) and anhydrous DMF (100 mL)are combined in an oil bath and slowly heated to 70° C. for 36 h underargon. The reaction mixture is allowed to cool to room temperature, andthe DMF is removed under reduced pressure. The remaining residue isdissolved in 1.00 L of EtOAc, washed with 1.0 N HCl (2×250 mL),saturated NaHCO₃ (2×250 mL), brine (250 mL), and dried (anhydrousNa₂SO₄). The solvent is removed under reduced pressure, and theremaining residue is purified by CombiFlash (eluting with 0-50% EtOAc inhexane) to give 31 (25.20 g, 64% yield) as pale yellow oil. ¹H NMR (300MHz, CDCl₃) δ 1.26 (s, 3H), 3.34 (br, s, 1H), 3.84-3.87 (m, 1H),4.02-4.07 (m, 2H), 4.35-4.52 (m, 6H), 5.11 (s, 2H), 5.94 (d, J=7.5 Hz,1H), 7.26-7.33 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 20.98, 39.70, 56.57,63.39, 67.34, 69.18, 79.66, 128.33, 128.44, 128.75, 136.38, 156.51,170.98; LC/MS m/s [M+H]⁺ 324.1.

32: Cbz-L-Ser-oxetane ester 31 (11.00 g, 34.00 mmol) is dissolved inanhydrous DCM (100 mL) and is cooled to 0° C. under argon. BF₃.Et₂O(0.13 mL, 0.92 mmol, 0.03 equiv) is diluted in DCM (5.0 mL) and added tothe reaction flask. The reaction mixture is allowed to warm to roomtemperature. After 5 h, Et₃N (1.40 mL, 9.86 mmol, 0.3 equiv) is addedwith the sitting is continued for an additional 30 min. Then the resultsolution is concentrated to dryness to thick oil. The crude product ispurified by CombiFlash (eluting with 0-5% MeOH in DCM) to afford 32(6.90 g, 62.7% yield) as whit foam. ¹H NMR (300 MHz, CDCl₃) δ 0.78 (s,3H), 2.64 (q, J=12.6 Hz, 1H), 3.62-3.95 (m, 9H), 5.03-5.14 (m, 2H), 5.37(d, J=9.0 Hz, 1H), 7.26-7.34 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 14.48,30.76, 55.60, 62.14, 67.12, 72.90, 108.68, 128.28, 128.36, 128.69,136.69, 156.67; LC/MS m/s [M+H]⁺ 324.1.

33: Cbz-L-Ser OBO ester 32 (6.87 g, 21.27 mmol) is dissolved inanhydrous DCM (100 mL) under argon and cooled to −78° C. in flask I.Oxalyl chloride (17.00 mL, 2.0 M in DCM, 70.19 mmol, 1.6 equiv) is addedto anhydrous DCM (100 mL) in a separate flask II under argon and cooledto −78° C. Anhydrous DMSO (5.36 mL, 70.19 mmol, 3.30 equiv) is added tothe oxalyl chloride solution (flask II), and the mixture stirred at −78°C. for 15 min. The alcohol solution is transferred by syringe at −78° C.to the flask II over a period of 20 min. The resulting cloudy whitemixture is stirred for 1.5 h at −78° C. DIPEA (18.44 mL, 106.35 mmol,5.0 equiv) is added and the solution is stirred for 30 min at −78° C.and 10 min at 0° C. Ice-cold DCM (200 mL) is added, and the solution iswashed with ice-cold 3% NH₄Cl (3×200 mL), brine (200 mL), dried(anhydrous Na₂SO₄). The crude product is crystallized from DCM/Hexane toobtain 33 (4.3 g, 63% yield) as yellow solid. ¹H NMR (300 MHz, CDCl₃) δ0.81 (s, 3H), 3.93 (s, 6H), 4.60 (d, J=8.7 Hz, 1H), 5.12 (s, 2H), 5.36(d, J=8.7 Hz, 1H), 7.26-7.40 (m, 5H), 9.68 (s, 1H); ¹³C NMR (75 MHz,CDCl₃) δ 14.47, 31.09, 63.50, 67.43, 73.12, 107.40, 128.36, 128.70,136.40, 156.42, 159.90; LC/MS m/s [M+H]⁺ 307.4.

35: Cbz-L-Ser(ald)-OBO ester 33 (1.60 g, 5.00 mmol) is dissolved inanhydrous DCM (20 mL) under argon. A solution of 4-Benzyloxyphenylmagnesium bromide in THF (20 mL, 20 mmol, 4.00 equiv) is added quicklyby syringe at ice-bath and stirred vigorously. After 3 min, the reactionmixture is allowed to warm to room temperature with stirring iscontinued for 70 min. Then the reaction mixture is quenched by sat.NH₄Cl 300 mL (pH=7) and is stirred for an additional 15 min. The mixtureis extracted with DCM (3×80 mL). The combined organic layers are washedwith brine (50 mL), dried (anhydrous Na₂SO₄). The crude product ispurified by CombiFlash (eluting with 0-7% EtOAc in DCM) to give 35(0.272 g, 54.0% yield) as foam solid. ¹H NMR (300 MHz, CDCl₃) δ 0.83 (s,3H), 3.36 (s, 1H), 3.98 (s, 6H), 4.07 (d, J=10.5 Hz, 1H), 4.88-5.08 (m,5H), 5.48 (d, J=10.5 Hz, 1H), 6.91 (d, J=9.0 Hz, 2H), 7.22-7.46 (m,12H); ¹³C NMR (75 MHz, CDCl₃) δ 14.56, 30.93, 58.87, 66.76, 70.16,70.65, 73.06, 109.04, 114.72, 127.36, 127.77, 127.99, 128.14, 128.63,128.80, 132.84, 136.99, 137.414, 156.61, 158.33; LC/MS m/s [M+H]⁺ 506.2

36: 35 (0.74 g, 1.47 mmol) is dissolved in anhydrous DCM (10 mL) underargon and cooled to −78° C. in flask I. Oxalyl chloride (1.20 mL, 2.0 Min DCM, 2.40 mmol, 1.6 equiv) is added to anhydrous DCM (10 mL) in aseparate flask II under argon and cooled to −78° C. Anhydrous DMSO (0.34mL, 4.85 mmol, 3.30 equiv) is added to the oxalyl chloride solution(flask II), and the mixture stirred at −78° C. for 15 min. The alcoholsolution is transferred by syringe at −78° C. to the flask II over aperiod of 20 min. The resulting cloudy white mixture is stirred for 2 hat −78° C. DIPEA (1.28 mL, 7.35 mmol, 5.0 equiv) is added and thesolution is stirred for 30 min at −78° C. and 10 min at 0° C. Ice-coldDCM (100 mL) is added, and the solution is washed with ice-cold 3% NH₄Cl(3×50 mL), brine (100 mL), dried (anhydrous Na₂SO₄). The crude productis purified by CombiFlash (eluting with 0-40% EtOAc in hexane) to give36 (0.62 g, 84% yield) as white foam. ¹H NMR (300 MHz, CDCl₃) δ 0.75 (s,3H), 3.86 (s, 6H), 5.10 (s, 2H), 5.13 (s, 2H), 5.55 (d, J=9.3 Hz, 1H),5.95 (d, J=9.3 Hz, 1H), 7.00 (d, J=9.0 Hz, 2H), 7.27-7.45 (m, 10H), 8.06(d, J=9.0 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 14.48, 30.90, 57.35, 67.23,70.37, 73.17, 107.60, 114.60, 127.76, 128.30, 128.48, 128.67, 128.93,129.91, 132.120, 136.43, 136.60, 156.16, 163.22, 193.49; LC/MS m/s[M+H]⁺ 504.1.

37: 36 (0.80 g, 1.60 mmol) is dissolved in anhydrous DCM (4 mL) underargon. A solution of methyl magnesium bromide in Et₃O (3.0 M, 3.10 mL,9.26 mmol, 5.8 equiv) is added quickly by syringe at ice-bath andstirred vigorously. After 3 min, the reaction mixture is allowed to warmto room temperature with stirring is continued for 10 h. Then thereaction mixture is quenched by sat. NH₄Cl 100 mL (pH=7) and is stirredfor an additional 15 min. The mixture is extracted with DCM (3×50 mL).The combined organic layers are washed with brine (50 mL), dried(anhydrous Na₂SO₄). The crude product is purified by CombiFlash (elutingwith 0-50% EtOAc in hexane) to give 37 (0.81 g, 98% yield) as whitesolid. ¹H NMR (300 MHz, CDCl₃) δ 0.73 (s, 3H), 1.50 (s, 3H), 3.73 (s,3H), 3.71-3.80 (m, 6H), 4.22 (d, J=10.2 Hz, 1H), 4.98-5.14 (m, 4H), 5.33(d, J=10.5 Hz, 1H), 6.90 (d, J=8.7 Hz, 2H), 7.28-7.43 (m, 12H); ¹³C NMR(75 MHz, CDCl₃) δ 14.45, 27.17, 30.62, 61.09, 66.96, 70.13, 72.60,76.04, 109.50, 113.93, 126.76, 127.11, 127.76, 128.12, 128.68, 128.75,136.90, 137.51, 138.83, 156.60, 157.49; LC/MS m/s [M+H]⁺ 520.2.

38: To a solution of 37 (0.62 g, 1.2 mmol) in anhydrous MeOH (10 mL) isadded 10% Pd/C (62.0 mg, 10%) at room temperature under a balloon ofhydrogen. The reaction mixture is stirred for 14 h. Then the catalyst isremoved by filtration through a celite pad and washed with MeOH (50 mL).The filtrate is evaporated under reduced vacuo to obtain the 37 (0.343g, 97% yield) as white solid, which is going to next step without futurepurification. ¹H NMR (300 MHz, CD₃OD) δ 0.77 (s, 3H), 1.60 (s, 3H), 2.96(s, 1H), 3.86 (s, 6H), 6.73 (d, J=8.7 Hz, 2H), 7.26 (d, J=8.7 Hz, 2H);¹³C NMR (75 MHz, CD₃OD) δ 12.98, 24.07, 30.11, 62.99, 72.29, 75.52,109.59, 114.24, 127.21, 136.78, 16.25; LC/MS m/s [M+H]⁺ 296.1.

39: To a stirred mixture of 38 (218 mg, 0.83 mmol) and 6 (295 mg, 1.00mmol, 1.20 equiv, prepared as in Example 1) in anhydrous DMF (5 mL) isadded N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDChydrochloride) (192 mg 1.00 mmol, 1.20 equiv), 1-hydroxybenzotriazole(HOBt) (135 mg, 1.00 mmol, 1.20 equiv) at room temperature. The mixtureis cooled with an ice-bath, and diisopropylethylamine (DIEA) (0.58 mL,3.33 mmol, 5.0 equiv) is added. The whole reaction mixture is stirredunder argon and at 0° C. for 1 h, then allowed to warm to temperaturewith the stirring is continued for additional 24 h. The resulting yellowsolution is condensed to dryness with a rotavapor, and the residue istreated with water (20 mL), extracted with DCM (3×50 mL). The combinedextracts are washed with brine (20 mL), and dried over anhydrous Na₂SO₄.Evaporation of the solvent affords the crude products, which is purifiedby CombiFlash (eluting with 0-10% MeOH in DCM) to afford 39 (350 mg, 78%yield) as yellow solid. ¹H NMR (300 MHz, DMSO-_(d6)) δ 0.70 (s, 3H),1.50 (s, 3H), 3.78 (s, 6H), 4.42 (d, J=8.7 Hz, 1H), 4.53 (s, 1H), 5.82(s, 1H), 6.53 (d, J=8.4 Hz, 4H), 7.18 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.4Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.68-7.73 (m, 3H), 9.00 (s, 1H); ¹³CNMR (75 MHz, DMSO-_(d6)) δ 14.29, 27.15, 30.57, 49.29, 60.06, 71.80,72.32, 75.56, 77.08, 80.89, 86.26, 105.86, 109.45, 114.27, 124.39,127.54, 132.44, 134.68, 135.48, 137.60, 151.54, 155.96, 165.50; LC/MSm/s [M+H]⁺ 539.4.

40: 39 (60.0 mg, 0.10 mmol) is dissolved in dioxane (2.0 mL). Themixture is diluted with acetic acid (2.0 mL) and water (2.0 mL) at roomtemperature under argon. The suspension mixture is stirred for 1 h. Thenthe yellow clear solution is concentrated to dryness. The residue istreated with saturated NaHCO₃ (20 mL) to pH=10, extracted with EtOAc(3×40 mL). The combined organic layers are washed with water (2×30 mL),brined (30 mL), and dried (anhydrous Na₂SO₄). The solvent is removed byrotavapor to give the 40 (61.4 mg, 99% yield) as yellow solid, which isgoing to next step without future purification. ¹H NMR (300 MHz, CD₃OD)δ 0.65 (s, 3H), 1.57 (s, 3H), 3.17-3.26 (m, 4H), 3.70 (d, J=10.8 Hz,1H), 3.93 (d, J=11.1 Hz, 1H), 5.06 (s, 1H), 6.62 (d, J=8.7 Hz, 2H), 6.79(d, J=8.7 Hz, 2H), 7.25 (d, J=9.0 Hz, 2H), 7.36 (d, J=8.7 Hz, 2H), 7.59(d, J=8.7 Hz, 2H), 7.83 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ15.52, 27.12, 40.38, 61.79, 64.47, 67.39, 70.80, 75.32, 76.80, 78.98,84.68, 108.33, 114.24, 114.82, 126.20, 126.35, 127.51, 132.19, 133.84,135.88, 150.20, 156.50, 168.00, 170.56; LC/MS m/s [M+H]⁺ 557.2.

CPD-051: 40 (55.6 mg, 0.10 mmol) is taken into a mixture of THF/MeOH(1:1 volume) 2.0 mL. 50% aq hydroxylamine (0.20 mL, 3.0 mmol, 30 equiv)is added and followed by potassium cyanide (6.5 mg, 0.10 mmol, 1.0equiv) at room temperature under argon. The reaction mixture is stirredroom temperature for 14 h. Then the yellow solution is concentrated todryness. The residue is treated water (30 mL), extracted with EtOAc(3×50 mL). The combined organic layers are washed with water (5×30 mL),brine (30 mL), and dried (anhydrous Na₂SO₄). The crude product ispurified by CombiFlash (eluting with 0-7% MeOH in DCM) to give CPD-051(28.0 mg, 59.7% yield) as yellow solid. ¹H NMR (300 MHz, CD₃OD) δ 1.50(s, 3H), 4.86 (s, 1H), 6.62 (d, J=8.7 Hz, 2H), 6.76 (d, J=8.7 Hz, 2H),7.24 (d, J=8.1 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 7.57 (d, J=8.1 Hz, 2H),7.82 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 25.86, 57.98, 70.73,75.68, 76.64, 78.96, 84.58, 108.30, 114.21, 114.73, 126.06, 126.45,127.57, 132.08, 133.81, 133.94, 135.69, 150.24, 156.48, 167.89; LC/MSm/s [M+H⁺] 470.8.

Example 5

41: Cbz-L-ser(ald)-OBO ester 40 (2.90 g, 9. Mmol) is dissolved inanhydrous DCM (11.0 mL) under argon. A solution of MeMgBr in Et₂O (11.7mL, 36.0 mmol, 4.00 equiv) is added quickly by syringe at −78° C. andstirred vigorously for 1.5 h. Then the reaction is quenched by saturatedNH₄Cl (300 mL) with the stirring is continued for an additional 15 min.The mixture is extracted with DCM (3×80 mL). The combined organic layersare washed with brine (50 mL), and dried (anhydrous Na₂SO₄). The crudeproduct is purified by CombiFlash (eluting with 0-50% EtOAc in hexane)to afford the 41 (1.52 g, 50% yield) as white solid. ¹H NMR (300 MHz,CDCl₃) δ 0.80 (s, 3H), 1.11 (d, J=6.3 Hz, 3H), 2.87 (s, 3H), 3.75 (d,J=10.5 Hz, 1H), 3.92 (s, 6H), 4.35 (q, J=19.5 Hz, 1H), 5.08-5.18 (m,2H), 5.34 (d, J=10.5 Hz, 1H), 7.26-7.36 (m, 5H); ¹³C NMR (75 MHz, CDCl₃)δ 14.53, 19.22, 30.84, 57.95, 65.43, 67.06, 72.93, 108.99, 127.77,128.19, 128.67, 136.85, 157.19; LC/MS m/s [M+H]⁺ 378.1.

42: Cbz-L-Threonine OBO ester 41 (1.30 g, 3.86 mmol) is dissolved inanhydrous DCM (10 mL) under argon and cooled to −78° C. in flask I.Oxalyl chloride (6.20 mL, 2.0 M in DCM, 6.17 mmol, 1.6 equiv) is addedto anhydrous DCM (10 mL) in a separate flask II under argon and cooledto −78° C. Anhydrous DMSO (0.55 mL, 12.74 mmol, 3.30 equiv) is added tothe oxalyl chloride solution (flask II), and the mixture stirred at −78°C. for 15 min. The alcohol solution is transferred by syringe at −78° C.to the flask II over a period of 20 min. The resulting cloudy whitemixture is stirred for 4 h at −78° C. DIPEA (3.85 mL, 19.3 mmol, 5.0equiv) is added and the solution is stirred for 30 min at −78° C. and 10min at 0° C. Ice-cold DCM (100 mL) is added, and the solution is washedwith ice-cold 3% NH₄Cl (3×100 mL), brine (100 mL), dried (anhydrousNa₂SO₄). The crude product is crystallized from DCM/Hexane to obtain 42(1.06 g, 82% yield) as white solid. ¹H NMR (300 Hz, CDCl₃) δ 0.791 (s,3H), 2.303 (s, 3H), 3.900 (s, 6H), 4.581 (d, J=8.4 Hz, 1H), 5.087 (s,2H), 5.624 (d, J=8.1 Hz, 1H), 7.255-7.342 (m, 5H); ¹³C NMR (300 Hz,CDCl₃) δ 14.441, 29.937, 30.874, 63.375, 67.259, 73.170, 107.131,128.295, 128.678, 136.500, 156.210, 202.864; LC/MS m/s [M+H]⁺ 356.2.

43: Cbz-L-Thre(keto)-OBO ester 42 (1.03 g, 3.07 mmol) is dissolved in asolution of 4-Benzyloxyphenyl magnesium bromide in THF (21.90 mL, 21.90mmol, 7.00 equiv) ice-bath and stirred vigorously under argon. After 3min, the reaction mixture is allowed to warm to room temperature withstirring is continued for 90 min. Then the reaction mixture is quenchedby sat. NH₄Cl 300 mL (pH=7) and is stirred for an additional 15 min. Themixture is extracted with DCM (3×80 mL). The combined organic layers arewashed with brine (50 mL), dried (anhydrous Na₂SO₄). The crude productis purified by CombiFlash (eluting with 0-50% EtOAc in hexane) to give43 (0.94 g, 55% yield) as white foam, which is crystallized from MeOH toafford 0.62 g (40.0% yield) as white solid. ¹H NMR (300 MHz, CDCl₃) δ0.82 (s, 3H), 1.66 (s, 3H), 3.48 (s, 1H), 3.87-3.99 (m, 6H), 4.19 (d,J=10.2 Hz, 1H), 4.87-5.06 (m, 4H), 5.31-5.33 (m, 2H), 7.26-7.46 (m,12H); ¹³C NMR (75 MHz, CDCl₃) δ 14.56, 29.71, 30.74, 60.71, 66.50,70.11, 72.72, 76.03, 109.78, 114.27, 126.23, 127.64, 127.77, 127.92,128.12, 128.55, 128.78, 137.08, 137.45, 138.45, 156.52, 157.60; LC/MSm/s [M+H]⁺ 520.2.

44: To a solution of 43 (0.60 g, 1.2 mmol) in anhydrous MeOH (10 mL) isadded 10% Pd/C (60.0 mg, 10% w/w) at room temperature under a balloon ofhydrogen. The reaction mixture is stirred for 14 h. Then the catalyst isremoved by filtration through a celite pad and washed with MeOH (50 mL).The filtrate is evaporated under reduced vacuo to obtain the 43 (0.339g, 99.0% yield) as white solid, which is going to next step withoutfuture purification. ¹H NMR (300 MHz, CDCl₃) δ 0.82 (s, 3H), 1.57 (s,3H), 3.93 (s, 6H), 4.06 (br, s, 2H), 5.29 (s, 1H), 6.54 (d, J=8.1 Hz,2H), 7.13 (d, J=7.8 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 14.51, 29.91,30.67, 61.76, 72.74, 74.88, 109.85, 115.72, 125.63, 137.17, 155.57;LC/MS m/s [M+H]⁺ 296.1.

45: To a stirred mixture of 44 (218 mg, 0.83 mmol) and 6 (295 mg, 1.00mmol, 1.20 equiv, prepared as in Example 1) in anhydrous DMF (5 mL) isadded N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDChydrochloride) (192 mg 1.00 mmol, 1.20 equiv), 1-hydroxybenzotriazole(HOBt) (135 mg, 1.00 mmol, 1.20 equiv) at room temperature. The mixtureis cooled with an ice-bath, and diisopropylethylamine (DIEA) (0.58 mL,3.33 mmol, 5.0 equiv) is added. The whole reaction mixture is stirredunder argon and at 0° C. for 1 h, then allowed to warm to temperaturewith the stirring is continued for additional 24 h. The resulting yellowsolution is condensed to dryness with a rotavapor, and the residue istreated with water (20 mL), extracted with DCM (3×50 mL). The combinedextracts are washed with brine (20 mL), and dried over anhydrous Na₂SO₄.Evaporation of the solvent affords the crude product, which is purifiedby CombiFlash (eluting with 0-3% MeOH in DCM) to afford 45 (353 mg,79.1% yield) as yellow solid. ¹H NMR (300 MHz, DMSO-_(d6)) δ 0.74 (s,3H), 1.56 (s, 3H), 3.84 (s, 6H), 4.38 (m 1H), 4.47 (s, 1H), 5.82 (s,2H), 6.51 (d, J=2.7 Hz, 2H), 6.54 (d, J=2.7 Hz, 2H), 7.16 (d, J=8.7 Hz,2H), 7.23 (d, J=8.4 Hz, 2H), 7.49-7.57 (m, 5H), 9.00 (s, 1H); ¹³C NMR(75 MHz, DMSO-_(d6)) δ 14.38, 29.55, 30.62, 59.47, 71.79, 72.33, 75.58,77.08, 80.81, 86.25, 105.85, 109.40, 114.26, 114.65, 124.35, 126.62,128.19, 132.53, 134.68, 135.42, 138.53, 151.53, 155.90, 165.04; LC/MSm/s [M+H]⁺ 539.2.

46: 45 (320 mg, 0.595 mmol) is dissolved in dioxane (2.0 mL). Themixture is diluted with acetic acid (2.0 mL) and water (2.0 mL) at roomtemperature under argon. The suspension mixture is stirred for 0.5 h.Then the yellow clear solution is concentrated to dryness. The residueis treated with saturated NaHCO₃ (20 mL) to pH=10, extracted with EtOAc(3×40 mL). The combined organic layers are washed with water (2×30 mL),brined (30 mL), and dried (anhydrous Na₂SO₄). The crude product ispurified by CombiFlash to give 46 (320 mg, 97% yield) as yellow solid.¹H NMR (300 MHz, CD₃OD) δ 0.91 (s, 3H), 1.69 (s, 3H), 3.42-3.51 (m, 4H),4.11 (q, J=31.8 Hz, 2H), 4.95 (s, 1H), 6.61 (d, J=6.9 Hz, 2H), 6.74 (d,J=9.0 Hz, 2H), 7.32 (d, J=8.7 Hz, 2H), 7.34 (d, J=8.7 Hz, 2H), 7.49 (d,J=8.7 Hz, 2H), 7.54 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 15.83,27.46, 40.77, 62.13, 64.47, 64.61, 67.39, 70.78, 75.10, 76.67, 78.95,84.60, 108.33, 114.23, 114.77, 125.98, 126.13, 127.21, 132.05, 133.81,136.31, 150.18, 156.36, 167.65, 170.50; LC/MS m/s [M+H]⁺ 557.2.

CPD-052: 46 (55.6 mg, 0.10 mmol) is taken into a mixture of THF/MeOH(1:1 volume) 2.0 mL. 50% aq hydroxylamine (0.40 mL, 6.0 mmol, 60 equiv)is added and followed by potassium cyanide (13.0 mg, 0.20 mmol, 2.0equiv) at room temperature under argon. The reaction mixture is stirredroom temperature for 24 h. Then the yellow solution is concentrated todryness. The residue is treated water (30 mL), extracted with EtOAc(3×50 mL). The combined organic layers are washed with water (5×30 mL),brine (30 mL), and dried (anhydrous Na₂SO₄). The crude product ispurified by CombiFlash (eluting with 0-7% MeOH in DCM) to give CPD-052(22.0 mg, 46.9% yield) as yellow solid, which is washed Et₂O (3×20 mL).The filtrate is concentrated to dryness to obtain pure CPD-052 (11.0 mg,yield 23.5%). ¹H NMR (300 MHz, CD₃OD) δ 1.63 (s, 3H), 4.75 (s, 1H), 6.61(d, J=8.4 Hz, 2H), 6.71 (d, J=8.7 Hz, 2H), 7.23 (d, J=8.4 Hz, 2H), 7.33(d, J=8.7 Hz, 2H), 7.49 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ26.93, 59.36, 70.71, 74.83, 76.57, 78.92, 84.53, 108.29, 114.20, 114.60,125.89, 126.21, 127.24, 131.98, 133.78, 136.00, 150.22, 156.28, 167.28,168.09, LC/MS m/s [M+H]⁺ 470.5.

Example 6

47: To a solution of 35 (0.50 g, 1.0 mmol) in anhydrous MeOH (10 mL) isadded 10% Pd/C (50.0 mg, 10% w/w) at room temperature under a balloon ofhydrogen. The reaction mixture is stirred for 14 h. Then the catalyst isremoved by filtration through a celite pad and washed with MeOH (50 mL).The filtrate is evaporated under reduced vacuo to obtain the 47 (0.277g, 99% yield) as white solid, which is going to next step without futurepurification. ¹H NMR (300 MHz, CD₃OD) δ 0.81 (s, 3H), 3.94 (s, 6H), 5.02(d, J=2.4 Hz, 1H), 6.73 (d, J=8.7 Hz, 2H), 7.17 (d, J=8.7 Hz, 2H); ¹³CNMR (75 MHz, CD₃OD) δ 13.05, 30.36, 60.33, 70.65, 72.57, 108.90, 114.70,127.11, 133.26, 156.48; LC/MS m/s [M+H]⁺ 282.2.

48: To a stirred mixture of 47 (218 mg, 0.83 mmol) and 6 (295 mg, 1.00mmol, 1.20 equiv, prepared as in Example 1) in anhydrous DMF (5 mL) isadded N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDChydrochloride) (192 mg 1.00 mmol, 1.20 equiv), 1-hydroxybenzotriazole(HOBt) (135 mg, 1.00 mmol, 1.20 equiv) at room temperature. The mixtureis cooled with an ice-bath, and diisopropylethylamine (DIEA) (0.58 mL,3.33 mmol, 5.0 equiv) is added. The whole reaction mixture is stirredunder argon and at 0° C. for 1 h, then allowed to warm to temperaturewith the stirring is continued for additional 24 h. The resulting yellowsolution is condensed to dryness with a rotavapor, and the residue istreated with water (20 mL), extracted with DCM (3×50 mL). The combinedextracts are washed with brine (20 mL), and dried over anhydrous Na₂SO₄.Evaporation of the solvent affords the crude product, which is purifiedby CombiFlash (eluting with 0-3% MeOH in DCM) to afford 48 (337 mg,98.3% yield) as yellow solid. ¹H NMR (300 MHz, CD₃OD) δ 0.79 (s, 3H),3.96 (s, 6H), 4.41 (d, J=1.5 Hz, 1H), 5.27 (s, 1H), 6.61 (d, J=9.0 Hz,2H), 6.67 (d, J=8.7 Hz, 2H), 7.17 (d, J=8.4 Hz, 2H), 7.25 (d, J=8.7 HZ,2H), 7.52 (d, J=8.7 Hz, 2H), 7.70 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz,CD₃OD) δ 13.08, 30.46, 58.04, 70.50, 7.91, 72.68, 76.58, 79.16, 84.58,108.38, 108.51, 114.28, 114.68, 125.72, 127.08, 127.36, 132.07, 132.68,133.87, 134.41, 150.159, 156.47, 167.73; LC/MS m/s [M+H]⁺ 525.2.

49: 48 (130 mg, 0.248 mmol) is dissolved in dioxane (1.0 mL). Themixture is diluted with acetic acid (1.0 mL) and water (1.0 mL) at roomtemperature under argon. The suspension mixture is stirred for 0.5 h.Then the yellow clear solution is concentrated to dryness. The residueis treated with saturated NaHCO₃ (20 mL) to pH=10, extracted with EtOAc(3×40 mL). The combined organic layers are washed with water (2×30 mL),brined (30 mL), and dried (anhydrous Na₂SO₄). The crude product ispurified by CombiFlash to give the 49 (120 mg, 90% yield) as yellowsolid. ¹H NMR (300 MHz, CD₃OD) δ 0.87 (s, 3H), 3.43-3.44 (m, 4H), 4.07(d, J=1.2 Hz, 2H), 4.91 (d, J=4.2 Hz, 1H), 5.28 (d, J=3.9 Hz, 1H), 6.60(d, J=8.7 Hz, 2H), 6.75 (d, J=8.7 Hz, 2H), 7.24 (d, J=5.4 Hz, 2H) 7.27(d, J=5.4 Hz, 2H), 7.53 (d, J=8.4 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H); ¹HNMR (75 MHz, CD₃OD) δ 15.68, 40.87, 59.83, 64.44, 67.43, 70.84, 72.84,76.68, 79.05, 84.60, 108.39, 114.26, 114.94, 126.00, 127.29, 127.46,131.73, 132.09, 133.84, 150.16, 157.03, 168.300, 170.73; LC/MS m/s[M+Na]⁺ 565.1.

CPD-049: 49 (54.2 mg, 0.10 mmol) is taken into a mixture of THF/MeOH(1:1 volume) 2.0 mL. 50% aq hydroxylamine (0.20 mL, 3.0 mmol, 30 equiv)is added and followed by potassium cyanide (6.5 mg, 0.10 mmol, 1.0equiv) at room temperature under argon. The reaction mixture is stirredroom temperature for 3.5 h. Then the yellow solution is concentrated todryness. The residue is treated water (30 mL), extracted with EtOAc (30%1-butanol) (3×50 mL). The combined organic layers are washed with milliQwater (5×30 mL), brine (30 mL), and dried (anhydrous Na₂SO₄). Thesolvent is removed by reduced pressure to give CPD-049 (36.0 mg, 79.1%yield) as yellow solid. ¹H NMR (300 MHz, DMSO-_(d6)) δ 4.55 (q, J=13.5Hz, 1H), 4.97 (t, J=9.9 Hz, 1H), 5.54 (d, J=6.0 Hz, 1H), 5.83 (s, 2H),6.54 (d, J=0.7 Hz, 2H), 6.64 (d, J=8.7 HZ, 2H), 7.14 (d, J=8.7 Hz, 2H),7.25 (d, J=8.4 HZ, 2H), 7.60 (d, J=8.4 Hz, 2H), 7.80 (d, J=8.7 Hz, 2H),8.12 (d, J=8.7 Hz, 1H), 8.79 (s, 1H), 9.22 (s, 1H), 10.60 (s, 1H); ¹³CNMR (75 MHz, DMSO-_(d6)) δ 58.86, 71.81, 72.90, 77.29, 80.83, 86.37,105.85, 114.28, 115.30, 124.72, 128.01, 128.47, 132.60, 133.06, 134.71,134.98, 151.56, 157.03, 165.99, 167.23; LC/MS [M+Na]⁺ 478.0.

Example 7

50: 36 (0.50 g, 1.00 mmol) is dissolved in anhydrous DCM (15 mL) andMeOH (15 mL) under argon, and then cooled to −78° C. Then a solution of2.0 M LiBH₄ in THF (4.80 mL, 8.00 mmol, 8.0 equiv) is added dropwise.The reaction mixture is stirred at −78° C. for 10 h, and then slowlywarm to room temperature. The mixture is diluted to with DCM (100 mL)and then quenched with saturated NH₄Cl (50 mL). The organic layer isseparated. And the aqueous layer is extracted with DCM (2×50 mL). Theorganic layers are combined, washed with saturated NH₄Cl (50 mL), brine(50 mL), and dried (anhydrous Na₂SO₄). The solvent is reduced in vacuumto dryness. The crude product is purified by CombiFlash (eluting with0-60% EtOAc in hexane) to obtain 50 (0.44 g, 88% yield) as white solid.¹H NMR (300 MHz, CD₃Cl) δ 0.83 (s, 3H), 3.96 (s, 6H), 4.11 (d, J=1.5 Hz,1H), 4.14-4.21 (m, 1H), 4.78-4.87 (m, 3H), 5.00 (s, 1H), 5.02 (s, 2H),6.91 (d, J=8.4 Hz, 2H), 7.11 (d, J=6.6 Hz, 2H), 7.25-7.45 (m, 10H); ¹³CNMR (75 MHz, CD₃Cl) δ 14.51, 30.92, 58.94, 66.72, 70.10, 73.03, 74.02,108.96, 114.51, 127.71, 127.83, 128.11, 128.60, 128.78, 129.12, 132.95,136.83, 137.38, 156.04, 158.62; LC/MS m/s [M+H]⁺ 505.2.

51: To a solution of 50 (0.40 g, 0.80 mmol) in anhydrous MeOH (20 mL) isadded 10% Pd/C (40.0 mg, 10% w/w) at room temperature under a balloon ofhydrogen. The reaction mixture is stirred for 14 h. Then the catalyst isremoved by filtration through a celite pad and washed with MeOH (50 mL).The filtrate is evaporated under reduced vacuo to obtain the 51 (0.280g, 96% yield) as white solid, which is going to next step without futurepurification. ¹H NMR (300 MHz, CD₃OD) δ 0.82 (s, 3H), 3.02 (d, J=7.2 Hz,1H), 3.95 (s, 6H), 4.72 (d, J=7.2 Hz, 1H), 6.75 (d, J=8.4 Hz, 2H), 7.19(d, J=8.7 HZ, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 12.97, 30.32, 59.78, 72.52,73.42, 108.66, 114.71, 128.85, 157.18; LC/MS m/s [M+H]+ 282.2.

52: To a stirred mixture of 51 (93 mg, 0.36 mmol) and 6 (120 mg, 0.43mmol, 1.20 equiv, prepared as in Example 1) in anhydrous DMF (5 mL) isadded N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDChydrochloride) (82 mg 0.43 mmol, 1.20 equiv), 1-hydroxybenzotriazole(HOBt) (58 mg, 0.43 mmol, 1.20 equiv) at room temperature. The mixtureis cooled with an ice-bath, and diisopropylethylamine (DIEA) (0.25 mL,1.44 mmol, 4.0 equiv) is added. The whole reaction mixture is stirredunder argon and at 0° C. for 1 h, then allowed to warm to temperaturewith the stirring is continued for additional 36 h. The resulting yellowsolution is condensed to dryness with a rotavapor, and the residue istreated with water (20 mL), extracted with DCM (3×50 mL). The combinedextracts are washed with brine (20 mL), and dried over anhydrous Na₂SO₄.Evaporation of the solvent affords the crude product, which is purifiedby CombiFlash (eluting with 0-4% MeOH in DCM) to afford 52 (165 mg, 87%yield) as yellow solid. ¹H NMR (300 MHz, CD₃OD) δ 0.82 (s, 3H), 3.98 (s,6H), 4.54 (d, J=8.4 Hz, 1H), 4.95 (d, J=8.4 Hz, 1H), 6.61 (d, J=8.7 Hz,2H), 6.68 (d, J=8.7 Hz, 2H), 7.21 (d, J=6.6 Hz, 2H), 7.23 (d, J=6.6 Hz,2H), 7.43 (s, 4H); ¹³C NMR (75 MHz, CD₃OD) δ 12.99, 30.460, 57.49,70.77, 72.67, 73.07, 76.29, 79.06, 84.38, 108.35, 108.66, 114.21,114.47, 125.41, 127.26, 128.85, 131.68, 131.79, 133.79, 134.74, 150.19,156.97, 167.68; LC/MS m/s [M+H]⁺ 525.1.

53: 52 (150 mg, 0.286 mmol) is dissolved in dioxane (1.0 mL). Themixture is diluted with acetic acid (1.0 mL) and water (1.0 mL) at roomtemperature under argon. The suspension mixture is stirred for 70 min.Then the yellow clear solution is concentrated to dryness. The residueis treated with saturated NaHCO₃ (20 mL) to pH=10, extracted with EtOAc(3×40 mL). The combined organic layers are washed with water (2×30 mL),brined (30 mL), and dried (anhydrous Na₂SO₄). The crude product ispurified by CombiFlash (eluting with 0-10% MeOH in DCM) to give 53 (126mg, 88% yield) as yellow solid. ¹H NMR (300 MHz, CD₃OD) δ 0.86 (s, 3H),3.45-3.43 (m, 4H), 4.09 (q, J=32.4 Hz, 2H), 4.89 (d, J=7.5 Hz, 1H), 5.05(d, J=7.5 Hz, 1H), 6.60 (d, J=8.7 Hz, 2H), 6.78 (d, J=8.4 Hz, 2H), 7.24(d, J=8.7 Hz, 2H), 7.26 (d, J=8.7 Hz, 2H), 7.48 (d, J=8.4 Hz, 2H), 7.60(d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 15.75, 40.83, 59.21, 64.58,67.31, 70.92, 73.33, 76.75, 79.10, 84.65, 108.44, 114.32, 115.03,125.98, 127.42, 127.96, 131.62, 132.07, 133.76, 133.88, 150.10, 157.23,167.84, 171.21; LC/MS m/s [M+H]⁺ 543.2.

CPD-050: 53 (54.2 mg, 0.10 mmol) is taken into a mixture of THF/MeOH(1:1 volume) 2.0 mL. 50% aq hydroxylamine (0.20 mL, 3.0 mmol, 30 equiv)is added and followed by potassium cyanide (10.0 mg, 0.10 mmol, 1.5equiv) at room temperature under argon. The reaction mixture is stirredroom temperature for 3.5 h. Then the yellow solution is concentrated todryness. The residue is treated water (5 mL), washed with EtOAc (10 mL).The precipitate is then washed with milliQ water (3×30 mL), dried underhigh vacuum to give CPD-050 (35.0 mg, 77% yield) as yellow solid. ¹H NMR(300 MHz, CD₃OD) δ 4.69 (d, J=8.7 Hz, 1H), 4.91 (d, J=9.0 Hz, 1H), 6.61(d, J=8.4 Hz, 2H), 6.72 (d, J=8.4 Hz, 2H), 7.23 (d, J=9.0 Hz, 2H), 7.27(d, J=8.4 Hz, 2H), 7.48 (d, J=8.1 Hz, 2H), 7.56 (d, J=8.1 Hz, 2H); ¹³CNMR (75 MHz, CD₃OD) δ 56.73, 70.72, 73.14, 76.49, 78.96, 84.48, 108.32,114.20, 114.81, 125.80, 127.34, 128.26, 131.91, 132.01, 133.78, 134.04,150.21, 157.21, 167.37, 168.52; LC/MS m/s [M+H]⁺ 456.2.

Example 8

55: ¹H (300 MHz, CDCl₃) δ 1.07-1.22 (m, 21H), 4.79 (s, 2H), 7.24 (d,J=9.6 Hz, 2H), 7.46 (d, J=8.4 Hz, 2H); ¹³C (75 MHz, CDCl₃) δ 12.25,18.26, 64.65, 120.66, 127.65, 131.47, 140.92; LC/MS m/s [M+H]⁺ 342.2.

57: ¹H (300 MHz, CDCl₃) δ 0.83 (s, 3H), 1.09-1.16 (m, 21H), 3.37 (s,1H), 3.89-3.98 (m, 6H), 4.09 (d, J=10.2 Hz, 1H), 4.82 (s, 2H), 4.97 (q,J=39.3 Hz, 2H), 5.34 (s, 1H), 5.48 (d, J=10.2 Hz, 1H), 7.20-7.35 (m,9H); ¹³C 75 MHz, CDCl₃) δ 12.29, 14.56, 18.32, 30.94, 58.80, 65.09,66.75, 70.91, 73.06, 109.09, 125.44, 125.72, 125.99, 127.96, 128.04,128.60, 136.96, 138.77, 140.88, 156.56; LC/MS m/s [M+H]⁺ 586.3.

58: ¹H (300 MHz, CDCl₃) δ 0.75 (s, 3H), 1.09-1.19 (m, 21H), 3.85 (s,6H), 4.89 (s, 2H), 5.10 (s, 2H), 5.59 (d, J=9.6 Hz, 1H), 5.95 (d, J=9.6Hz, 1H), 7.26-7.35 (m, 5H), 7.44 (d, J=8.1 Hz, 2H), 8.04 (d, J=8.1 Hz,2H); ¹³C 75 MHz, CDCl₃) δ 12.24, 14.47, 18.27, 30.91, 57.61, 64.90,67.29, 73.17, 107.55, 125.51, 128.31, 128.68, 129.80, 135.37, 136.53,147.80, 156.18, 194.99; LC/MS m/s [M+H]⁺ 584.0.

59: ¹H (300 MHz, CDCl₃) δ 0.70 (s, 3H), 1.08-1.16 (m, 21H), 1.50 (s,3H), 3.66-3.76 (m, 6H), 4.19 (s, 1H), 4.27 (d, J=10.5 Hz, 1H), 4.82 (s,2H), 5.08 (q, J=38.1 Hz, 2H), 5.39 (d, J=10.8 Hz, 1H), 7.25-7.38 (m,9H); ¹³C 75 MHz, CDCl₃) δ 12.29, 14.42, 18.31, 27.63, 30.57, 60.99,65.16, 67.01, 72.53, 76.33, 109.49, 125.01, 125.25, 128.14, 128.20,128.46, 128.69, 136.89, 139.71, 144.86, 156.75; LC/MS m/s [M+H]⁺ 600.1

60: ¹H (300 MHz, CDCl₃) δ 0.61 (s, 3H), 1.54 (s, 3H), 2.97 (br, s, 3H),3.09 (br, s, 3H), 3.67 (d, J=10.5 Hz, 2H), 3.81 (d, J=10.8 Hz, 2H), 4.60(s, 2H), 4.71 (d, J=9.0 Hz, 1H), 5.12 (q, J=31.2 Hz, 2H), 6.11 (d, J=9.3Hz, 1H), 7.29-7.43 (m, 9H); ¹³C 75 MHz, CDCl₃) δ 16.61, 27.54, 40.06,61.87, 64.95, 65.92, 67.67, 68.13, 76.24, 125.29, 128.12, 128.38,128.58, 128.83, 136.18, 140.30, 143.72, 156.79, 172.03; LC/MS m/s [M+H]⁺560.4.

61: ¹H (300 MHz, CD₃OD) δ 0.72 (s, 3H), 1.63 (s, 3H), 3.23 (br, s, 3H),3.69 (s, 1H), 3.74 (d, J=11.1 Hz, 1H), 3.84 (d, J=11.1 Hz, 1H), 4.58 (s,2H), 7.32 (d, J=8.4 Hz, 2H), 7.42 (d, J=8.1 Hz, 2H); ¹³C 75 MHz, CD₃OD)δ 15.67, 26.09, 40.30, 63.63, 63.75, 64.42, 67.14, 75.06, 125.47,126.68, 140.34, 144.08, 173.01; LC/MS m/s [M+H]⁺ 326.1

62: ¹H NMR (300 MHz, DMSO-_(d6)) δ 0.49 (s, 3H), 1.50 (s, 3H), 2.99 (br,s, 4H), 3.56 (d, J=10.8 Hz, 1H), 3.74 (d, J=10.8 Hz, 1H), 4.27 (br, s,2H), 4.96 (s, 1H), 5.12 (br, s, 1H), 5.52 (s, 1H), 5.84 (br, s, 1H),6.54 (d, J=8.7 Hz, 2H), 7.26 (d, J=8.7 Hz, 4H), 7.43 (d, J=8.4 Hz, 2H),7.68 (d, J=8.4 Hz, 2H), 7.87 (d, J=8.4 Hz, 2H); ¹³C NMR (300 MHz,DMSO-_(d6)) δ 16.73, 28.63, 62.50, 63.41, 63, 94, 67.76, 71.80, 75.37,77.49, 80.75, 86.50, 105.83, 110.42, 114.27, 119.70, 125.10, 125.52,126.64, 128.48, 132.82, 134.72, 141.31, 144.77, 151.55, 166.35, 170.17;LC/MS m/s [M+H]+.

CPD-062: (20 mg, 47% yield), ¹H NMR (300 MHz, DMSO-_(d6)) δ 1.42 (s,3H), 3.78 (d, J=5.7 Hz, 1H), 4.45 (d, J=5.4 Hz, 1H), 4.82 (d, J=9.6 Hz,1H), 5.12 (t, J=11.1 Hz, 1H), 5.83 (s, 2H), 6.54 (d, J=8.4 Hz, 2H),7.21-7.26 (m, 4H), 7.42 (d, J=8.4 Hz, 2H), 7.83-7.89 (m, 2H), 8.43 (d,J=9.6 Hz, 1H), 8.84 (s, 1H), 10.58 (s, 1H); ¹³C NMR (75 MHz,DMSO-_(d6)); δ 27.29, 58.35, 63.36, 71.81, 75.64, 77.31, 80.83, 86.39,105.84, 114.29, 124.79, 125.86, 126.48, 128.45, 128.70, 132.57, 134.71,14.95, 141.38, 145.04, 151.56, 166.25, 166.98; LC/MS m/s [M+H]⁺ 484.5.

Example 9

To a solution of dibenzylamine 63 (13.8 mL, 71.9 mmol, 1.1 equiv) inabsolute ethanol (50 mL), ethyl bromoacetate (7.25 mL, 65.4 mmol) isadded. The reaction mixture is refluxed for 12 h under argon. Afterevaporation under vacuum of most of the ethanol, 1N sodium hydroxide(100 mL) and dichloromethane (700 mL) are added, and the phasesseparated. The organic layer is washed with water (100 mL), brine (100mL) and dried (anhydrous Na₂SO₄). The crude product is crystallized fromethanol/water to give 64 (12.50 g, 67% yield) as white needle solid.

To a solution of 64 (2.00 g, 0.71 mmol) and ethyl fluoroacetate (15.53mmol) in anhydrous tetrahydrofuran (15 mL), sodium hydride (50%suspension in mineral oil) (1.02 g, 25.42 mmol) is added. The reactionmixture is refluxed for 5 h under argon and then cooled to 0° C. andtreated with acetic acid (1.42 mL, 26.10 mmol). Sodium borohydride (668mg, 17.66 mmol) is then added and the suspension is stirred overnight(14 h) at room temperature. The result deep red solution is treated with1N hydrochloride acid to pH=5, stirred for 10 min, and then treated withsat. NaHCO₃ (100 mL) to pH=9-10. The mixture is extracted with EtOAc(3×80 mL). The combined organic layers are washed with water (30 mL),brine (30 mL), and dried (anhydrous Na₂SO₄). The crude product ispurified by CombiFlash (eluting with 0-10% EtOAc in hexane) to obtainthe 66 as a white solid.

A solution of 66 (4.68 mmol) in absolute ethanol (20 mL) is added 10%Pd/C (0.34 g, 20% w % w). The reaction mixture is stirred at roomtemperature under a balloon of hydrogen for overnight (14 h). Filtrationof the catalyst and evaporation of the filtrate to dryness give a whitesolid 67, which is going to next step without the future purification.

To a stirred mixture of 6 (120 mg, 0.46 mmol, prepared as in Example 1)and 67 (0.55 mmol, 1.20 equiv) in anhydrous DMF (5 mL) is addedN-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDChydrochloride) (105.8 mg 0.55 mmol, 1.20 equiv), 1-hydroxybenzotriazole(HOBt) (74.6 mg, 0.55 mmol, 1.20 equiv) at room temperature. The mixtureis cooled with an ice-bath, and diisopropylethylamine (DIEA) (0.32 mL,1.84 mmol, 4.00 equiv) is added. The whole reaction mixture is stirredunder argon and at 0° C. for 1 h, then allowed to warm to temperaturewith the stirring is continued for additional 16 h. The resulting yellowsolution is condensed to dryness with a rotavapor, and the residue istreated with water (20 mL), extracted with EtOAc (3×50 mL). The combinedextracts are washed with water (20 mL), brine (20 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent affords the crude product,which is purified by flash chromatography (eluting with 0-1.5% MeOH inDCM) to give 68 as yellow solid.

To an ice-cold solution of 68 (0.229 mmol) dissolved in anhydrous MeOH(1 mL) and THF (1 mL) is added hydroxylamine hydrochloride (79.7 mg,1.147 mmol, 5.0 equiv) followed by 25% sodium methoxide in methanolsolution (0.40 mL, 1.72 mmol, 7.5 equiv). The reaction mixture isstirred under argon and at 0° C. for 2 h, then allowed to warm toambient temperature with the stirring is continued overnight (14 h). Theresulting yellow suspension is condensed to dryness with a rotavapor,and the residue is treated water (20 mL) and saturated NH₄Cl (2 mL),extracted with EtOAc (3×50 mL). The combined extracts are washed withwater (30 mL), brine (30 mL), and dried over anhydrous Na₂SO₄.Evaporation of the solvent affords the crude product, which is purifiedby CombiFlash (eluting with 0-5% MeOH in DCM) to afford title compoundas a yellow solid.

64 ¹H (300 MHz, CDCl₃) δ 1.29 (t, J=15.0 Hz, 3H), 3.32 (s, 2H), 3.84 (s,4H), 4.18 (q, J=21.9 Hz, 2H), 7.24-7.44 (m, 10H); ¹³C (75 MHz, CDCl₃) δ14.547, 53.793, 57.981, 60.409, 127.354, 128.541, 129.156, 139.295,171.653; LC/MS m/s [M+H]⁺ 284.5.

65a: (2.00 g, 78% yield), ¹H (300 MHz, CDCl₃) δ 1.41 (t, J=15.3 Hz, 3H),3.47 (d, J=9.9 Hz, 1H), 3.54 (d, J=12.9 Hz, 2H), 3.82 (s, 1H), 4.02 (d,J=13.2 Hz, 2H), 4.15-4.26 (m, 1H), 4.27-4.41 (m, 2H), 5.47-5.85 (m, 1H),7.26-7.38 (m, 10H); ¹³C (75 MHz, CDCl₃) δ 14.72, 55.21, 59.65, 61.45,66.94, 67.25, 67.56, 112.47, 115.70, 118.94, 128.04, 128.96, 129.47,137.66, 169.34; LC/MS m/s [M+H]⁺ 379.2.

66a: (0.81 g, 95% yield), ¹H (300 MHz, CDCl₃) δ 1.27 (t, J=14.4 Hz, 3H),3.74 (d, J=1.5 Hz, 1H), 4.04-4.13 (m, 1H), 4.22 (q, J=22.2 Hz, 2H),5.62-6.01 (m, 1H); ¹³C (75 MHz, CDCl₃) δ 14.27, 53.29, 62.16, 170.50,70.84, 71.17, 112.59, 115.82, 119.05, 172.81; LC/MS m/s [M+H]⁺ 184.0.

68a: (0.176 g, 90% yield), ¹H (300 MHz, CD₃OD) δ 1.30 (t, J=14.4 Hz,3H), 4.25 (q, J=21.3 Hz, 2H), 4.31-4.40 (m, 1H), 5.01 (d, J=1.8 Hz, 1H),5.62-5.01 (m, 1H), 6.60 (d, J=8.7 Hz, 2H), 7.25 (d, J=9.0 Hz, 2H), 7.58(d, J=8.4 Hz, 2H), 7.84 (d, J=8.7 Hz, 2H); ¹³C (75 MHz, CD₃OD) δ 13.27,53.57, 61.95, 70.11, 70.44, 70.78, 76.74, 79.00, 84.63, 108.34, 112.09,114.24, 115.31, 118.53, 126.20, 127.65, 132.13, 133.66, 133.84, 150.20,168.46, 169.62; LC/MS m/s [M+H⁺] 427.1.

CPD-056: (70.0 mg, 72% yield) ¹H (300 MHz, CD₃OD) δ 4.21-4.31 (m, 1H),4.87-4.86 (m, 1H), 5.63-6.01 (m, 1H), 6.62 (d, J=8.7 Hz, 2H), 7.24 (d,J=8.7 Hz, 2H), 7.57 (d, J=8.7 Hz, 2H), 7.86 (d, J=8.7 Hz, 2H); ¹³C (75MHz, CD₃OD) δ 52.38, (69.91, 70.23, 70.56), 70.74, 76.74, 78.97, 84.64,108.31, (112.12, 115.34, 118.57), 114.22, 126.21, 127.67, 132.08,133.53, 133.82, 150.22, 167.26, 167.95; LC/MS m/s [M+H⁺] 414.2.

66b: (2.00 g, 30% yield) as a white solid. ¹H (300 MHz, CDCl₃) δ ¹1.42t, J=15.3 Hz, 3H), 3.45 (d, J=13.2 Hz, 2H), 3.54 (d, J=9.6 Hz, 1H), 3.99(d, J=13.2 Hz, 2H), 4.19-4.49 (m, 4H), 7.27-7.40 (m, 10H); ³C (75 MHz,CDCl₃) δ 14.70, 54.95, 59.07, 61.72, (65.25, 65.66, 66.07, 66.48),(119.23, 122.96, 126.69, 130.41), 127.44, 128.24, 128.55, 129.06,129.50, 137.02, 168.41; LC/MS m/s [M+H]⁺ 397.1.

67b: (0.81 g, 88% yield) ¹H (300 MHz, CDCl₃) δ 1.29 (t, J=14.1 Hz, 3H),3.90 (s, 1H), 4.21-4.29 (m, 4H); ¹³C (75M Hz, CDCl₃) δ 14.19, 52.314,62.67, (68.56, 68.97, 69.37, 69.77), (119.26, 123.01, 126.77, 130.53),171.17; LC/MS m/s [M+H]⁺ 201.0.

68b: (0.176 g, 69% yield) as a yellow solid. ¹H (300 MHz, CD₃OD) δ 1.30(t, J=14.7 Hz, 3H), 4.27 (q, J=21.3 Hz, 2H), 4.67-4.78 (m, 1H), 5.18 (d,J=1.5 Hz, 1H), 6.62 (d, J=8.1 Hz, 2H), 7.25 (d, J=8.1 Hz, 2H), 7.59 (d,J=8.1 Hz, 2H), 7.83 (d, J=8.1 Hz, 2H); ¹³C (75 MHz, CD₃OD) δ 13.21,52.80, 62.16, (68.79, 69.20), 70.71, 76.68, 78.95, 84.60, 108.29,114.20, 122.81, 126.20, 126.56, 127.61, 132.11, 133.81, 150.24, 168.24,169.01; LC/MS m/s [M+H]⁺ 445.1.

CPD-057: (70.0 mg, 82% yield) as a yellow solid. ¹H (300 MHz, CD₃OD) δ4.58-4.66 (m, 1H), 5.03 (d, J=2.7 Hz, 1H), 6.62 (d, J=8.1 Hz, 2H), 7.25(d, J=8.1 Hz, 2H), 7.59 (d, J=7.8 Hz, 2H), 7.84 (d, J=8.1 Hz, 2H); ¹³C(75 MHz, CD₃OD) δ 51.87, (68.11, 68.52, 68.93, 69.33), 70.72, 76.75,78.94, 84.65, 108.28, 114.21, (119.25, 122.99, 126.74, 130.49), 126.25,127.64, 132.10, 133.56, 133.81, 150.24, 166.66, 167.85; LC/MS m/s [M+H]⁺432.3

Example 10

To a solution of diisopropylamine (16.21 mmol) in anhydrous THF (30 mL)is added BuLi (1.70 in hexane, 9.15 mL, 15.56 mmol, 1.20 equiv) at −78°C. After 30 min, a solution of S(−)-methyl p-Tol sulfoxide in anhydrousTHF (10 mL) is added dropwise. Then the reaction mixture is stirred at−78° C. for 30 min. Ethyl fluoroacetate (15.56 mmol, 1.20 equiv) isadded dropwise. The reaction mixture is stirred at −78° C. for 2 h underargon. Then the mixture is quenched with saturated NH₄Cl (100 mL),extracted with EtOAc (3×100 mL). The combined extracts are washed withwater (100 mL), brine (100 mL) and dried (anhydrous Na₂SO₄). The crudeproduct is purified by CombiFlash (eluting with EtOAc in hexane 0-50%)to give the 70 as a white solid.

To a solution of 70 (11.2 mmol) in anhydrous Diethyl ether (50 mL) isadded Cu₂O (0.16 g, 1.12 mmol, 0.10 equiv) at 0° C. under argon. Thereaction mixture is added dropwise methyl isocyanoacetate (2.210 g, 2.00equiv). The reaction mixture is stirred at 0° C. for 2 hours, then isallowed to warm to room temperature for 14 hours. The mixture isconcentrated to dryness. The crude product is purified by CombiFlash(eluting with EtOAc in hexane 0-60%) to give the 71 as yellow oil.

To a solution of 71 (1.20 g, 3.78 mmol) in CHCl₃ (1 mL) is added milliQwater (30 mL). The reaction mixture is stirred at room temperature underargon for 24 hours. Then the mixture is diluted with DCM (100 mL),washed with water (40 mL), brine (40 mL) and dried (anhydrous Na₂SO₄).The crude product is purified by CombiFlash (eluting with MeOH in DCM0-5%) to give 72 as white solid.

To a solution of 72 (3.4 mmol) in acetone (20 mL) is added Sodium iodide(1.18 g, 7.84 mmol, 2.4 equiv) at −10° C. under argon. A solution oftrifluoroacetatic anhydride (0.75 mL in 2 mL acetone) is added dropwisein 8 min. The reaction mixture is stirred at −10° C. for 9 min, then isconcentrated to dryness. The residue is diluted with water (30 mL),extracted with EtOAc (3×50 mL). The combined organic layers are washedwith water (30 mL), brine (30 mL) and dried (anhydrous Na₂SO₄). Thecrude product is purified by CombiFlash (eluting with MeOH in DCM 0-3%)to give 73 as yellow oil.

To a solution of 73 (2.82 mmol) in acetate buffer (pH 5.2) and MeOH(1:2, 90 mL) is added Raney Ni (suspension in methanol, 54 mL) followedby addition of sodium hyphophite monohydrate (3.18 g in milliQ water 12mL) immediately. The reaction mixture is stirred at room temperature for14 hours under argon. The mixture is filtered through a celite pad andwashed with MeOH (200 ml). The filtrate is concentrated to dryness. Theresidue is treated with water (50 mL), extracted with EtOAc (3×50 mL).The combine organic layers are washed with water (30 mL), 10% NaHCO₃(2×30 mL), brine (30 mL), and dried (anhydrous Na₂SO₄). The crudeproduct is purified by CombiFlash (eluting with MeOH in DCM 0-5%) togive 74 as white solid.

Hydrochloride acid (0.188 mL, 2.26 mmol, 1.0 equiv) in methanol (1 mL)is added to a solution of 74 (2.26 mmol) in methanol (5 mL). Thereaction mixture is stirred at room temperature for 14 hours. Then themixture is concentrated to dryness. The residue is treated with water(30 mL), adjusted pH to 10 with 10% NaHCO₃, extracted with EtOAC (3×50mL). The combined extracts are washed with water (30 mL), brine (30 mL)and dried (anhydrous Na₂SO₄). Evaporation of the solvent is affords 75as white solid, which is going to next step without future purification.

To a solution of 6 (100 mg, 0.383 mmol, prepared as in Example 1) inanhydrous DMF (5 mL) is added 75 (0.402 mmol, 1.05 equiv), EDC.HCl (88.1mg, 0.460 mmol, 1.2 equiv), HOBt (62.2 mg, 0.46 mmol, 1.2 equiv) at roomtemperature under argon. The mixture is cooled to 0° C., DIEA (0.27 mL,1.53 mmol, 4.00 equiv) is added. The reaction mixture is stirred at 0°C. for 2 hours, then is allowed to warm to room temperature for 14hours. The yellow solution is then concentrated to dryness. The residueis treated with water (30 mL), extracted with EtOAc (3×30 mL). Thecombined extracts are washed with water (30 mL), brine (30 mL), anddried (anhydrous Na₂SO₄). The crude product is purified by CombiFlash(eluting with MeOH in DCM 0-2.5%) to give 76 as a yellow solid.

To an ice-cold solution of 76 (0.235 mmol) dissolved in anhydrous MeOH(1 mL) and THF (1 mL) is added hydroxylamine hydrochloride (81 mg, 1.173mmol, 5.0 equiv) followed by 25% sodium methoxide in methanol solution(0.401 mL, 1.762 mmol, 7.5 equiv). The reaction mixture is stirred underargon and at 0° C. for 2 h, then allowed to warm to ambient temperaturewith the stirring is continued overnight (14 h). The resulting yellowsuspension is condensed to dryness with a rotavapor, and the residue istreated water (20 mL) and saturated NH₄Cl (2 mL), extracted with EtOAc(3×50 mL). The combined extracts are washed with water (30 mL), brine(30 mL), and dried over anhydrous Na₂SO₄. Evaporation of the solventaffords the crude product, which is purified by CombiFlash (eluting with0-5% MeOH in DCM) to afford the title compound as a yellow solid.

70a: ¹H (300 MHz, CDCl₃) δ 2.40 (s, 3H), 3.87 (dd, J=3.3, 13.2 Hz, 1H),3.94 (dd, J=2.7, 13.8 Hz, 1H), 4.70 (s, 1H), 4.86 (s, 1H), 7.33 (d,J=7.8 Hz, 2H), 7.51 (d, J=8.4 Hz, 2H); ¹³C (75 MHz, CDCl₃) δ 21.69,63.86, (84.72, 87.19), 124.21, 130.51, 139.24, 142.83, (197.25, 197.52);LC/MS m/s [M+H]⁺ 215.0.

71a: ¹H (300 MHz, CDCl₃) δ 2.37 (s, 3H), 2.84-2.90 (m, 1H), 3.03 (d,J=13.5 Hz, 1H), 3.68 (s, 3H), 4.60 (dd, J=10.8, 45.6 Hz, 1H), 4.91 (s,1H), 5.11 (ddd, J=1.2, 10.8, 48.3 Hz, 1H), 7.02 (s, 1H), 7.29 (d, J=7.5Hz, 2H), 7.46 (d, J=8.1 Hz, 2H); ¹³C (75 MHz, CDCl₃) δ 21.61, 52.96,60.47, (71.41, 71.49), 82.24, 84.62, (85.33, 85.57), 124.11, 130.48,140.38, 142.52, 155.80, 169.20; LC/MS m/s [M+H]⁺ 314.1.

72a: ¹H (300 MHz, CDCl₃) δ 2.37 (s, 3H), 3.12 (s, 2H), 3.73 (s, 3H),4.50 (s, 1H), 4.66 (s, 1H), 5.01 (d, J=9.0 Hz, 1H), 5.40 (s, 1H), 7.28(d, J=8.1 Hz, 2H), 7.40 (d, J=9.3 Hz, 1H), 7.51 (d, J=7.8 Hz, 2H), 8.20(s, 1H); ¹³C (75 MHz, CDCl₃) δ 21.61, 53.25, 55.48, 62.04, (74.40,74.64), (83.53, 85.87), 124.37, 130.41, 140.08, 142.27, 162.19, 169.92;LC/MS m/s [M+H]⁺ 331.1.

73a: ¹H (300 MHz, CDCl₃) δ 2.29 (s, 3H), 3.27-3.28 (m, 2H), 3.74 (s,3H), 3.77 (d, J=4.5 Hz, 1H), 4.33 (s, 1H), 4.48 (s, 1H), 5.01 (d, J=9.3Hz, 1H), 6.89 (d, J=8.4 Hz, 1H), 7.08 (d, J=7.8 Hz, 2H), 7.30 (d, J=7.2Hz, 2H), 8.20 (s, 1H); ¹³C (75 MHz, CDCl₃) δ 21.24, 40.08, 53.16, 54.40,(75.01, 75.25), (82.64, 84.97), 130.18, 130.97, 132.14, 137.45, 161.73,170.12; LC/MS m/s [M+H]⁺ 316.1.

74a: ¹H (300 MHz, CDCl₃) δ 1.24 (d, J=2.1 Hz, 3H), 3.73 (s, 3H), 4.17(s, 1H), 4.32 (s, 1H), 4.41 (br, s, 1H), 4.74 (d, J=8.7 Hz, 1H), 7.23(d, J=8.4 Hz, 1H), 8.17 (s, 1H); ¹³C (75 MHz, CDCl₃) δ 21.04, 52.87,55.38, (72.79, 73.04), (85.37, 87.70), 162.35, 170.63; LC/MS m/s [M+H]⁺194.2.

75a: ¹H (300 MHz, CDCl₃) δ 1.06 (d, J=2.4 Hz, 3H), 3.57 (s, 1H), 3.72(s, 3H), 4.26 (dd, J=9.3, 13.8 Hz, 1H), 4.52 (dd, J=4.44 (dd, J=9.3,14.1 Hz, 1H); ¹³C (75 MHz, CDCl₃) δ 19.78, 19.84, 52.46, 57.49, (72.25,72.48), (85.34, 87.66), 147.05; LC/MS m/s [M+H]⁺ 166.0.

76a: ¹H (300 MHz, CD₃OD) δ 1.37 (d, J=2.1 Hz, 3H), 3.76 (s, 3H), 4.267(dd, J=9.3, 19.5 Hz, 1H), 4.42 (dd, J=9.3, 19.8 Hz, 1H), 4.81 (s, 1H),6.61 (d, J=8.4 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.1 Hz, 2H),7.82 (d, J=8.1 Hz, 2H); ¹³C (75 MHz, CD₃OD) δ 20.51, 51.69, 70.91,(71.94, 72.19), 76.86, 79.08, 84.73, (85.50, 87.83), 108.34, 114.27,126.19, 127.20, 127.57, 132.18, 133.60, 133.89, 150.16, 168.18, 170.60;LC/MS m/s [M+H]⁺ 437.1.

70b: (2.64 g, 88% yield). ¹H (300 MHz, CDCl₃) δ 2.40 (s, 3H), 3.08 (q,J=39.9 Hz, 2H), 5.44 (t, J=111.0 Hz, 1H), 7.33 (d, J=8.4 Hz, 2H), 7.56(d, J=7.8 Hz, 2H); ¹³C (75 MHz, CDCl₃) δ 21.67, 58.08, 62.48, (93.80,94.13, 94.47), (110.57, 113.87, 117.18), 124.45, 130.59, 139.13, 142.91;LC/MS m/s [M+H]⁺ 233.0.

71b: (1.38 g, yield 38%). (Less polar one is product). ¹H (300 MHz,CDCl₃) δ 2.38 (s, 3H), 2.83 (dd, J=3, 13.8 Hz, 1H), 3.20 (d, J=14.1 Hz,1H), 3.68 (s, 3H), 5.08 (d, J=2.4 Hz, 1H), 6.58 (q, J=110.7 H2, 1H),7.05 (s, 1H), 7.30 (d, J=8.7 Hz, 2H), 7.49 (s, J=8.1 Hz, 2H); ¹³C (75MHz, CDCl₃) δ 21.62, 53.12, 58.78, 70.40, (84.01, 84.31, 84.70),(109.33, 112.64, 115.92), 124.18, 130.54, 140.13, 142.71, 155.26,168.72; LC/MS m/s [M+H]⁺ 331.0

72b: (1.20 g, 94% yield). ¹H (300 MHz, CDCl₃) δ 2.39 (s, 3H), 3.09 (dd,J=2.1, 14.4 Hz, 1H), 3.21 (d, J=14.1 Hz, 1H), 3.79 (s, 3H), 5.16 (d,J=9.6 Hz, 1H), 5.59 (s, 1H), 6.04 (d, J=110.7 Hz, 1H), 7.22 (d, J=9.6Hz, 1H), 7.30 (d, J=7.8 Hz, 2H), 7.55 (d, J=8.4 Hz, 2H), 8.22 (s, 1H);¹³C (75 MHz, CDCl₃) δ 21.64, 53.49, 54.07, 58.98, (74.91, 75.20, 75.50),(111.77, 115.07, 118.38), 124.39, 130.48, 139.69, 142.56, 161.95,169.46; LC/MS m/s [M+H]⁺ 350.1.

73b: (1.0 g, 88% yield). ¹H (300 MHz, CDCl₃) δ 2.30 (s, 3H), 3.35 (s,2H), 3.76 (s, 3H), 4.20 (s, 1H), 5.10 (d, J=9.6 Hz, 1H), 5.92 (t,J=110.4 Hz, 1H), 6.76 (d, J=9.6 Hz, 1H), 7.09 (d, J=8.1 Hz, 2H), 7.31(d, J=8.4 Hz, 2H), 8.21 (s, 1H); ¹³C (75 MHz, CDCl₃) δ 21.24, 38.43,53.27, 53.48, (75.06, 75.34, 75.63), (112.44, 115.75, 119.06), 130.23,130.37, 131.15, 131.39, 132.00, 137.72, 161.62, 169.69; LC/MS m/s [M+H]⁺334.0.

74b: (0.519 g, 87% yield). ¹H (300 MHz, CD₃OD) δ 3.75 (s, 3H), 4.68 (s,1H), 5.75 (t, J=112.2 Hz, 1H), 8.13 (s, 1H); ¹³C (75 MHz, CD₃OD) δ16.18, 51.68, 55.05, (72.24, 72.53, 72.82), (112.58, 115.85, 119.13),162.60, 169.54; LC/MS m/s [M+H]⁺ 212.1.

75b: (0.412 g, 99% yield) ¹H (300 MHz, CD₃OD) δ 1.31 (s, 3H), 3.87 (s,3H), 4.18 (s, 1H), 5.99 (t, J=110.1 Hz, 1H); ¹³C (75 MHz, CD₃OD) δ20.02, 56.75, 60.09, 75.37, (116.33, 119.60, 122.87), 170.87; LC/MS m/s[M+H]⁺ 184.0.

76b: (120 mg, 74% yield). ¹H (300 MHz, CD₃OD) δ 1.38 (s, 3H), 3.77 (s,3H), 4.85 (s, 1H), 5.87 (t, J=111.9 Hz, 1H), 6.61 (d, J=8.7 Hz, 2H),7.25 (d, J=8.7 Hz, 2H), 7.57 (d, J=8.7 Hz, 2H), 7.82 (d, J=8.7 Hz, 2H);¹³C (75 MHz, CD₃OD) δ 16.78, 51.78, 57.12, 70.83, 72.88, 76.83, 79.01,84.69, 108.35, 114.25, 116.05, 126.27, 127.60, 13216, 133.48, 133.86,150.17, 168.16, 169.91; LC/MS m/s [M+H]⁺ 455.1.

CPD-058: (70.0 mg, 82% yield), ¹H (300 MHz, CD₃OD) δ 1.36 (s, 3H), 4.73(s, 1H), 5.80 (t, J=112.2 Hz, 1H), 6.61 (d, J=8.7 Hz, 2H), 7.24 (d,J=8.7 Hz, 2H), 7.57 (d, J=8.1 Hz, 2H), 7.82 (d, J=8.4 Hz, 2H); ¹³C (75MHz, CD₃OD) δ 16.54, 54.87, 70.81, (72.60, 72.90, 73.19), 76.83, 78.97,84.68, 108.36, (112.72, 115.96, 119.23), 114.26, 126.27, 127.53, 132.16,133.47, 133.84, 150.16, 166.52, 167.51; LC/MS m/s [M+NH]⁺ 428.2.

CPD-061: (30 mg, 40% yield), ¹H NMR (300 MHz, CD₃OD) δ 1.32 (s, 3H),3.62 (d, J=5.7 Hz, 2H), 4.61 (s, 1H), 6.62 (d, J=8.1 Hz, 2H), 7.24 (d,J=8.1 Hz, 2H), 7.58 (d, J=8.1 Hz, 2H), 7.85 (d, J=7.5 Hz, 2H); ¹³C NMR(75 MHz, CD₃OD); δ 21.53, 29.58, 55.07, (60.86, 61.35), (70.72, 72.30),76.66, 78.96, 84.59, 108.29, 114.20, 126.10, 127.63, 132.06, 133.81,150.24, 166.52, 168.69; LC/MS m/s [M+H]⁺ 410.3.

Example 11

A mixture of 4-nitrophenol 77 (10.0 g, 71.8 mmol) and K₂CO₃ (14.90 g,71.8 mmol, 1.0 equiv) in anhydrous acetone (60 mL) is stirred for 2 h,at room temperature. Propargyl bromide (9.56 mL, 86.16 mmol, 1.2 equiv)is then added. The reaction mixture is heated under reflux for 20 hunder argon. Acetone is removed from the mixture, and the residue ispoured in water (200 mL). The mixture is extracted with chloroform(3×100 mL). The combined organic layers are washed with water (100 mL),brine (100 mL), and dried (anhydrous Na₂SO₄). Evaporation of the solventthe crude product is purified by CombinFlash (eluting with DCM in Hexane0-50%) to give 78 (10.90 g, 85% yield) as yellow solid.

To 78 (10.80 g, 61.1 mmol) in anhydrous THF (20 mL) and acetic acid (140mL) along with activated powdered molecular sieves 4A (18.53 g) isstirred mildly for 2 h at room temperature under argon. The flask isthen immersed in 0° C. bath and stirred well for 20 min. To the cooledreaction mixture is then added the Fe powder (30 g), then is allowed towarm to room temperature with stirring continued for 48 h. The mixtureis then diluted with THF (300 mL) and filtered through a celite pad withwashing THF (100 mL). The solution is rotary evaporated under fullvacuum to dryness. The residue is treated with H₂O (300 mL). And themixture is added 4N NaOH to tune the pH to 10. Then the mixture isextracted with DCM (3×300 mL). The combined organic layers are washedwith water (300 mL), brine (300 mL), and dried (anhydrous Na₂SO₄). Thecrude product is purified by CombinFlash (eluting with MeOH in DCM 0-5%)to obtain 79 (4.28 g, 47% yield) as red oil.

To an oven-dried round bottom flask equipped with water cooled westcondenser and magnetic stir bar are added the Methyl 4-iodobenzoate(6.14 g, 23.46 mmol), bis(triphenylphosphine) palladium (II) dichloride(0.487 g, 0.69 mmol, 0.02 equiv) and copper (I) iodide (0.220 g, 1.16mmol, 0.04 equiv.). The vessel is then sealed with a rubber septum underargon triethylamine (100 mL). Finally, 79 (4.15 g, 28.2 mmol, 1.2 equiv)in triethylamin (30 mL) is added. The reaction mixture is stirred atroom temperature for 36 h. The resulting dark solution is filtered. Thefiltrate is concentrated to dryness with a rotavapor, and the residue istreated with water (100 mL), extracted with EtOAc (3×200 mL). Thecombined extracts are washed with water (50 mL) and brine (anhydrousNa₂SO₄). The crude products are purified by flash chromatography(eluting with 0-30% EtOAc in hexane) to afford 81 (6.0 g, 76%) as yellowsolid.

A 1N solution of NaOH (22 mL, 21.3 mmol, 2.00 equiv) is added to stirsolution of 81 (3.00 g, 10.6 mmol) in MeOH (100 mL) at room temperature.The reaction solution is heated to reflux for 1 h. Then the reactionturned clear. All of the starting material is gone by TLC. The reactionis cooled to room temperature and some MeOH (50 mL) is removed byevaporation under reduced pressure (50 mL). Water (20 mL) is added tothe mixture. Conc. HCl is added dropwise to the stirred solution untilacidic by pH paper (pH=2). The yellow precipitate that formed iscollected by suction filtration. The solid is washed with water (2×30mL) to give 82 (2.8 g, 99% yield).

To a solution of 82 (300 mg, 1.12 mmol) in anhydrous DMF (8 mL) is addedL-threonine methyl ester 83 (0.229 g, 1.35 mmol, 1.2 equiv), EDC.HCl(0.259 mg, 1.35 mmol, 1.2 equiv), HOBt (0.182 mg, 1.35 mmol, 1.2 equiv)at room temperature under argon. The mixture is cooled to 0° C., DIEA(00.98 mL, 5.60 mmol, 5.00 equiv) is added. The reaction mixture isstirred at 0° C. for 2 hours, then is allowed to warm to roomtemperature for 14 hours. The yellow solution is then concentrated todryness. The residue is treated with water (30 mL), extracted with EtOAc(3×50 mL). The combined extracts are washed with water (30 mL), brine(30 mL), and dried (anhydrous Na₂SO₄). The crude product is purified byCombiFlash (eluting with MeOH in DCM 0-5%) to give 84 (170 mg, 40%yield) as yellow solid.

To an ice-cold solution of 84 (120 mg, 0.29 mmol) dissolved in anhydrousMeOH (1 mL) and THF (1 mL) is added hydroxylamine hydrochloride (102 mg,1.47 mmol, 5.0 equiv) followed by 25% sodium methoxide in methanolsolution (0.51 mL, 2.18 mmol, 7.5 equiv). The reaction mixture isstirred under argon and at 0° C. for 2 h, then allowed to warm toambient temperature with the stirring is continued overnight (14 h). Theresulting yellow suspension is condensed to dryness with a rotavapor,and the residue is treated water (20 mL) and saturated NH₄Cl (2 mL),extracted with EtOAc (3×50 mL). The combined extracts are washed withwater (30 mL), brine (30 mL), and dried over anhydrous Na₂SO₄.Evaporation of the solvent affords the crude product, which is purifiedby CombiFlash (eluting with 0-5% MeOH in DCM) to afford CPD-059 (64 mg,57% yield) as yellow solid. ¹H NMR (300 MHz, DMSO-_(d6)) δ 1.07 (d,J=6.3 Hz, 3H), 3.99-4.03 (m, 1H), 4.23 (q, J=13.5 Hz, 1H), 4.67 (s, 2H),4.86 (s, 2H), 6.52 (d, J=9.0 Hz, 2H), 6.76 (d, J=8.7 Hz, 2H), 7.52 (d,J=8.4 Hz, 2H), 7.89 (d, J=8.1 Hz, 2H), 8.11 (d, J=8.4 Hz, 1H), 8.84 (br,s, 1H), 10.66 (br, s, 1H); ¹³C NMR (75 MHz, DMSO-_(d6)); δ 21.02, 57.57,58.80, 67.11, 86.05, 88.60, 115.46, 116.88, 125.26, 128.55, 131.93,134.78, 143.95, 149.31, 166.36, 167.65; LC/MS m/s [M+H]⁺ 384.2.

Example 12

(R)-4-(3-(4-aminophenoxy)prop-1-ynyl)-N-(1-hydroxy-2-oxopyrrolidin-3-yl)benzamide

CPD-060: Following the procedure of CPD-059, (30 mg, 45% yield), ¹H NMR(300 MHz, DMSO-_(d6)) δ 1.88-2.01 (m, 1H), 2.27-2.36 (m, 1H), 3.42-3.47(m, 2H), 4.52 (q, J=26.7 Hz, 1H), 4.86 (s, 2H), 6.51 (d, J=8.7 Hz, 2H),6.75 (d, J=9.0 Hz, 2H), 7.52 (d, J=8.4 Hz, 2H), 7.84 (d, J=8.4 Hz, 2H),8.88 (d, J=8.4 Hz, 1H), 9.77 (s, 1H); ¹³C NMR (75 MHz, DMSO-_(d6)); δ24.18, 46.59, 48.96, 57.55, 86.00, 88.68, 115.47, 116.87, 125.34,128.29, 132.06, 134.54, 143.90, 149.32, 165.91, 167.35; LC/MS m/s [M+H]⁺366.3.

Example 13

A mixture of Methyl 4-hydroxybenzoate 86 (5.0 g, 32.8 mmol) in anhydrousacetone (60 mL) is added K₂CO₃ (4.54 g, 32.8 mmol, 1.0 equiv) andpropargyl benzesulfonate (7.8 mL, 49.2 mmol, 1.5 equiv). The reactionmixture is heated under reflux for 2.5 h under argon. TLC shows that thestarting material is consumed. Acetone is then removed from the mixture,and the residue is poured in water (100 mL). The mixture is extractedwith EtOAc (3×100 mL). The combined organic layers are washed with water(100 mL), brine (100 mL), and dried (anhydrous Na₂SO₄). Evaporation ofthe solvent the crude product is purified by CombinFlash (eluting withEtOAc in Hexane 0-16%) to give 87 (6.0 g, 96% yield) as white solid.

To an oven-dried round bottom flask equipped with water cooled westcondenser and magnetic stir bar are added the 1-iodo-4-nitrobenol (0.79g, 3.2 mmol, 1.2 equiv), bis(triphenylphosphine) palladium (II)dichloride (0.046 g, 0.065 mmol, 0.025 equiv) and copper (I) iodide(0.046 g, 0.015 mmol, 0.04 equiv.). The vessel is then sealed with arubber septum under argon triethylamine (20 mL). Then 87 (0.50 g, 2.60mmol) is added. The reaction mixture is stirred at room temperature for18 h. The resulting suspension dark solution is filtered. The filtrateis concentrated to dryness with a rotavapor, and the residue is treatedwith water (50 mL), extracted with EtOAc (3×50 mL). The combinedextracts are washed with water (30 mL) and brine (30 mL), and dried(anhydrous Na₂SO₄). The crude products are purified by flashchromatography (eluting with 0-20% EtOAc in hexane) to afford 89 (0.52g, 64%) as yellow solid.

To a solution of 89 (480 mg, 1.54 mmol) in anhydrous THF (5 mL) is addedAcOH (5 mL). The mixture is cooled to 0° C. under argon with stirringcontinued for 30 min. Then zinc dust (1.25 g, 19.2 mmol, 30 equiv) isadded. The reaction mixture is stirred at 0° C. for 2 h, then is allowedto warm to room temperature for 18 h. The zinc dust is filtered througha celite pad and washed with THF (50 mL). The filtrate is concentratedto dryness. The residue is treated with 0.25 mM EDTA (20 mL), and isadjusted pH to 12 with 1 N NaOH. The mixture is extracted with EtOAc(3×50 mL). The combined organic layers are washed with water (50 mL),brine (50 mL), and dried (anhydrous Na₂SO₄). The crude product ispurified by CombinFlsh (eluting with EtOAc in Hexane 0-40%) to obtain 90(148 mg, 34% yield) as white solid.

A 1N solution of NaOH (10 mL, 10 mmol, 4.0 equiv) is added to stirsolution of 90 (0.70 g, 2.5 mmol) in MeOH (30 mL) at room temperature.The reaction solution is heated to reflux for 1 h. Then the reactionturned clear. All of the starting material is gone by TLC. The reactionis cooled to room temperature and some MeOH (20 mL) is removed byevaporation under reduced pressure. Water (20 mL) is added to themixture. Conc. HCl is added dropwise to the stirred solution untilacidic by pH paper (pH=2). The yellow precipitate that formed iscollected by suction filtration. The solid is washed with water (2×30mL) to give 91 (0.6 g, 91% yield).

To a solution of 91 (200 mg, 0.75 mmol) in anhydrous DMF (8 mL) is addedL-threonine methyl ester 83 (152 mg, 0.90 mmol, 1.2 equiv), EDC.HCl (173mg, 0.90 mmol, 1.2 equiv), HOBt (122 mg, 0.90 mmol, 1.2 equiv) at roomtemperature under argon. The mixture is cooled to 0° C., DIEA (0.65 mL,3.75 mmol, 5.00 equiv) is added. The reaction mixture is stirred at 0°C. for 2 hours, then is allowed to warm to room temperature for 14hours. The yellow solution is then concentrated to dryness. The residueis treated with water (30 mL), extracted with EtOAc (3×50 mL). Thecombined extracts are washed with water (30 mL), brine (30 mL), anddried (anhydrous Na₂SO₄). The crude product is purified by CombiFlash(eluting with MeOH in DCM 0-5%) to give 92 (191 mg, 50% yield) as yellowsolid.

To an ice-cold solution of 92 (100 mg, 0.26 mmol) dissolved in anhydrousMeOH (1 mL) and THF (1 mL) is added hydroxylamine hydrochloride (91 mg,1.30 mmol, 5.0 equiv) followed by 25% sodium methoxide in methanolsolution (0.46 mL, 1.95 mmol, 7.5 equiv). The reaction mixture isstirred under argon and at 0° C. for 2 h, then allowed to warm toambient temperature with the stirring is continued overnight (14 h). Theresulting yellow suspension is condensed to dryness with a rotavapor,and the residue is treated water (20 mL) and saturated NH₄Cl (2 mL),extracted with EtOAc (3×50 mL). The combined extracts are washed withwater (30 mL), brine (30 mL), and dried over anhydrous Na₂SO₄.Evaporation of the solvent affords the crude product, which is purifiedby CombiFlash (eluting with 0-8% MeOH in DCM) to afford CPD-063 (55 mg,55% yield) as yellow solid. ¹H NMR (300 MHz, DMSO-_(d6)) δ 1.07 (d,J=6.3 Hz, 3H), 3.99-4.03 (m, 1H), 4.25 (q, J=13.8 Hz, 1H), 4.87 (br, s,1H), 5.03 (s, 2H), 5.52 (s, 2H), 6.49 (d, J=8.7 Hz, 2H), 7.08 (d, J=9.9Hz, 2H), 7.83 (s, 1H), 7.88 (d, J=9.0 Hz, 2H); ¹³C NMR (75 MHz,DMSO-_(d6)) δ 21.04, 57.21, 58.56, 67.20, 81.98, 89.21, 107.89, 114.21,115.02, 127.54, 129.95, 133.49, 150.43, 160.50, 166.55, 167.92; LC/MSm/s [M+H]⁺ 384.2.

Example 14

To a solution of sodium 4-ethynylbenzoate 93 (3.70 g, 22 mmol) inanhydrous DMF (100 mL) is added D-serine methyl ester 94 (4.80 g, 30.8mmol, 1.4 equiv), EDC.HCl (5.90 mg, 30.8 mmol, 1.4 equiv), HOBt (4.16 g,30.8 mmol, 1.4 equiv) at room temperature under argon. The mixture iscooled to 0° C., DIEA (9.58 mL, 110 mmol, 5.00 equiv) is added. Thereaction mixture is stirred at 0° C. for 2 hours, then is allowed towarm to room temperature for 14 hours. The yellow solution is thenconcentrated to dryness. The residue is treated with water (100 mL),extracted with EtOAc (3×100 mL). The combined extracts are washed withwater (100 mL), brine (100 mL), and dried (anhydrous Na₂SO₄). The crudeproduct is purified by CombiFlash (eluting with MeOH in DCM 0-5%) togive 95 (4.20 g, 77% yield) as white solid.

Copper (II) acetate (3.67 g, 20.2 mmol, 2.0 equiv) is added at roomtemperature and under stream of argon to a stirred solution of 95 (2.50g, 10.1 mmol) and 96 (5.50 g, 25.3 mmol, 2.5 equiv) dissolved inanhydrous pyridine (30 mL), and MeOH (30 mL), and the mixture arestirred at room temperature for 24 h. The resulting blue solution iscondensed to dryness with a rotavapor, and the residue is treated withwater (100 mL), extracted with EtOAc (3×100 mL). The combined organiclayers are washed water (80 mL), brine (80 mL), and dried over anhydrousNa₂SO₄. The crude products are purified by flash chromatography (elutingwith 0-70% EtOAc in hexane) to afford 97 (1.80 g, 38% yield) as yellowsolid.

To an ice-cold solution of 97 (1.70 g, 3.68 mmol) dissolved in anhydrousMeOH (10 mL) and THF (10 mL) is added hydroxylamine hydrochloride (1.28g, 18.40 mmol, 5.0 equiv) followed by 25% sodium methoxide in methanolsolution (6.5 mL, 27.6 mmol, 7.5 equiv). The reaction mixture is stirredunder argon and at 0° C. for 2 h, then allowed to warm to ambienttemperature with the stirring is continued overnight (14 h). Theresulting yellow suspension is condensed to dryness with a rotavapor,and the residue is treated water (100 mL) and saturated NH₄Cl (50 mL).The yellow suspension solution is filtered. The solid is washed withwater (2×30 mL), EtOAc (3×30 mL). Then the pad is dried on high vacuumto obtain 98 (1.30 g, 76% yield).

To a solution of 98 (1.10 g, 2.38 mmol) in anhydrous MeOH (30 mL) andTHF (30 mL) is added triethylamine (0.36 mL, 2.62 mmol, 1.10 equiv). Themixture solution is cooled to 0° C., then benzylchloride 99 (0.28 mL,2.38 mmol, 1.00 mmol) is added dropwise. The reaction mixture is stirredat 0° C. for 20 min, then is concentrated to dryness. The residue istreated with water (80 mL), extracted with EtOAc (3×80 mL). The combinedorganic layers are washed with water (80 mL), brine (80 mL), and dried(anhydrous Na₂SO₄). The crude product is purified by CombinFlash(eluting with MeOH in DCM 0-3%) to obtain 100 (1.04 g, 77% yield) asyellow solid.

To a solution of 100 (100 mg, 0.176 mmol) in anhydrous MeCN (5 mL) andTHF (5 mL) is added TPP (49 mg, 0.185 mmol, 1.05 equiv), CCl₄ (0.044mL), and triethylamine (0.027 mL, 0.194 mmol, 1.1 equiv). The reactionmixture is stirred at room temperature for 48 h under argon. Then theyellow suspension solution is concentrated to dryness. The residue isdiluted with water (30 mL), extracted with EtOAc (3×50 mL). The combinedorganic layers are washed with water (30 mL), brine (30 mL), and dried(anhydrous Na₂SO₄). The crude product is purified by CominFlash (elutingwith MeOH in DCM 0-2.5%) to give CPD-064 (30 mg, 38% yield) as yellowsolid. ¹H NMR (300 MHz, DMSO-_(d6)) δ 1.46 (s, 9H), 4.17-4.21 (m, 1H),4.55 (t, J=17.4 Hz, 1H), 5.73-5.77 (m, 1H), 5.51 (br, s, 4H), 7.69 (d,J=8.1 Hz, 2H), 7.91 (d, J=8.4 Hz, 2H), 8.33 (s, 1H), 9.37 (d, J=8.1 Hz,1H), 9.68 (s, 1H); ¹³C NMR (75 MHz, DMSO-_(d6)) δ 28.72, 59.27, 69.98,73.04, 76.58, 80.39, 81.26, 84.25, 113.61, 118.62, 124.60, 128.53,133.00, 134.06, 134.75, 142.10, 153.15, 158.79, 165.88; LC/MS m/s [M+H]⁺445.5.

Example 15

Copper (II) acetate (11.33 g, 62.6 mmol, 2.0 equiv) is added at roomtemperature and under stream of argon to a stirred solution of 3 (5.0 g,31 mmol) and 3-ethynylbenzenamin 101 (10.99 g, 93.9 mmol, 3.0 equiv)dissolved in anhydrous pyridine (5 mL), and MeOH (5 mL), and the mixtureare stirred at room temperature for 48 h. The resulting blue solution iscondensed to dryness with a rotavapor, and the residue is treated withwater (100 mL), extracted with EtOAc (3×150 mL). The combined organiclayers are washed with water (100 mL), brine (100 mL), and dried overanhydrous Na₂SO₄. The crude product is purified by flash chromatography(eluting with 0-20% EtOAc in hexane) to afford 102 (2.10 g, 25% yield)as yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 3.92 (s, 3H), 4.34 (s, 2H),6.66-6.71 (m, 2H), 7.14-7.19 (m, 1H), 7.35 (d, J=8.1 Hz, 1H), 7.57 (d,J=6.9 Hz, 2H), 8.01 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃), δ 52.57,77.03, 78.97, 80.50, 81.95, 110.99, 114.70, 118.21, 126.80, 128.59,129.79, 131.21, 132.49, 133.40, 145.00, 166.57; LC/MS m/s [M+H]⁺ 276.3.

A 1N solution of NaOH (20 mL) is added to stir solution of 102 (1.0 g,3.6 mmol) in MeOH (50 mL) at room temperature. The reaction solution isheated to reflux for 1 h. Then the reaction turned clear. All of thestarting material is gone by TLC. The reaction is cooled to roomtemperature and some MeOH is removed by evaporation under reducedpressure (30 mL). Water (30 mL) is added to the mixture. Conc. HCl isadded dropwise to the stirred solution until acidic by pH paper (pH=2).The yellow precipitate that formed is collected by suction filtration.The solid is washed with water (2×30 mL), methanol (2×30 mL) to give 103(0.72 g, 75% yield). ¹H NMR (300 MHz, DMSO-_(d6)) δ 5.69 (br, s, 2H),6.47-6.53 (m, 1H), 6.70 (d, J=7.8 Hz, 1H), 7.08-7.14 (m, 1H), 7.23-7.26(m, 1H), 7.67 (d, J=6.9 Hz, 2H), 7.95 (d, J=8.7 Hz, 2H); ¹³C NMR (75MHz, DMSO-_(d6)) δ 77.61, 78.40, 82.15, 82.43, 103.43, 114.99, 116.58,125.98, 130.29, 131.90, 132.98, 133.71, 152.52, 167.23; LC/MS m/s [M+H]⁺262.3.

To a solution of 103 (180 mg, 0.69 mmol) in anhydrous DMF (5 mL) isadded 104 (237 mg, 0.97 mmol, 1.4 equiv), EDC.HCl (185 mg, 0.97 mmol,1.2 equiv), HOBt (131 mg, 0.97 mmol, 1.4 equiv) at room temperatureunder argon. The mixture is cooled to 0° C., DIEA (0.5 mL, 2.76 mmol,5.00 equiv) is added. The reaction mixture is stirred at 0° C. for 2hours, then is allowed to warm to room temperature for 14 hours. Theyellow solution is then concentrated to dryness. The residue is treatedwith water (30 mL), extracted with EtOAc (3×50 mL). The combinedextracts are washed with water (30 mL), brine (30 mL), and dried(anhydrous Na₂SO₄). The crude product is purified by CombiFlash (elutingwith MeOH in DCM 0-1.5%) to give 105 (230 mg, 68% yield) as yellowsolid. ¹H NMR (300 MHz, CDCl₃) δ 1.45 (s, 9H), 1.47 (s, 3H), 1.51 (s,3H), 4.35 (s, 1H), 4.73 (t, J=8.1 Hz, 2H), 6.64-6.70 (m, 2H), 7.12-7.18(m, 1H), 7.33 (d, J=8.1 Hz, 1H), 7.59 (d, J=8.1 Hz, 2H), 7.91 (d, J=8.4Hz, 2H), 9.14 (br, s, 1H); ¹³C NMR (75 MHz, CDCl₃); δ 24.87, 28.22,28.54, 52.44, 54.54, 62.47, 76.28, 79.04, 80.03, 80.70, 82.13, 106.12,114.67, 118.15, 125.38, 127.65, 131.09, 132.67, 133.36, 134.20, 145.00,156.65, 166.34, 170.77; LC/MS m/s [M+H]⁺ 490.3.

To an ice-cold solution of 105 (190 mg, 0.39 mmol) dissolved inanhydrous DCM (6 mL) is added TFA (1 mL). The reaction mixture isstirred at 0° C. for 2 h under argon, then is allowed to warm to roomtemperature for 12 h. The mixture is quenched with saturated Na₂CO₃. Themixture is concentrated to dryness. The residue is diluted with water(30 mL), extracted with EtOAc (3×50 mL). The combined extracts arewashed with water (30 mL), brine (30 mL), and dried (anhydrous Na₂SO₄).The crude product was purified by CombinFlash (eluting with MeOH in DCM0-5%) to obtain 106 (135 mg, 88% yield) as yellow solid.

To an ice-cold solution of 106 (100 mg, 0.256 mmol) dissolved inanhydrous THF (1 mL) and MeOH (1 mL) is added hydroxylaminehydrochloride (89 mg, 1.28 mmol, 5.0 equiv) followed by 25% sodiummethoxide in methanol solution (0.46 mL, 1.95 mmol, 7.5 equiv). Thereaction mixture is stirred under argon and at 0° C. for 2 h, thenallowed to warm to ambient temperature with the stirring is continuedovernight (14 h). The resulting yellow suspension is condensed todryness with a rotavapor, and the residue is treated water (20 mL) andsaturated NH₄Cl (2 mL), extracted with EtOAc (3×80 mL). The combinedextracts are washed with water (30 mL), brine (30 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent affords the crude product,which is purified by CombiFlash (eluting with 0-15% MeOH in DCM) toafford CPD-065 (71 mg, 71% yield) as yellow solid. ¹H NMR (300 MHz,CD₃OD) δ 1.17 (s, 3H), 1.25 (s, 3H), 4.46 (s, 1H), 6.57-6.62 (m, 1H),6.74 (d, J=8.1 Hz, 1H), 7.10-7.15 (m, 1H), 7.24-7.27 (m, 1H), 7.60 (d,J=8.4 Hz, 2H), 7.86 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD); δ 25.87,26.76, 52.58, 75.91, 77.77, 80.24, 80.98, 105.00, 114.53, 117.03,125.63, 127.69, 130.88, 132.19, 132.82, 134.17, 151.16, 167.81, 167.98;LC/MS m/s [M+H]+ 391.5.

Example 16

To a solution of 103 (180 mg, 0.69 mmol, prepared as in Example 15) inanhydrous DMF (5 mL) is added 107 (237 mg, 0.97 mmol, 1.4 equiv),EDC.HCl (185 mg, 0.97 mmol, 1.2 equiv), HOBt (131 mg, 0.97 mmol, 1.4equiv) at room temperature under argon. The mixture is cooled to 0° C.,DIEA (0.5 mL, 2.76 mmol, 5.00 equiv) is added. The reaction mixture isstirred at 0° C. for 2 hours, then is allowed to warm to roomtemperature for 14 hours. The yellow solution is then concentrated todryness. The residue is treated with water (30 mL), extracted with EtOAc(3×50 mL). The combined extracts are washed with water (30 mL), brine(30 mL), and dried (anhydrous Na₂SO₄). The crude product is purified byCombiFlash (eluting with MeOH in DCM 0-3%) to give 108 (150 mg, 56%yield) as yellow solid. ¹H NMR (300 MHz, CD₃OD) δ; ¹³C NMR (75 MHz,CD₃OD); LC/MS m/s [M+H]⁺ 391.1

To an ice-cold solution of 108 (100 mg, 0.256 mmol) dissolved inanhydrous THF (1 mL) and MeOH (1 mL) is added hydroxylaminehydrochloride (89 mg, 1.28 mmol, 5.0 equiv) followed by 25% sodiummethoxide in methanol solution (0.46 mL, 1.95 mmol, 7.5 equiv). Thereaction mixture is stirred under argon and at 0° C. for 2 h, thenallowed to warm to ambient temperature with the stirring is continuedovernight (14 h). The resulting yellow suspension is condensed todryness with a rotavapor, and the residue is treated water (20 mL) andsaturated NH₄Cl (2 mL), extracted with EtOAc (3×80 mL). The combinedextracts are washed with water (30 mL), brine (30 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent affords the crude product,which is purified by CombiFlash (eluting with 0-15% MeOH in DCM) toafford CPD-066 (50 mg, 50% yield) as yellow solid. ¹H NMR (300 MHz,CD₃OD) δ 1.27 (s, 3H), 1.34 (s, 3H), 4.50 (s, 1H), 6.57-6.62 (m, 1H),6.73-6.76 (m, 1H), 7.10-7.15 (m, 1H), 7.24-7.68 (m, 1H), 7.61 (d, J=8.7Hz, 2H), 7.86 (d, J=8.4 Hz); ¹³C NMR (75 MHz, CD₃OD); δ 25.79, 26.10,58.79, 71.57, 75.90, 77.75, 80.23, 80.96, 104.98, 114.52, 117.02,125.64, 127.59, 130.88 132.22, 132.80, 134.19, 151.16, 167.77, 168.04;LC/MS m/s [M+H]⁺ 392.2.

Example 17

To a solution of 103 (180 mg, 0.69 mmol, prepared as in Example 15) inanhydrous DMF (5 mL) is added 75b (237 mg, 0.97 mmol, 1.4 equiv),EDC.HCl (185 mg, 0.97 mmol, 1.2 equiv), HOBt (131 mg, 0.97 mmol, 1.4equiv) at room temperature under argon. The mixture is cooled to 0° C.,DIEA (0.5 mL, 2.76 mmol, 5.00 equiv) is added. The reaction mixture isstirred at 0° C. for 2 hours, then is allowed to warm to roomtemperature for 14 hours. The yellow solution is then concentrated todryness. The residue is treated with water (30 mL), extracted with EtOAc(3×50 mL). The combined extracts are washed with water (30 mL), brine(30 mL), and dried (anhydrous Na₂SO₄). The crude product is purified byCombiFlash (eluting with MeOH in DCM 0-1.5%) to give 109 (150 mg, 80%yield) as yellow solid. ¹H NMR (300 MHz, CD₃OD) δ 1.38 (s, 3H), 3.78 (s,3H), 4.85 (s, 1H), 5.88 (t, J=112.2 Hz, 1H), 6.57-6.63 (m, 1H), 6.74 (d,J=8.7 Hz, 1H), 7.01-7.16 (m, 1H), 7.24-7.27 (m, 1H), 7.62 (d, J=8.7 Hz,2H), 7.84 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 16.77, 51.76,57.15, (72.59, 72.88, 73.18), 75.97, 77.73, 80.27, 80.93, 104.97,114.52, (112.76, 116.05, 119.33), 117.02, 125.81, 127.65, 130.89,132.24, 132.81, 133.86, 151.17, 152.36, 168.10, 169.89; LC/MS m/s [M+H]⁺427.1.

To an ice-cold solution of 109 (100 mg, 0.256 mmol) dissolved inanhydrous THF (1 mL) and MeOH (1 mL) is added hydroxylaminehydrochloride (89 mg, 1.28 mmol, 5.0 equiv) followed by 25% sodiummethoxide in methanol solution (0.46 mL, 1.95 mmol, 7.5 equiv). Thereaction mixture is stirred under argon and at 0° C. for 2 h, thenallowed to warm to ambient temperature with the stirring is continuedovernight (14 h). The resulting yellow suspension is condensed todryness with a rotavapor, and the residue is treated water (20 mL) andsaturated NH₄Cl (2 mL), extracted with EtOAc (3×80 mL). The combinedextracts are washed with water (30 mL), brine (30 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent affords the crude product,which is purified by CombiFlash (eluting with 0-15% MeOH in DCM) toafford CPD-067 (71 mg, 71% yield) as yellow solid. ¹H NMR (300 MHz,CD₃OD) δ 1.35 (s, 3H), 4.73 (s, 1H), 5.80 (t, J=112.2 Hz, 1H), 6.57-6.62(m, 1H), 6.74 (d, J=9.0 Hz, 1H), 7.10-7.16 (m, 1H), 7.24-7.27 (m, 1H),7.62 (d, J=8.7 Hz, 2H), 7.85 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD)δ 16.55, 54.89, (72.64, 72.90, 73.24), 75.98, 77.73, 80.28, 80.92,104.97, 114.53, (112.73, 115.99, 119.25), 117.02, 125.81, 127.59,130.89, 132.26, 132.81, 133.86, 151.17, 166.51, 167.45; LC/MS m/s [M+H]⁺428.3.

Example 18

To a solution of 6 (180 mg, 0.69 mmol, prepared as in Example 1) inanhydrous DMF (5 mL) is added L-threonine methyl ester hydrochloride 83(164 mg, 0.97 mmol, 1.4 equiv), EDC.HCl (185 mg, 0.97 mmol, 1.2 equiv),HOBt (131 mg, 0.97 mmol, 1.4 equiv) at room temperature under argon. Themixture is cooled to 0° C., DIEA (0.5 mL, 2.76 mmol, 5.00 equiv) isadded. The reaction mixture is stirred at 0° C. for 2 hours, then isallowed to warm to room temperature for 14 hours. The yellow solution isthen concentrated to dryness. The residue is treated with water (30 mL),extracted with EtOAc (3×50 mL). The combined extracts are washed withwater (30 mL), brine (30 mL), and dried (anhydrous Na₂SO₄). The crudeproduct is purified by CombiFlash (eluting with MeOH in DCM 0-3%) togive 110 (228 mg, 88% yield) as yellow solid. ¹H NMR (300 MHz, CDCl₃) δ1.28 (d, J=6.3 Hz, 3H), 3.80 (s, 3H), 3.94 (br, s, 1H), 4.47-4.44 (m,1H), 4.79-4.83 (m, 1H), 6.60 (d, J=8.7 Hz, 2H), 6.94 (d, J=8.4 Hz, 2H),7.34 (d, J=8.7 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.80 (d, J=8.4 Hz, 2H);¹³C NMR (75 MHz, CDCl₃) δ 20.36, 52.97, 57.79, 68.45, 72.02, 79.90,84.54, 110.51, 114.84, 126.33, 127.45, 132.73, 133.63, 134.43, 148.01,167.21, 171.73; LC/MS, m/s [M+H]⁺ 377.3.

CPD-045: To a stirred mixture of 110 (100 mg, 0.266 mg) in anhydrousmethanol (2 mL) is added N₂H₄.H₂O (0.27 mL, 2.660 mmol, 10.0 equiv)under argon. The reaction mixture is stirred at room temperature for 16h. The precipitate is filtered and washed with EtOAc (2×20 mL), and thendried by full vacuum overnight to give CPD-045 (77.5 mg, 77% yield) awhite solid. ¹H (300 Hz, DMSO-_(d6)) δ 1.061 (d, 2H, J=6.3 Hz), 4.021(q, 1H, J=18.0 Hz), 4.214 (d, 2H, J=3.3 Hz), 4.318 (d, 2H, J=13.5 Hz),4.865 (d, 1H, J=6.3 Hz), 5.832 (s, 2H), 6.532 (d, 2H, J=8.7 HZ), 7.244(d, 2H, J=8.4 Hz), 7.637 (d, 2H, J=8.7 Hz), 7.906 (d, 2H, J=8.4 Hz),8.091 (d, 2H, J=8.7 Hz), 9.161 (s, 1H); ¹³C (300 Hz, DMSO-^(d6)) δ21.01, 59.41, 67.24, 71.77, 77.27, 80.83, 86.34, 105.82, 114.25, 124.72,128.58, 132.57, 134.68, 135.01, 151.52, 166.27, 170.11; LC/MS m/s [M+H]⁺377.1.

CPD-046: To a stirred mixture of 110 (100 mg, 0.266 mmol) in methanol (2mL) is added NaOH (11.0 mg, 0.266 mmol, 1.0 equiv) in milliQ water (0.50mL) under argon. The reaction mixture is stirred at room temperature for16 h, and then concentrated to dryness. The residue is treated withwater (20 mL) and tuned the pH to 6 with 0.1 N HCl. The yellow solutionis then concentrated to dryness. The crude product is treated withmethanol (20 mL) and filtered to give CPD-046 (95 mg, 99% yield) asyellow solid. ¹H (300 MHz, CD₃OD) δ 1.21 (d, J=6.6 Hz, 3H), 4.28-4.33(m, 1H), 4.48 (d, J=3.3 Hz, 1H), 6.62 (d, J=9.0 Hz, 2H), 7.24 (d, J=8.7Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.89 (d, J=8.7 Hz, 2H); ¹³C (75 MHz,CD₃OD) δ 19.32, 60.23, 68.33, 70.77, 76.46, 79.05, 84.44, 108.35,114.21, 125.73, 127.37, 132.07, 133.79, 134.51, 150.19, 167.42, 176.00;LC/MS m/s [M+H]⁺ 363.5.

CPD-047: To a stirred mixture of 110 (100 mg, 0.266 mmol) in anhydrousmethanol (1 mL) is added 7 N NH₃ in methanol (10 mL) at pressure flask.The reaction mixture is stirred at 5° C. for 90 h. LC/MS monitoringshowed it is completed. Then the yellow suspension is concentrated todryness. The crude product is washed with EtOAc (3×5 mL) to give CPD-047(98.0 mg, 98% yield) as yellow solid. ¹H (300 MHz, CD₃OD) δ 1.24 (d,J=6.6 Hz, 2H), 4.32 (q, J=10.2 Hz, 1H), 4.55 (d, J=3.6 Hz, 1H), 6.64 (d,J=8.4 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.88 (d,J=8.4 Hz, 2H); ¹³C (75 MHz, CD₃OD) δ 19.23, 59.27, 67.42, 70.79, 76.70,79.02, 84.61, 108.33, 114.24, 126.08, 127.56, 132.12, 133.83, 150.20,168.11, 174.09; LC/MS m/s [M+H]⁺ 362.1.

Example 19

(i) 111, PdCl₂(PPh₃)₂, CuI, TEA, THF room temperature, 24 h; (ii)NH₂OH.HCl, NaOMe, MeOH/THF, 0° C., 2 h, then, room temperature, 16 h.

111: To a stirred mixture of sodium 4-ethynylbenzoate (2.52 g, 15 mmol)and L-threonine methyl ester hydrochloride (3.05 g, 18 mmol, 1.2 equiv)in anhydrous DMF (100 mL) is addedN-ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl)(3.45 g 18 mmol, 1.2 equiv) and 1-hydroxybenzotriazole hydrate (HOBt)(2.45 g 18 mmol, 1.2 equiv) at room temperature. The mixture is chilledwith an ice-bath, and diisopropylethylamine (DIEA) (10.45 mL, 60 mmol,4.0 equiv) is added. The whole reaction mixture is stirred under argonat 0° C. for 1 h, and then allowed to warm to ambient temperature, andwith the stirring continued for additional 20 h. The resulting yellowsolution is condensed to dryness with a rotavapor, and the residue istreated with water (100 mL), extracted with EtOAc (3×100 mL). Thecombined extracts are washed with 1N HCl (2×70 mL) and brine (100 mL),and dried (anhydrous Na₂SO₄). Evaporation of the solvents affords thecrude product (3.5 g), which is crystallized from EtOAc/hexane to give111 (1.9 g, 48% yield) as light yellow crystal. ¹H NMR (300 MHz, CDCl₃):δ 1.28 (d, J=6.3 Hz, 3H), 3.21 (s, 2H), 3.79 (s, 3H), 4.41-4.49 (m, 1H),4.80 (dd, J=2.4, 8.7 Hz, 1H), 6.94 (d, J=9.0 Hz, 1H), 7.55 (d, J=8.4 Hz,2H), 7.79 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): δ 20.34, 52.95,57.81, 68.42, 79.94, 82.89, 126.06, 127.39, 132.55, 133.86, 167.28,171.74; MS (ESI, positive): m/z 284 [M+Na]⁺.

113: To an ice-cold solution of methyl ester 111 (1.1 mmol) dissolved inanhydrous MeOH (5 mL) and THF (5 mL) is added hydroxylaminehydrochloride (3.3 mmol, 3 equiv) followed by 25% sodium methoxide inmethanol solution (5 mmol, 4.5 equiv). The reaction mixture is stirredunder argon and at 0° C. for 2 h, then allowed to warm to ambienttemperature with the stirring is continued overnight (16 h). Theresulting yellow suspension is condensed to dryness with a rotavapor,and the residue is treated with 1N HCl aqueous solution (10 mL). Themixture is extracted with EtOAc (100 mL), washed with brine (30 mL), anddried (anhydrous Na₂SO₄). Evaporation of the solvent affords the crudeproduct, which is purified by flash chromatography (eluting with 4-10%MeOH in DCM) to afford hydroxamic acid as yellow solid.

Example 20

CPD-007,4-(5-(dimethylamino)penta-1,3-diynyl)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide

CPD-007: 32% yield; ¹H NMR (300 MHz, CD₃OD): δ 1.22 (d, J=5.7 Hz, 3H),2.36 (s, 6H), 3.50 (s, 2H), 4.20 (m, 1H), 4.40 (d, 1H), 7.58 (d, J=7.8Hz, 2H), 7.86 (d, J=7.8 Hz, 2H); MS (ESI, negative): 342 (M−1).

Example 21

CPD-009,N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(phenylbuta-1,3-diynyl)benzamide

CPD-009: 57% yield; ¹H NMR (300 MHz, CD₃OD): δ 1.20 (d, J=4.8 Hz, 3H),4.19 (m, 1H), 4.40 (d, J=3.9 Hz, 1H), 7.35-7.51 (m, 5H), 7.59 (d, J=6Hz, 2H), 7.86 (d, J=6 Hz, 2H); MS (ESI, negative): 361 (M−1).

Example 22

(i) substituted acetylene, Cu(OAc)₂, pyridine, MeOH, room temperature.(ii) hydroxylamine hydrochloride, 25% NaOMe/MeOH, THF, 0° C., 2 h, thenroom temperature, 16 h.

General procedure for Glaser coupling with 114: Copper (II) acetate(0.36 g, 2 mmol, 2.0 equiv) is added at room temperature to a stirredsolution of 114 (0.26 g, 1 mmol) and substituted acetylene (5 mmol, 5equiv) dissolved in anhydrous pyridine (4 mL) and MeOH (4 mL), and thereaction mixture is stirred at room temperature for 18 h (80 h for3-ethynybenzenamine and 2-ethynybenzenamine). The resulting bluesolution is condensed to dryness with a rotavapor, and the residue istreated with water (50 mL) and extracted with EtOAc (3×50 mL). Thecombined organic layers are washed with water (50 mL) and brine (50 mL),and dried (Na₂SO₄). The crude product is purified by CombiFlash (elutingwith 50-75% EtOAc in hexane) to afford diacetylene methyl ester 115a-fas yellow solid.

115a: 67% yield; ¹H NMR (300 MHz, CDCl₃): δ 1.28 (d, J=6.3 Hz, 3H), 3.79(s, 3H), 3.94 (br, s, 1H), 4.47-4.44 (m, 1H), 4.80 (dd, J=2.4, 8.7 Hz,1H), 6.59 (d, J=8.7 Hz, 2H), 6.93 (d, J=8.4 Hz, 2H), 7.33 (d, J=8.7 Hz,2H), 7.57 (d, J=8.4 Hz, 2H), 7.79 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz,CDCl₃): δ 20.35, 52.96, 57.79, 68.44, 72.01, 79.89, 84.53, 110.51,114.84, 126.32, 127.44, 132.72, 133.62, 134.43, 148.01, 167.21, 171.72;MS (ESI, positive): m/z 399 [M+Na]⁺.

115b: 62% yield; ¹H NMR (300 MHz, CDCl₃): δ 1.26 (d, J=6.3 Hz, 3H), 3.76(s, 3H), 4.42-4.44 (m, 1H), 4.78 (dd, J=2.4, 9.0 Hz, 1H), 6.68 (d, J=8.1Hz, 1H), 6.80 (s, 1H), 6.92 (d, J=7.5 Hz, 1H), 7.09 (t, J=15.6 Hz, 1H),7.54 (d, J=8.7 Hz), 7.77 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃): δ20.35, 52.94, 58.00, 68.35, 73.19, 80.33, 83.54, 116.79, 118.66, 122.28,123.24, 125.88, 127.51, 129.64, 132.84, 133.89, 146.60, 167.34, 171.73;MS (ESI, positive): m/z 399 [M+Na]⁺.

115c: 26% yield; ¹H NMR (300 MHz, CDCl₃): δ 1.27 (d, J=6.3 Hz, 3H), 3.77(s, 3H), 4.35 (br, 1H), 4.41-4.46 (m, 1H), 4.79 (dd, J=2.4, 8.7 Hz, 1H),6.64-6.69 (m, 2H), 7.06 (d, J=8.7 Hz, 1H), 7.12-7.18 (m, 1H), 7.77 (dd,J=1.5, 8.1 Hz, 2H), 7.55 (d, J=8.7 Hz, 2H), 7.79 (d, J=8.4 Hz, 2H); ¹³CNMR (75 MHz, CDCl₃): δ 20.35, 52.95, 57.98, 68.37, 76.70, 98.95, 80.33,81.81, 105.95, 114.70, 118.20, 125.87, 127.54, 131.16, 132.72, 133.38,133.90, 149.98, 167.29, 171.73; MS (ESI, positive): m/z 399 [M+Na]⁺.

115d: 23% yield; ¹H NMR (300 MHz, DMSO-d₆): δ 1.12 (d, J=6.3 Hz, 3H),3.63 (s, 3H), 4.14-4.17 (m, 1H), 4.47 (q, J=12.3 Hz, 1H), 4.95 (d, J=7.5Hz, 1H), 6.42 (d, J=6.0 Hz, 1H), 6.68 (s, 2H), 7.54 (d, J=10.8 Hz, 1H),7.66 (d, J=8.4 Hz, 2H), 7.90 (d, J=8.7 Hz, 2H), 8.17 (s, 1H), 8.40 (d,J=8.4 Hz, 1H); ¹³C NMR (75 MHz, DMSO-d₆): δ 20.93, 52.63, 59.77, 67.07,74.21, 76.88, 81.47, 83.40, 104.28, 108.40, 124.67, 128.59, 132.81,134.79, 140.91, 153.94, 160.49, 166.71, 171.69; MS (ESI, positive): m/z378 [M+H]⁺.

115e: 27% yield; ¹H NMR (300 MHz, DMSO-d₆): δ 1.12 (d, J=6.3 Hz, 3H),3.63 (s, 3H), 4.13-4.19 (m, 1H), 4.45-4.49 (m, 1H), 4.95 (d, J=7.5 Hz,1H), 7.39 (s, 1H), 7.681 (d, J=8.4 Hz, 2H), 7.91 (d, J=8.4 Hz, 2H), 8.48(s, 2H); ¹³C NMR (75 MHz, DMSO-d₆): δ 20.92, 52.63, 59.78, 67.06, 76.37,76.86, 80.09, 82.35, 104.37, 124.36, 128.62, 132.91, 135.00, 162.47,162.65, 166.69, 177.68; MS (ESI, positive): m/z 397 [M+H]⁺.

115f: 30% yield; ¹H NMR (300 MHz, CD₃OD): δ 1.24 (d, J=6.6 Hz, 3H), 3.77(s, 3H), 4.36-4.42 (m, 1H), 4.69 (d, J=3.3 Hz, 1H), 7.46 (q, J=13.8 Hz,1H), 7.66 (d, J=8.7 Hz, 2H), 7.91 (d, J=8.4 Hz, 2H), 7.99 (d, J=8.1 Hz,1H), 8.56 (d, J=6.3 Hz, 1H), 8.71 (s, 1H); ¹³C NMR (75 MHz, CD₃OD): δ19.30, 51.74, 58.85, 67.30, 76.38, 78.36, 81.44, 119.42, 123.91, 124.73,127.70, 132.56, 134.77, 140.30, 149.07, 152.28, 168.22, 171.30; MS (ESI,positive): m/z 363 [M+H]⁺.

General procedure for converting 115a-f into the correspondinghydroxamic acids: To an ice-cold solution of 115 (120 mg, 0.32 mmol)dissolved in anhydrous MeOH (1.5 mL) and THF (1.5 mL) is addedhydroxylamine hydrochloride (110 mg, 1.60 mmol, 5 equiv) followed by 25%sodium methoxide in methanol solution (0.53 mL, 2.20 mmol, 7 equiv). Thereaction mixture is stirred under argon and at 0° C. for 2 h, thenallowed to warm to ambient temperature with the stirring continuedovernight (16 h). The resulting yellow suspension is condensed todryness with a rotavapor, and the residue is treated water (50 mL). Themixture is extracted with EtOAc (3×50 mL). The combined organic layersare washed with brine (30 mL) and dried. Evaporation of the solventaffords the crude product, which is purified by CombiFlash (eluting withMeOH in DCM 7-10%) to afford hydroxamic acid as yellow solid.

CPD-011,(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide:61% yield; ¹H (300 MHz, CD₃OD): δ 1.23 (d, J=6.6 Hz, 3H), 4.21-4.17 (m,1H), 4.43 (d, J=5.1 Hz, 1H), 6.62 (d, J=6.9 Hz, 1H), 7.24 (d, J=8.7 Hz,1H), 7.58 (d, J=8.7 Hz, 2H), 7.63 (d, J=8.4 Hz), 7.87 (d, J=8.4 Hz, 2H),7.72 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD): δ 19.14, 57.90, 67.23,70.73, 76.63, 78.97, 84.57, 108.32, 114.22, 126.06, 127.56, 132.07,133.81, 150.22, 168.08, 168.41; HRMS: calculated for C₂₁H₁₉N₃O₄377.1376. found 377.1376 (M⁺).

CPD-012,(2S,3R)-2-{4′-[(3″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide:66% yield; ¹H NMR (300 MHz, CD₃OD): δ 1.23 (d, J=6.3 Hz, 3H), 4.18-4.21(m, 1H), 4.43 (d, J=5.1 Hz, 1H), 6.73-6.77 (m, 1H), 6.80-6.84 (m, 2H),7.05-7.10 (m, 1H), 7.60 (d, J=8.4 Hz, 2H), 7.88 (d, J=8.4 Hz, 2H); ¹³CNMR (75 MHz, CD₃OD): δ 19.16, 57.91, 67.24, 71.82, 75.76, 79.52, 83.29,116.72, 118.17, 121.69, 121.76, 125.47, 127.61, 129.18, 132.30, 134.22,148.19, 168.02, 168.41; HRMS: calculated for C₂₁H₁₉N₃O₄ 377.1376. found377.1369 (M⁺).

CPD-013,(2S,3R)-2-{4′-[(2″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide:74% yield; ¹H NMR (300 MHz, CD₃OD): δ 1.23 (d, J=6.3 Hz, 3H), 4.18-4.22(m, 1H), 4.44 (d, J=5.1 Hz, 1H), 6.57-6.62 (m, 1H), 6.74 (dd, J=0.6, 8.1Hz, 1H), 7.09-7.15 (m, 1H), 7.26 (dd, J=1.2, 7.5 Hz, 1H), 7.60 (d, J=8.4Hz, 2H), 7.88 (d, J=6.9 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD): δ 19.16,57.92, 67.26, 75.86, 77.75, 80.21, 80.99, 105.01, 114.53, 117.03,125.61, 127.38, 127.63, 130.87, 132.03, 132.19, 132.80, 134.14, 151.15,168.03, 168.39; HRMS: calculated for C₂₁H₁₉N₃O₄ 377.1376. found 377.1374(M⁺).

CPD-035,(2S,3R)-2-{4′-[[(2″-amino)pyridin-5″-yl]buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide:35% yield; ¹H NMR (300 MHz, DMSO-d₆): δ 1.06 (d, J=6.3 Hz, 3H), 4.10 (q,J=12.0 Hz, 1H), 4.23 (q, J=14.1 Hz, 1H), 4.90 (d, J=5.7 Hz, 1H), 6.42(d, J=8.7 Hz, 1H), 6.68 (s, 2H), 7.52 (d, J=8.7 Hz, 1H), 7.65 (d, J=8.1Hz, 2H), 7.91 (d, J=8.4 Hz, 2H), 8.18 (t, J=9.6 Hz, 2H), 7.91 (d, J=8.4Hz, 2H), 8.85 (s, 1H), 10.68 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆): δ21.00, 58.86, 67.07, 74.22, 76.76, 81.54, 83.31, 104.30, 108.42, 124.41,128.64, 132.68, 135.22, 140.91, 153.91, 160.48, 166.25, 167.61; HRMS:calculated for C₂₀H₁₈N₄O₄ 378.1328. found 378.1318 (M⁺).

CPD-036,(2S,3R)-2-{4′-[[(2″-amino)pyrimidin-5″-yl]buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide:30% yield; ¹H NMR (300 MHz, DMSO-d₆): δ 1.10 (d, J=6.0 Hz, 3H),4.01-4.04 (m, 1H), 4.24-4.28 (m, 1H), 4.90 (d, J=6.0 Hz, 1H), 7.41 (s,2H), 7.70 (d, J=8.0 Hz, 2H), 7.92-7.96 (m, 2H), 8.19 (d, J=9.0 Hz, 1H),8.56 (s, 2H), 8.87 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆): δ 20.79, 59.65,66.939, 76.05, 76.67, 79.80, 82.21, 104.18, 110.00, 123.89, 128.45,132.57, 135.23, 162.21, 162.44, 128.46, 132.57, 135.23, 162.21, 162.439,166.02, 167.37; HRMS: calculated for C₁₉H₁₇N₅O₄ 379.1281. found 379.1292(M⁺).

CPD-038,(2S,3R)-2-{4′-[(pyridin-3″-yl]buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide:52% yield; ¹H NMR (300 MHz, DMSO-d₆): δ 1.08 (d, J=6.0 Hz, 3H),4.01-4.05 (m, 1H), 4.22-4.27 (m, 1H), 4.89 (d, J=6.0 Hz, 1H), 7.48 (q,J=12.6 Hz, 1H), 7.73 (d, J=8.1 Hz, 2H), 7.95 (d, J=7.8 Hz, 2H), 8.05 (d,J=7.5 Hz, 1H), 8.22 (d, J=8.4 Hz, 1H), 8.65 (s, 1H), (8.81 (s, 1H), 8.87(s, 1H), 10.69 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆): δ 21.02, 58.86,67.09, 75.47, 76.80, 80.32, 82.77, 118.38, 123.52, 124.40, 128.72,133.09, 135.88, 140.48, 149.74, 150.70, 153.41, 166.21, 167.58; HRMS:calculated for C₂₀H₁₇N₃O₄H⁺ 364.1297. found 364.1301 (MH⁺).

Example 23

(i) benzoyl chloride, Et₃N, MeOH, 0° C., 2 h, 92%. (ii) SOCl₂, 0° C., 5days, 94%. (iii) (1) 5N HCl, reflux, 5 h; (2) SOCl₂, MeOH, reflux, 1 h,98%. (iv) 6, EDC.HCl, HOBt, DIEA, DMF, 0° C., 1 h, then roomtemperature, 18 h, 92%. (v) hydroxylamine hydrochloride, 25% NaOMe/MeOH,THF, 0° C., 2 h, then room temperature, 14 h, 70%.

117: L-Threonine methyl ester hydrochloride 116 (5.0 g, 29.5 mmol) isdissolved in anhydrous MeOH (25 mL), and Et₃N (12.4 mL, 81 mmol) isadded at room temperature. After being stirred at room temperature for15 min, the reaction mixture is cooled to 0° C., and benzoyl chloride(3.76 mL, 32.4 mmol, 1.1 equiv) is added dropwise (over 10 min). Thereaction mixture is stirred for 2 h at 0° C. The MeOH and the excessEt₃N are evaporated by a rotaevaporator (water bath 40° C.). Water (300mL) is added to the residue, and the mixture is extracted with EtOAc(3×80 mL). The combined organic layers are washed with water (50 mL),brine (50 mL) and dried. The solvent is evaporated, and the resultingresidue is mixed with anhydrous diethyl ether (50 mL), and refluxed for1 h with stirring. After cooling, a white precipitate resulted, and thewhite solid is collected by filtration to give methyl(2S,3R)-3-hydroxy-2-(phenylformamido)butanoate 117 (6.45 g, 92% yield)as white solid. ¹H NMR (300 MHz, CDCl₃): δ 1.24 (d, J=6.3 Hz, 3H), 3.26(d, J=5.1 Hz, 1H), 3.73 (s, 3H), 4.37-4.46 (m, 1H), 4.78 (dd, J=1.8, 9.0Hz, 1H), 7.13 (d, J=8.7 Hz, 1H), 7.35-7.50 (m, 3H), 7.79-7.82 (m, 2H);¹³C NMR (75 MHz, CDCl₃): δ 20.25, 52.82, 58.06, 68.30, 127.47, 128.81,132.14, 133.86, 168.36, 171.81; MS (ESI, positive): m/z 238 [M+H]⁺.

118: 117 (6.5 g, 26.5 mmol) is added in portions to an ice-cold stirredsolution of thionyl chloride (20 mL), keeping the inner temperaturebelow 3° C. during the addition. After the completion of the addition,the reaction flask is kept in a 5° C. refrigerator for 5 days. Excessthionyl chloride is then removed under 100 torr at 33° C. (bathtemperature). The residue is dissolved in anhydrous chloroform (40 mL),and immediately, the chloroform solution is poured slowly into saturatedNa₂CO₃ solution with efficient stirring. If necessary, solid Na₂CO₃ isadded to prevent the solution from becoming acidic. The chloroform layeris separated. The aqueous layer is extracted with chloroform (3×50 mL).The combined organic layers are washed with water (50 mL), brine (50mL), and dried. The solvent is removed under reduced pressure to givemethyl (4S,5S)-5-methyl-2-phenyl-4,5-dihydro-1,3-oxazole-4-carboxylate118 (5.48 g, 94% yield) as white solid. ¹H NMR (300 MHz, CDCl₃): δ 1.37(d, J=6.0 Hz, 3H), 3.76 (s, 3H), 4.96-5.08 (m, 2H), 7.37-7.51 (m, 3H),7.96-7.98 (m, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 16.46, 52.30, 71.99,127.47, 128.53, 128.76, 132.02, 166.37, 170.64; MS (ESI, positive): m/z220 [MαH]⁺.

119: A mixture of 118 (5.4 g, 24.6 mmol) and 6N HCl (60 mL) is refluxedfor 5 h, and after cooling to ambient temperature, the reaction mixtureis extracted with diethyl ether (3×70 mL) to remove benzoic acid. Theaqueous layer is evaporated to dryness under reduced pressure, and theresidue is further dried under high vacuum overnight to afford crudeallo-L-threonine. MeOH (25 mL) is cooled to 0° C., and thionyl chloride(1.80 mL, 25.2 mmol) is added dropwise. To the resulting HCl methanolsolution is added the crude allo-L-threonine, and the reaction mixtureis heated under reflux for 1 h. The solvent is removed in vacuo, andanother batch of HCl methanol solution (prepared in the same manner) isadded, and then the reaction mixture is heated under reflux for another1 h. The solvent is removed in vacuo to obtain allo-L-threonine methylester hydrochloride 119 (4.15 g, 98% overall yield for the two steps) astiny red solid. ¹H NMR (300 MHz, CD₃OD): δ 1.27 (d, J=6.6 Hz, 3H), 4.03(d, J=3.3 Hz, 1H), 4.27-4.33 (m, 1H); ¹³C NMR (75 MHz, CD₃OD): δ 17.13,58.17, 65.11, 162.67; MS (ESI, positive): m/z 134 [M+H]⁺.

120: To a stirred mixture of acid 6 (120 mg, 0.46 mmol, prepared as inExample 1) and allo-L-threonine methyl ester hydrochloride 119 (94 mg,0.55 mmol, 1.2 equiv) in anhydrous DMF (5 mL) is added EDC.HCl (106 mg0.55 mmol, 1.2 equiv), HOBt (75 mg, 0.55 mmol, 1.2 equiv) at roomtemperature. The mixture is chilled to 0° C. with an ice-bath, anddiisopropylethylamine (0.32 mL, 1.84 mmol, 4 equiv) is added. Thereaction mixture is stirred under argon and at 0° C. for 1 h, thenallowed to warm to ambient temperature with the stirring is continuedfor additional 18 h. The resulting yellow solution is condensed todryness with a rotavapor, and the residue is treated with water (20 mL),extracted with EtOAc (3×50 mL). The combined extracts are washed withbrine (40 mL), and dried. Evaporation of the solvent affords the crudeproduct, which is purified by CombiFlash (eluting with 1-3% MeOH in DCM)to afford methyl(2S,3S)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-hydroxybutanoate120 (159 mg, 92% yield) as yellow solid. ¹H NMR (300 MHz, DMSO-d₆): δ1.16 (d, J=6.3 Hz, 3H), 3.62 (s, 3H), 3.98-4.08 (m, 1H), 4.37 (t, J=14.4Hz, 1H), 5.06 (d, J=6.0 Hz, 1H), 5.83 (br s, 2H), 6.53 (d, J=8.7 Hz,2H), 7.24 (d, J=8.4 Hz, 2H), 7.63 (d, J=8.4 Hz, 2H), 7.87 (d, J=8.7 Hz,2H), 8.64 (d, J=7.8 Hz, 1H); ¹³C NMR (75 MHz, DMSO-d₆): δ 21.06, 52.34,60.14, 67.08, 71.78, 77.41, 80.78, 86.43, 105.83, 114.27, 124.96,128.63, 132.64, 134.55, 134.70, 151.56, 166.39, 171.94; MS (ESI,positive): m/z 377 [M+H]⁺.

CPD-053: To an ice-cold solution of 120 (100 mg, 0.26 mmol) dissolved inanhydrous MeOH (1 mL) and THF (1 mL) is added hydroxylaminehydrochloride (92 mg, 1.33 mmol, 5 equiv) followed by 25% sodiummethoxide in methanol solution (0.47 mL, 2.0 mmol, 7.5 equiv). Thereaction mixture is stirred under argon and at 0° C. for 2 h, thenallowed to warm to ambient temperature with the stirring is continuedovernight (14 h). The resulting yellow suspension is condensed todryness with a rotavapor, and the residue is treated with water (20 mL),extracted with EtOAc (3×50 mL). The combined extracts are washed withbrine (20 mL), and dried. Evaporation of the solvent affords the crudeproduct, which is purified by CombiFlash (eluting with 1-8% MeOH in DCM)to afford(2S,3S)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide(CPD-053) (70 mg, 70% yield) as yellow solid. ¹H NMR (300 MHz, DMSO-d₆):δ 1.09 (d, J=6.3 Hz, 3H), 3.97 (br s, 1H), 4.23 (t, J=16.5 Hz, 1H), 4.94(br s, 1H), 5.82 (s, 2H), 6.54 (d, J=8.4 Hz, 2H), 7.24 (d, J=8.7 Hz,2H), 7.60 (d, J=8.1 Hz, 2H), 7.87 (d, J=8.7 Hz, 2H), 8.42 (d, J=8.7 Hz,1H), 8.81 (br s, 1H), 10.58 (br s, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ21.09, 57.95, 66.84, 71.79, 77.26, 80.83, 86.34, 105.83, 114.27, 124.70,128.62, 132.55, 134.69, 135.02, 151.54, 165.93, 167.69; HRMS: calculatedfor C₂₁H₁₉N₃O₄H⁺ 378.1454. found 378.1454 [M+H]⁺.

Example 24

(i) (1) SOCl₂, MeOH, reflux, 1 h, 99%; (2) 6, EDC.HCl, HOBt, DIEA, DMF,0° C., 1 h, then room temperature, 18 h, 92%. (ii) hydroxylaminehydrochloride, 25% NaOMe/MeOH, THF, 0° C., 2 h, then room temperature,14 h, 93%.

(i) (1) SOCl₂, MeOH, reflux, 1 h, 99%; (2) 6, EDC.HCl, HOBt, DIEA, DMF,0° C., 1 h, then room temperature, 18 h, 69%. (ii) hydroxylaminehydrochloride, 25% NaOMe/MeOH, THF, 0° C., 2 h, then room temperature,14 h, 69%.

Anhydrous MeOH (10 mL) is cooled to 0° C., and thionyl chloride (1.22mL, 16.8 mmol) is added dropwise. To the resultant solution of HCl inmethanol is added D-threonine 121 (2.0 g, 16.8 mmol), and the reactionmixture is heated under reflux for 1 h. After the solvent is removed invacuo, another batch of HCl in methanol solution (10 mL), prepared inthe same manner, is added, and the reaction mixture is heated underreflux for another 1 h. The solvent is removed in vacuo to obtainD-threonine methyl ester hydrochloride (2.8 g, 99% yield) as whitesolid, which is used for next step without further purification. ¹H NMR(300 MHz, CD₃OD): δ 1.33 (d, J=6.9 HZ, 3H), 3.85 (s, 3H), 3.95 (d, J=4.2Hz, 1H), 4.24-4.31 (m, 1H); ¹³C NMR (75 MHz, CD₃OD): δ 19.40, 52.60,58.69, 65.24, 168.49; MS (ESI, positive): m/z 134 [M+H]⁺.

By following the similar procedure, allo-D-threonine (0.228 g, 1.9 mmol)is converted into allo-D-threonine methyl ester hydrochloride (0.320 g,99% yield). ¹H NMR (300 MHz, CD₃OD): δ 1.26 (d, J=6.0 Hz, 3H), 3.84 (s,3H), 4.08 (br s, 1H), 4.26 (br s, 1H); ¹³C NMR (75 MHz, CD₃OD): δ 17.69,52.55, 58.30, 65.41, 167.61; MS (ESI, positive): m/z 134 [M+H]⁺.

By following the similar procedure as in Example 22, methyl methyl(2R,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-hydroxybutanoate(122) and methyl(2R,3S)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-hydroxybutanoate(124) are obtained.

122: 92% yield; ¹H NMR (300 MHz, DMSO-d₆): δ 1.13 (d, J=6.0 Hz, 3H),3.64 (s, 3H), 4.14-4.19 (m, 1H), 4.46-4.50 (m, 1H), 4.94 (d, J=7.5 Hz,1H), 5.83 (br s, 2H), 6.53 (d, J=8.1 Hz, 2H), 7.24 (d, J=7.2 Hz, 2H),7.65 (d, J=6.9 Hz, 2H), 7.90 (d, J=7.2 Hz, 2H), 8.37 (d, J=7.5 Hz, 1H);¹³C NMR (75 MHz, DMSO-d₆): δ 20.92, 52.59, 59.76, 67.08, 71.77, 77.42,80.77, 86.44, 105.82, 114.27, 125.00, 128.56, 132.71, 134.70, 151.56,166.74, 171.69; MS (ESI, positive): m/z 377 [M+H]⁺.

124: 69% yield: ¹H NMR (300 MHz, DMSO-d₆): δ 1.15 (d, J=6.3 Hz, 3H),3.63 (s, 3H), 4.00-4.06 (m, 1H), 4.36 (t, J=13.2 Hz, 1H), 5.06 (d, J=4.2Hz, 1H), 5.83 (br s, 2H), 6.53 (d, J=6.9 Hz, 2H), 7.24 (d, J=6.9 Hz,2H), 7.63 (d, J=6.6 Hz, 2H), 7.87 (d, J=8.1 Hz, 2H), 8.64 (d, J=6.9 Hz,1H); ¹³C NMR (75 MHz, DMSO-d₆): δ 21.07, 52.33, 60.14, 67.06, 71.76,77.40, 80.79, 86.43, 105.81, 114.26, 124.95, 128.63, 132.64, 134.54,134.70, 151.56, 166.38, 171.94; MS (ESI, positive): m/z 377 [M+H]⁺.

By following the similar procedure as in Example 22,(2R,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide(CPD-054) and(2R,3S)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide(CPD-055) have been synthesized.

CPD-054: 93% yield; ¹H NMR (300 MHz, DMSO-d6): δ 1.07 (d, J=5.4 Hz, 3H),3.98-4.04 (m, 1H), 4.24 (t, J=12.9 Hz, 1H), 4.87 (d, J=5.7 Hz, 1H), 5.82(br s, 2H), 6.53 (d, J=8.4 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.63 (d,J=8.1 Hz, 2H), 7.90 (d, J=6.6 Hz, 2H), 8.13 (d, J=7.8 Hz, 1H), 8.84 (brs, 1H), 10.65 (br s, 1H); ¹³C NMR (75 MHz, DMSO-d₆): δ 21.00, 58.80,67.09, 71.79, 77.29, 80.84, 86.36, 105.84, 114.27, 124.74, 128.59,132.58, 134.69, 135.02, 151.54, 166.28, 167.62; HRMS: calculated forC₂₁H₁₉N₃O₄H⁺ 378.1454. found 378.1453 [M+H]⁺.

CPD-055: 69% yield; ¹H NMR (300 MHz, DMSO-d₆): δ 1.09 (d, J=6.0 Hz, 3H),3.95-3.98 (m, 1H), 4.23 (t, J=16.2 Hz, 1H), 4.94 (d, J=3.9 Hz, 1H), 5.82(br s, 2H), 6.53 (d, J=7.8 Hz, 2H), 7.24 (d, J=7.2 Hz, 2H), 7.61 (d,J=8.1 Hz, 2H), 7.87 (d, J=7.5 Hz, 2H), 8.42 (d, J=8.7 Hz, 1H), 8.81 (brs, 1H), 10.58 (br s, 1H); ¹³C NMR (75 MHz, DMSO-d₆): δ 21.09, 57.95,66.84, 71.79, 77.26, 80.83, 86.34, 105.84, 114.27, 124.70, 128.62,132.55, 134.69, 135.03, 151.55, 165.93, 167.70; HRMS: calculated forC₂₁H₁₉N₃O₄H⁺ 378.1454. found 378.1460 [M+H]⁺.

Example 25

(i) amino acid methyl ester, EDC.HCl, HOBt, DIEA, DMF, 0° C., then roomtemperature, overnight. (ii) hydroxyamine hydrochloride, 25% NaOMe/MeOH,THF, 0° C., 2 h, and then room temperature.

The following compounds are prepared essentially according to theprocedures set forth above.

To a stirred mixture of diacetylene acid 6 (100 mg, 0.38 mmol, preparedas in Example 1) and amino acid methyl ester hydrochloride (0.54 mmol,1.40 equiv) in anhydrous DMF (5 mL) is addedN-ethyl-N′-(3-dimethylaminopropyl)carbodiimide (EDC.HCl) (103 mg 0.54mmol, 1.40 equiv), 1-hydroxybenzotriazole (HOBt) (73 mg, 0.54 mmol, 1.40equiv) at room temperature. The mixture is cooled with an ice-bath, anddiisopropylethylamine (DIEA) (0.27 mL, 1.53 mmol, 4.0 equiv) is added.The whole reaction mixture is stirred under argon at 0° C. for 1 h, thenis allowed to warm to room temperature with the stirring is continuedfor additional 18 h. The resulting yellow solution is condensed todryness with a rotavapor, and the residue is treated with water (20 mL).The mixture is extracted with EtOAc (3×50 mL). The combined extracts arewashed with water (50 mL), brine (20 mL) and dried over anhydrousNa₂SO₄. Evaporation of the solvent affords the crude product, which ispurified by flash chromatography (eluting with 1-2% MeOH in DCM) toafford amid methyl ester 125 a-q as yellow solid.

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-3-(1′H-imidazol-4′-yl)propanoate(125a); ¹H NMR (300 MHz, CDCl₃): δ 3.20 (br s, 2H), 3.67 (s, 3H), 4.93(br s, 1H), 6.59 (d, J=8.7 Hz, 2H), 7.32 (d, J=11.1 Hz, 2H), 7.54 (d,J=8.4 Hz, 3H), 7.80-7.83 (m, 3H), 8.348 (br s, 1H); ¹³C NMR (75 MHz,CDCl₃): δ 29.24, 52.65, 53.38, 72.07, 79.784, 80.10, 83.07, 84.44,110.45, 114.84, 115.08, 125.99, 127.52, 132.49, 132.65, 134.41, 135.47,148.06, 166.70, 172.17; MS (ESI, positive): m/z 413 [M+H⁺].

5-tert-butyl 1-methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′-3′-diyn-1′-yl]phenyl}formamido)pentanedioate(125b); ¹H NMR (300 MHz, CDCl₃): δ 1.39 (s, 9H), 2.02-2.22 (m, 2H),2.24-2.35 (m, 2H), 3.71 (s, 3H), 3.96 (br s, 2H), 4.69 (q, J=20.1 Hz,1H), 6.54 (d, J=8.4 Hz, 2H), 7.27 (d, J=8.4 Hz, 2H), 7.39 (d, J=7.2 Hz,1H), 7.48 (d, J=8.1 Hz, 2H), 7.73 (d, J=8.1 Hz, 2H); ¹³C NMR (75 MHz,CDCl₃): δ 26.87, 28.25. 31.89, 52.79, 52.93, 72.01, 79.99, 81.46, 84.69,110.00, 114.78, 126.06, 127.43, 132.57, 133.47, 134.36, 148.37, 166.62,172.66, 173.06; MS (ESI, positive): m/z 416 [M+H⁺].

4-tert-butyl 1-methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)butanedioate(125c); ¹H NMR (300 MHz, CDCl₃): δ 1.43 (s, 9H), 2.84 (dd, J=4.5, 17.1Hz, 1H), 3.02 (dd, J=4.5, 17.1 Hz, 1H), 3.77 (s, 3H), 4.00 (br s, 2H),5.00 (m, 1H), 6.58 (d, J=8.7 Hz, 2H), 7.27 (d, J=6.9 Hz, 1H), 7.31 (d,J=8.7 Hz, 2H), 7.54 (d, J=8.7 Hz, 2H), 7.74 (d, J=8.1 Hz, 2H); ¹³C NMR(75 MHz CDCl₃) 28.24, 37.63, 49.38, 53.02, 72.01, 79.92, 82.21, 84.58,110.31, 114.82, 126.21, 127.36, 132.700, 133.66, 134.41, 148.15, 166.28,170.62, 171.60; MS (ESI, positive): m/z 447 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)propanoate(125d); ¹H NMR (300 MHz, DMSO-d₆) δ 1.39 (d, J=7.5 Hz, 3H), 3.63 (s,3H), 4.47 (q, J=28.8 Hz, 1H), 5.83 (br s, 2H), 6.54 (d, J=8.4 Hz, 2H),7.25 (d, J=8.7 Hz, 2H), 7.64 (d, J=8.1 Hz, 2H), 7.89 (d, J=8.4 Hz, 2H),8.88 (d, J=6.9 Hz, 2H); ¹³C NMR (75 MHz, DMSO-d₆) δ 17.37, 49.04, 52.59,71.80, 77.40, 80.79, 86.42, 105.85, 114.28, 124.94, 128.51, 132.67,134.46, 134.71, 151.56, 166.05, 173.73; MS (ESI, positive): m/z 347[M+H]⁺.

(2S)-3-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxypropanamide(125e). 90% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 0.91 (d, J=6.9 Hz, 3H),0.96 (d, J=6.6 Hz, 3H), 2.13-2.20 (m, 1H), 3.64 (s, 3H), 4.27 (t, J=15.3Hz, 1H), 5.84 (s, 2H), 6.53 (d, J=8.4 Hz, 2H), 7.25 (d, J=7.2 Hz, 2H),7.63 (d, J=7.5 Hz, 2H), 7.88 (d, J=7.2 Hz, 2H), 8.71 (d, J=7.8 Hz, 1H);¹³C NMR (75 MHz, DMSO-d₆) δ 19.73, 19.81, 30.18, 52.24, 59.40, 71.78,77.34, 80.82, 86.40, 105.80, 114.26, 124.87, 128.75, 132.59, 134.71,151.57, 166.83, 172.82; MS (ESI, positive): m/z 375 [M+H⁺].

Methyl(2S,3R)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3′-methylpentanoate(125f). 91.3% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 0.82-0.89 (m, 6H),1.19-1.27 (m, 1H), 1.46-1.49 (m, 1H), 1.92-1.95 (m, 1H), 3.63 (s, 3H),4.32 (t, J=15.3 Hz, 1H), 5.84 (s, 2H), 6.53 (d, J=8.7 Hz, 2H), 7.24 (d,J=8.7 Hz, 2H), 7.63 (d, J=8.4 Hz, 2H), 7.88 (d, J=8.4 Hz, 2H), 8.72 (d,J=7.5 Hz, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 11.55, 16.19, 25.91, 36.28,52.34, 58.12, 71.77, 77.35, 80.82, 86.40, 105.80, 114.26, 124.87,128.74, 132.59, 134.71, 151.57, 166.73, 172.87; MS (ESI, positive): m/z389 [M+H⁺].

Methyl2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)acetate(125 g). 83.3% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 3.64 (s, 3H), 4.01 (d,J=5.7 Hz, 2H), 5.85 (s, 2H), 6.53 (d, J=8.7 Hz, 2H), 7.25 (d, J=8.4 Hz,2H), 7.65 (d, J=8.4 Hz, 2H), 7.87 (d, J=8.1 Hz, 2H), 9.07 (t, J=7.5 Hz,1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 41.95, 52.49, 71.80, 77.42, 80.76,86.45, 105.78, 114.27, 125.00, 128.34, 132.81, 134.38, 134.73, 151.59,166.42, 170.97; MS (ESI, positive): m/z 333 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-phenylpropanoate(125 h). 89.3% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 3.06-3.19 (m, 2H),3.62 (s, 3H), 4.60-4.68 (m, 1H), 5.85 (s, 2H), 6.53 (d, J=8.7 Hz, 2H),7.16-7.27 (m, 7H), 7.62 (d, J=8.1 Hz, 2H), 7.78 (d, J=8.4 Hz, 2H), 8.96(d, J=7.8 Hz, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 36.86, 52.71, 55.05,71.774, 77.40, 80.75, 86.45, 105.77, 114.26, 124.96, 127.21, 128.43,128.95, 129.74, 132.70, 134.38, 134.71, 138.30, 144.23, 151.57, 166.23,172.75; MS (ESI, positive): m/z 424 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-4-methylpentanoate(125i). 83% yield; ¹H NMR (300 MHz, CD₃OD) δ 0.95-0.100 (m, 6H),1.68-1.80 (m, 3H), 3.73 (s, 3H), 4.64-4.69 (m, 1H), 6.62 (d, J=8.7 Hz,2H), 7.24 (d, J=8.7 Hz, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.83 (d, J=8.4 Hz,2H); ¹³C NMR (75 MHz, CD₃OD) δ 20.58, 22.14, 25.03, 39.93, 51.65, 70.73,76.60, 78.99, 84.55, 108.27, 114.20, 125.97, 127.56, 132.04, 133.81,150.24, 168.32, 173.52; MS (ESI, positive): m/z 389 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-hydroxypropanoate(125j). 87.6% yield; ¹H NMR (300 MHz, CD₃OD) δ 3.77 (s, 3H), 3.94-3.99(m, 2H), 4.73 (t, J=9.3 Hz, 1H), 6.62 (d, J=9.3 Hz, 2H), 7.25 (d, J=9.0Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.86 (d, J=8.4 Hz, 2H); ¹³C NMR (75MHz, CD₃OD) δ 51.76, 55.80, 61.55, 70.77, 76.66, 79.00, 84.60, 108.29,114.21, 126.06, 127.58, 132.08, 133.83, 150.22, 168.12, 171.09; MS (ESI,positive): m/z 363 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-4-(methylsulfanyl)butanoate(125k). 73.6% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 2.03 (s, 3H), 2.48-2.58(m, 4H), 3.63 (s, 3H), 4.56 (q, J=14.4 Hz, 1H), 5.84 (s, 2H), 6.53 (d,J=8.4 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.64 (d, J=8.4 Hz, 2H), 7.88 (d,J=8.4 Hz, 2H), 8.87 (d, J=7.5 Hz, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ15.24, 30.55, 30.71, 52.43, 52.74, 71.77, 77.42, 80.79, 86.45, 105.78,114.26, 124.98, 128.58, 132.69, 134.44, 134.72, 151.57, 166.56, 173.04;MS (ESI, positive): m/z 407 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-(1′H-indol-3′-yl)propanoate(125l). 98.0% yield; ¹H NMR (300 MHz, CD₃OD) δ 3.29-3.40 (m, 2H), 3.41(d, J=5.4 Hz, 1H), 3.70 (s, 3H), 6.60 (d, J=8.4 Hz, 2H), 6.99 (t, J=14.4Hz, 1H), 7.06-7.12 (m, 2H), 7.23 (d, J=8.1 Hz, 2H), 7.32 (d, J=7.8 Hz,1H), 7.499 (d, J=8.4 Hz, 2H), 7.55 (d, J=7.8 Hz, 1H), 7.69 (d, J=8.1 Hz,2H); ¹³C NMR (75 MHz, CD₃OD) δ 27.05, 51.63, 54.44, 70.81, 76.61, 79.03,84.55, 108.33, 109.78, 111.22, 114.23, 117.98, 118.73, 121.36, 123.23,125.89, 127.49, 132.00, 133.83, 136.88, 150.19, 168.07, 172.86; MS (ESI,positive): m/z 462 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-6-{([tert-butoxy)carbonyl]amino}hexanoate(125m). 87.3% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 1.32 (br s, 13H), 1.76(d, J=5.7 Hz, 2H), 2.87 (d, J=5.4 Hz, 2H), 3.61 (s, 3H), 4.36 (q, J=13.8Hz, 1H), 5.84 (s, 2H), 6.52 (d, J=8.4 Hz, 2H), 6.76 (m, 1H), 7.24 (d,J=8.7 Hz, 2H), 7.63 (d, J=8.1 Hz, 2H), 7.88 (d, J=8.1 Hz, 2H), 8.79 (d,J=7.2 Hz, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 23.77, 28.93, 29.79, 30.82,52.56, 53.50, 71.77, 77.38, 78.01, 80.79, 86.42, 105.79, 114.26, 124.91,128.57, 132.65, 134.52, 134.70, 151.57, 156.25, 166.46, 173.35; MS (ESI,positive): m/z 526 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-5-carbamimidamidopentanoate(125n). 79.8% yield; ¹H NMR (300 MHz, CD₃OD) δ 1.65-1.74 (m, 2H),1.85-1.91 (m, 2H), 1.99-2.06 (m, 2H), 3.23 (t, J=12.0 Hz, 2H), 3.75 (s,3H), 4.69 (q, J=14.4 Hz, 1H), 6.62 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.7 Hz,2H), 7.57 (d, J=8.7 Hz, 2H), 7.85 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz,CD₃OD) δ 25.36, 28.25, 40.69, 51.77, 52.75, 70.77, 76.74, 78.98, 84.67,108.25, 114.23, 126.11, 127.60, 132.09, 133.67, 133.84, 150.25, 157.50,168.34, 172.61.

General procedure for deprotecting of 125b, 125c, 125m, 125p: A flaskcontaining 125 (0.44 mmol) is treated with TFA/DCM (⅓ mL) and stirred at0° C. under argon for 1 h, then is allowed to warm to ambienttemperature with the stirring is continued for additional 14 h. Thereaction mixture is then concentrated by rotary evaporation to give ayellow solid. The residue is treated with water (10 mL), adjusted pH(125b, 125c pH (5); 125m, 125p (11)). The mixture is then extracted withEtOAc (3×50 mL). The combined extracts are washed with water (30 mL),brine (30 mL) and dried over anhydrous Na₂SO₄. Evaporation of thesolvent affords crude product, which is purified by flash chromatography(eluting with 1-3% MeOH in DCM) to afford 126 a-d as yellow solid.

(4S)-4-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-5-methoxy-5-oxopentanoicacid (126a). 98.8% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 1.92-2.14 (m, 2H),2.36 (t, J=14.1 Hz, 2H), 3.38 (br s, 1H), 3.63 (s, 3H), 4.46 (m, 1H),5.84 (br s, 2H), 6.54 (d, J=8.4 Hz, 2H), 7.25 (d, J=8.7 Hz, 2H), 7.64(d, J=8.1 Hz, 2H), 7.89 (d, J=8.4 Hz, 2H), 8.86 (d, J=7.2 Hz, 1H); ¹³C(75 MHz, DMSO-d₆) δ 26.43, 30.85, 52.63, 52.81, 71.81, 77.44, 80.79,86.43, 105.89, 113.16, 114.29, 125.00, 128.55, 131.24, 132.68, 134.44,134.71, 151.54, 166.51, 172.94, 174.46; MS (ESI, positive): m/z 405[M+H⁺].

(3S)-3-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-4-methoxy-4-oxobutanoicacid (126b). 97% yield; ¹H NMR (300 MHz, CD₃OD) 6.89 (dd, J=7.5, 16.8Hz, 1H), 3.04 (dd, J=5.7, 8.4 Hz, 1H), 3.75 (s, 3H), 4.96-4.98 (m, 1H),6.62 (d, J=8.7 Hz, 2H) 7.24 (d, J=8.7 Hz, 2H), 7.56 (d, J=8.7 Hz, 2H),7.81 (d, J=9.0 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 35.45, 49.91, 51.92,70.78, 76.68, 79.00, 84.59, 108.36, 114.26, 126.09, 127.51, 132.10,133.69, 133.83, 150.16, 167.86, 171.67, 172.76; MS (ESI, positive): m/z391 [M+H⁺].

Methyl(2S)-6-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)hexanoate(126c). 97% yield; ¹H NMR (300 MHz, CD₃OD) δ 1.43-1.57 (m, 4H),1.83-1.94 (m, 2H), 2.67 (t, J=13.5 Hz, 2H), 3.74 (s, 3H), 4.59 (q,J=14.4 Hz, 1H), 6.61 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.57 (d,J=8.4 Hz, 2H), 7.84 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 23.30,30.84, 31.24, 40.76, 51.63, 53.28, 70.78, 76.66, 79.02, 84.61, 108.25,114.210 125.99, 127.60, 132.07, 133.84, 150.25, 168.35, 173.07; MS (ESI,positive): m/z 406 [M+H⁺].

Methyl(2S)-3-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)propanoate(126d). 82% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 2.95 (br s, 2H), 3.63 (s,3H), 4.42 (m, 1H), 5.85 (s, 2H), 6.54 (d, J=8.7 Hz, 2H), 7.25 (d, J=8.4Hz, 2H), 7.65 (d, J=8.4 Hz, 2H), 7.91 (d, J=8.1 Hz, 2H), 8.73 (d, J=5.4Hz, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 43.48, 52.54, 57.16, 71.79, 77.40,80.82, 86.43, 105.80, 114.27, 124.92, 128.61, 132.67, 134.73, 151.58,166.65, 172.30; MS (ESI, positive): m/z 362 [M+H⁺].

CPD-014,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-(1′H-imidazol-4′-yl)propanamide:48% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 3.12 (q, 2H, J=20.7 Hz, 4.74 (q,J=14.4 Hz, 1H), 6.62 (d, J=9.0 Hz, 2H), 6.93 (s, 1H), 7.22 (d, J=8.7 Hz,2H), 7.51-7.56 (m, 3H), 7.68 (d, J=1.5 Hz, 1H), 7.76-7.80 (m, 3H); ¹³CNMR (75 MHz, DMSO-d₆) δ 29.24, 52.06, 70.70, 76.59, 78.96, 80.00, 84.56,108.28, 114.20, 116.74, 125.96, 127.54, 131.85, 131.99, 133.79, 135.09,150.24, 167.80, 169.17; HRMS: calculated for C₂₃H₁₈N₅O₃H⁺ 414.1566.found 414.1564 [M+H]⁺.

CPD-017, Tert-butyl(4S)-4-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-4-(hydroxycarbamoyl)butanoate:55% yield; ¹H NMR (300 MHz, CD₃OD) δ 1.43 (s, 9H), 1.97-2.16 (m, 2H),2.37 (t, J=14.7 Hz, 3H), 4.49 (q, J=5.4 Hz, 1H), 6.61 (d, J=8.7 Hz, 2H),7.24 (d, J=8.7 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.84 (d, J=8.4 Hz, 2H);¹³C NMR (75 MHz, CD₃OD) δ 27.16, 31.52, 51.31, 70.79, 76.65, 79.03,80.82, 84.58, 108.33, 114.24, 114.62, 126.01, 127.62, 132.04, 133.82,150.21, 167.96, 169.53, 172.76; HRMS: calculated for C₂₆H₂₇N₃O₅H⁺462.2029. found 462.2016 [M+H]⁺.

CPD-020,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxypropanamide:65% yield; ¹H NMR (300 MHz, DMSO-d₆) 61.31 (d, J=7.2 Hz, 3H), 4.38 (m,1H), 5.83 (s, 2H), 6.54 (d, J=8.7 Hz, 2H), 7.25 (d, J=8.7 Hz, 2H), 7.62(d, J=8.7 Hz, 2H), 7.90 (d, J=8.7 Hz, 2H), 8.61 (d, J=7.2 Hz, 1H), 8.81(br s, 1H), 10.65 (br s, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 18.71, 47.73,71.82, 77.26, 80.87, 86.33, 105.87, 114.29, 124.67, 128.65, 132.51,134.70, 134.93, 151.55, 165.85, 169.83; HRMS: calculated for C₂₀H₁₇N₃O₃347.1270. found 347.1280

CPD-022,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-methylbutanamide:78% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 0.88 (m, 6H), 2.07-2.11 (m, 1H),4.06 (t, J=17.4 Hz, 1H), 5.83 (s, 2H), 6.52 (d, J=8.7 Hz, 2H), 7.24 (d,J=8.4 Hz, 2H), 7.60 (d, J=8.1 Hz 2H), 7.88 (d, J=8.1 Hz, 2H), 8.52 (d,J=8.4 Hz, 1H), 8.88 (s, 1H), 10.73 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ19.90, 30.35, 57.81, 71.79, 77.21, 80.85, 86.31, 105.81, 114.26, 124.63,128.65, 132.54, 134.69, 135.05, 151.55, 166.15, 168.29; HRMS: calculatedfor C₂₂H₂₁N₃O₃ 375.1583. found 375.1576 M⁺.

CPD-023,(2S,3R)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxy-3-methylpentanamide:60% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 0.78-0.85 (m, 6H), 1.12-1.16 (m,1H), 1.46-1.53 (m, 1H), 1.88-1.93 (m, 1H), 4.14 (t, J=18.3 Hz, 1H), 5.84(s 2H), 6.53 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.60 (d, J=8.4Hz, 2H), 7.88 (d, J=8.4 Hz, 2H), 8.55 (d, J=8.7 Hz, 1H), 8.88 (s, 1H),10.74 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 11.17, 16.00, 25.56, 35.97,56.13, 71.80, 77.22, 80.86, 86.32, 105.82, 114.26, 124.63, 128.64,132.54, 134.70, 135.04, 151.55, 166.03, 168.36; HRMS: calculated forC₂₃H₂₃N₃O₃ 389.1739. found 389.1731 M⁺.

CPD-024,2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxyacetamide:95% yield; ¹H NMR (300 Hz, DMSO-d₆) δ 3.72 (s, 2H), 5.84 (s, 2H), 6.53(d, J=8.7 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.60 (d, J=8.1 Hz, 2H), 7.86(d, J=7.8 Hz, 2H), 8.59 (br s, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 42.15,71.83, 77.14, 80.88, 86.27, 105.84, 114.26, 124.49, 128.33, 132.62,134.70, 135.29, 151.55, 165.23, 165.85; HRMS: calculated for C₁₉H₁₅N₃O₃333.1113. found 333.1109 M⁺.

CPD-025,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-phenylpropanamide:77% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 3.00 (d, J=6.6 Hz 2H), 4.57 (m,1H), 5.84 (s, 2H), 6.53 (d, J=8.7 Hz, 2H), 7.15 (d, J=7.2 Hz, 2H),7.20-7.31 (m, 5H), 7.58 (d, J=8.1 Hz, 2H), 7.80 (d, J=7.8 Hz, 2H), 8.76(d, J=6.6 Hz, 2H); ¹³C NMR (75 MHz, DMSO-d₆) δ 38.13, 53.66, 71.80,77.23, 80.84, 86.33, 105.82, 114.26, 124.63, 126.94, 128.50, 129.77,132.52, 134.70, 138.94, 151.54, 165.91, 168.46; HRMS: calculated forC₂₆H₂₁N₃O₃ 423.1583; found 423.1581 M⁺.

CPD-026,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxy-4-methylpentanamide:50% yield; ¹H NMR (300 MHz, CD₃OD) δ 0.94-0.99 (m, 6H), 1.62-1.77 (m,3H), 4.54-4.59 (m, 1H), 6.61 (d, J=8.4 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H),7.55 (d, J=8.4 Hz, 2H), 7.82 (d, J=8.1 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD)δ 21.06, 22.05, 24.87, 40.75, 50.26, 70.81, 76.62, 79.05, 84.55, 108.33,114.24, 125.91, 127.59, 132.02, 133.82, 150.18, 167.95, 170.37; HRMS:calculated for C₂₃H₂₃N₃O₃ 389.1739. found 389.1733 [M+H]⁺.

CPD-027,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N,3-dihydroxypropanamide:66% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 3.65 (s, 2H), 4.36-4.42 (m, 1H),4.95 (s, 1H), 5.84 (s, 2H), 6.53 (d, J=8.4 Hz, 2H), 7.24 (d, J=8.7 Hz,2H), 7.62 (d, J=8.1 Hz, 2H), 7.90 (d, J=8.4 Hz, 2H), 8.40 (d, J=8.1 Hz,1H), 8.83 (s, 1H), 10.67 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 55.01,62.13, 71.80, 77.27, 80.86, 86.35, 105.81, 114.27, 124.70, 128.66,132.54, 134.72, 134.97, 151.56, 166.15, 167.43; HRMS: calculated forC₂₀H₁₇N₃O₄H⁺ 364.1297. found 364.1295 [M+H]⁺.

CPD-028,(2S)-2-({4′-(4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxy-4-(methylsulfanyl)butanamide:45% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 1.94-2.00 (m, Hz, 2H), 2.10 (s,3H), 2.37-2.48 (m, 2H), 4.42 (q, J=16.2 Hz, 1H), 5.84 (s, 2H), 6.52 (d,J=8.7 Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.61 (d, J=8.1 Hz, 2H), 7.89 (d,J=8.4 Hz, 2H), 8.62 (d, J=7.8 Hz, 1H), 8.84 (s, 1H), 10.73 (s, 1H); ¹³CNMR (75 MHz, DMSO-d₆) δ 15.30, 30.57, 31.92, 51.39, 71.79, 77.27, 80.87,86.35, 105.80, 114.26, 124.70, 128.69, 132.52, 134.70, 134.89, 151.56,166.26, 168.75; HRMS: calculated for C₂₂H₂₀N₃O₃SH⁺ 408.1382. found408.1390 [M+H]⁺.

CPD-029,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-(1′H-indol-3′-yl)propanamide:70% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 3.13 (d, J=6.9 Hz, 2H), 4.63 (m,1H), 5.84 (s, 2H), 6.52 (d, J=8.4 Hz, 2H), 6.93-7.05 (m, 2H), 7.18 (s,1H), 7.22-7.29 (m, 3H), 7.58 (d, J=8.1 Hz, 2H), 7.65 (d, J=7.8 Hz, 1H),7.82 (d, J=8.4 Hz, 2H), 8.7 (d, J=8.1 Hz, 1H), 8.88 (s, 1H), 10.76 (s,1H), 10.86 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 28.31, 52.74, 71.80,77.25, 80.84, 86.34, 105.81, 110.94, 112.00, 114.26, 118.94, 119.18,121.58, 124.41, 124.64, 127.83, 128.55, 132.51, 134.71, 134.88, 136.72,151.55, 165.92, 169.04; HRMS: calculated for C₂₈H₂₂N₄O₃H⁺ 463.1770.found 463.1764 [M+H]⁺.

CPD-030, Tert-butylN-[(5S)-5-({4-[4-(4-aminophenyl)buta-1,3-diyn-1-yl]phenyl}formamido)-5-(hydroxycarbamoyl)phenyl]carbamate:yield; ¹H NMR (300 MHz, DMSO-d₆) δ 1.32 (br s, 13H), 1.63-1.67 (m, 2H),2.8-2.86 (m, 2H), 4.25-4.28 (m, 1H), 5.83 (s, 2H), 6.52 (d, J=8.4 Hz,2H), 6.74 (t, J=6.9 Hz, 1H), 7.23 (d, J=8.4 Hz, 2H), 7.60 (d, J=8.4 Hz,2H), 7.88 (d, J=8.4 Hz, 2H), 8.81 (s, 1H), 10.67 (s, 1H); ¹³C NMR (75MHz, DMSO-d₆) δ 23.74, 28.94, 29.79, 32.04, 52.04, 71.80, 77.23, 78.00,80.87, 86.32, 105.82, 114.26, 124.63, 128.66, 132.51, 134.70, 135.00,151.55, 156.24, 166.13, 169.17; HRMS: calculated for C₂₈H₃₂N₄O₅504.2373. found 504.2376 [M+H]⁺.

CPD-031,(2S)-1-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}carbonyl)-N-hydroxypyrrolidine-2-carboxamide:81% yield; ¹H NMR (300 MHz, CD₃OD) δ 1.84-1.90 (m, 1H), 1.97-2.07 (m,1H), 2.23-2.30 (m, 1H), 3.47-3.55 (m, 1H), 3.61-3.67 (m, 1H), 4.43 (q,J=13.8 Hz, 1H), 6.61 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.55 (d,J=6.3 Hz, 2H), 7.60 (d, J=7.8 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 25.23,29.96, 50.47, 58.68, 70.75, 76.02, 79.02, 84.26, 108.31, 114.21, 124.71,126.76, 127.50, 131.99, 132.19, 133.80, 136.15, 150.21, 169.97, 170.53;HRMS: calculated for C₂₂H₁₉N₃O₃H⁺ 374.1505. found 374.1499 [M+H]⁺.

CPD-033,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3′-(4′-hydroxyphenyl)propanamide:67% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 2.87 (d, J=7.2 Hz, 2H), 4.47 (m,1H), 5.83 (s, 2H), 6.53 (d, J=8.7 Hz, 2H), 6.60 (d, J=8.4 Hz, 2H), 7.08(d, J=8.4 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.59 (d, J=8.1 Hz, 2H), 7.80(d, J=8.4 Hz, 2H), 8.68 (d, J=8.4 Hz, 1H), 8.86 (s, 1H), 9.14 (s, 1H),10.75 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 53.96, 71.81, 77.23, 80.85,86.33, 105.82, 114.26, 115.59, 124.63, 128.53, 128.86, 130.74, 132.53,134.70, 134.93, 151.55, 156.42, 165.96. 168.75; HRMS: calculated forC₂₆H₂₁N₃O₄H⁺ 440.1610. found 440.1605 [M+H]⁺.

CPD-034,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-5′-carbamimidamido-N-hydroxypentanamide:70% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 1.50-1.54 (m, 2H), 1.71-1.74 (ms, 2H), 3.08-3.11 (m, 2H), 4.28 (m, 2H), 5.84 (s, 2H), 6.53 (d, J=8.7Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.55 (d, J=7.8 Hz, 2H), 7.83 (d, J=6.6Hz, 2H); ¹³C NMR (75 MHz, DMSO-d₆) δ 26.00, 30.12, 49.29, 52.19, 71.85,77.07, 80.92, 86.22, 105.87, 114.26, 124.32, 128.27, 132.56, 134.69,135.47, 151.53, 157.67, 165.10, 166.73; HRMS: calculated forC₂₃H₂₄N₆O₃H⁺ 433.1988. found 433.1990 [M+H]⁺.

Example 26

(i) TFA, DCM, 0° C. to room temperature. (ii) hydroxylaminehydrochloride, 25% NaOMe/MeOH, THF, 0° C., 2 h, then room temperature.

Amid methyl ester 125 o-q are prepared as noted in Example 24.

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-(4′-hydroxyphenyl)propanoate(125o). 90.8% yield; ¹H NMR (300 MHz, CD₃OD) δ 3.00 (dd, J=9.3, 23.1 Hz,1H), 3.18 (dd, J=5.4, 13.8 Hz, 1H), 3.70 (s, 3H), 4.81 (m, 1H), 6.61 (d,J=8.7 Hz, 2H), 6.70 (d, J=8.7 Hz, 2H), 7.06 (d, J=8.7 Hz, 2H), 7.24 (d,J=8.7 Hz, 2H), 7.52 (d, J=8.7 Hz, 2H), 7.71 (d, J=8.7 Hz, 2H); ¹³C NMR(75 MHz, CD₃OD) δ 36.23, 51.61, 55.07, 70.81, 76.62, 79.05, 84.57,108.32, 114.23, 115.12, 125.92, 127.48, 127.84, 130.06, 132.04, 133.84,150.20, 156.22, 168.10, 172.56; MS (ESI, positive): m/z 439 [M+H⁺].

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-{[(tert-butoxy)carbonyl]amino}propanoate(125p). 88% yield; ¹H NMR (300 MHz, CD₃OD) δ 1.42 (s, 9H), 3.57 (t,J=11.4 Hz, 2H), 3.75 (s, 3H), 4.66 (t, J=11.4 Hz, 1H), 6.62 (d, J=8.7Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.57 (d, J=7.8 Hz, 2H), 7.84 (d, J=8.1Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 27.52, 41.10, 51.52, 54.52, 70.80,76.74, 79.00, 79.49, 84.65, 108.28, 114.22, 126.12, 127.54, 132.09,133.57, 133.84, 150.24, 157.86, 167.87, 171.01; MS (ESI, positive): m/z462 [M+H⁺].

Methyl(2S)-1-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′yl]phenyl}carbonyl)pyrrolidine-2-carboxylate(125q). 79% yield; ¹H NMR (300 MHz, DMSO-d₆); δ 1.85 (t, J=3.3 Hz, 3H),2.22-2.26 (m, 1H), 3.47-3.58 (m, 2H), 3.64 (s, 3H), 4.43-4.48 (m, 1H),5.83 (s, 2H), 6.52 (d, J=8.4 Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.34 (d,J=7.8 Hz, 2H), 7.60 (d, J=8.1 Hz, 2H), 7.60 (d, J=8.4 Hz, 2H); ¹³C NMR(75 MHz, DMSO-d₆) δ 25.69, 29.54, 50.114, 52.59, 59.62, 71.81, 76.79,80.75, 86.14, 105.82, 114.25, 123.69, 127.60, 128.27, 132.70, 134.690,137.01, 151.54, 168.03, 172.90; MS (ESI, positive): m/z 373 [M+H⁺].

General procedure for hydroxamic acid of amid methyl ester 125a-q,127a-d: To an ice-cold solution of amide methyl ester 125 (0.26 mmol)dissolved in anhydrous MeOH (1 mL) and THF (1 mL) is added hydroxylaminehydrochloride (93 mg, 1.34 mmol, 5.0 equiv), followed by adding 25%sodium methoxide in methanol solution (0.49 mL, 2.03 mmol, 7.5 equiv).The reaction mixture is stirred under argon at 0° C. for 2 h, then isallowed to warm to ambient temperature with the stirring is continuedovernight (16 h). The resulting yellow suspension is condensed todryness with a rotavapor, and the residue is treated water (30 mL),saturated NH₄Cl (20 mL). The mixture is extracted with EtOAc (3×50 mL).And the combined extracts are washed with water (30 mL), brine (30 mL)and dried over anhydrous Na₂SO₄. Evaporation of the solvent affords thecrude product, which is purified by combine flash (eluting with 2-5%MeOH in DCM) to afford 127 as yellow solid.

CPD-018,(4S)-4-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-4-(hydroxycarbamoyl)butanoicacid: 99% yield; ¹H NMR (300 MHz, CD₃OD) δ 2.11-2.18 (m, 2H), 2.45 (m,2H), 4.51 (t, J=14.1 Hz, 1H), 6.62 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.7 Hz,2H), 7.55 (d, J=8.4 Hz, 2H), 7.84 (d, J=8.1 Hz, 2H); ¹³C (75 MHz, CD₃OD)δ 27.05, 30.10, 41.30, 51.46, 70.77, 76.61, 79.03, 84.55, 108.34,114.24, 125.78, 127.60, 132.03, 133.81, 150.18, 168.01, 169.53, 175.36;HRMS: calculated for C₂₂H₁₉N₃O₅H⁺ 406.1403. found 406.1398 [M+H]⁺.

CPD-019,(3S)-3-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-(hydroxycarbamoyl)propaneacid: 46.0% yield; ¹H NMR (300 MHz, CD₃OD) δ 2.83 (dd, J=7.8, 16.5 Hz,1H), 2.94 (dd, J=6.3, 16.5 Hz, 1H), 6.61 (d, J=8.7 Hz, 2H), 7.24 (d,J=8.7 Hz, 2H), 7.55 (d, J=8.4 Hz, 2H), 7.83 (d, J=8.7 Hz, 2H); ¹³C (75MHz, CD₃OD) δ 35.56, 70.76, 76.62, 79.01, 84.55, 108.35, 114.24, 126.00,127.62, 132.00, 133.80, 150.18, 167.83, 168.84, 172.60; HRMS: calculatedfor C₂₁H₁₇N₃O₅H⁺ 392.1246. found 392.1242 [M+H]⁺.

CPD-021,(2S)-3-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxypropanamide:75% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 2.83 (d, J=6.6 Hz, 2H), 4.26 (m,1H), 5.84 (s, 2H), 6.53 (d, J=8.4 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.62(d, J=8.1 Hz, 2H), 7.91 (d, J=8.1 Hz, 2H), 8.47 (br s, 1H); ¹³C NMR (75MHz, DMSO-d₆) δ 44.25, 55.72, 71.80, 77.24, 80.88, 86.33, 105.82,114.27, 124.65, 128.68, 132.51, 134.70, 135.07, 151.55, 166.44, 168.30;HRMS: calculated for C₂₀H₁₈N₄O₃H⁺ 363.1457. found 363.1457 [M+H]⁺.

CPD-032,(2S)-6-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxyhexanamide:84% yield; ¹H NMR (300 MHz, DMSO-d₆) δ 1.32 (br s, 6H), 1.67 (m, 2H),4.28 (m, 1H), 5.84 (s, 2H), 6.52 (d, J=8.4 Hz, 2H), 7.24 (d, J=8.4 Hz,2H), 7.60 (d, J=8.1 Hz, 1H), 7.88 (d, J=8.4 Hz, 2H), 8.57 (d, J=7.5 Hz,1H); ¹³C NMR (75 MHz, DMSO-d₆) δ 23.74, 32.22, 33.46, 42.07, 52.14,71.80, 77.21, 80.87, 86.31, 105.81, 114.25, 124.60, 128.64, 132.51,134.69, 135.02, 151.54, 166.08, 169.13; HRMS: calculated for C₂₃H₂₄N₄O₃404.1848. found 404.1843 M⁺.

Example 27

(i) SOCl₂, MeOH, reflux 70 h. (ii) EDC. HCl, HOBt, DIEA, DMF, 6, 0° C.,1 h, then room temperature 14 h, 79% (two steps). (iii) Hydroxylaminehydrochloride, 25% NaOMe/MeOH, THF, 0° C., 2 h, then room temperature,18 h, 72%.

129: To an ice-cold anhydrous MeOH (8 mL) is added dropwise thionylchloride (0.54 mL, 7.51 mmol, 2.0 equiv), and the solution is stirred atroom temperature for 5 min. (S)-(+)-2-amino-3-methylbutanic acid 128(500 mg, 3.76 mmol) is then added to the solution in one portion, andthe reaction mixture is heated at 70° C. for 48 hours. LC/MS analysisshowed the completion of the reaction. After cooled to ambienttemperature, the solvents are evaporated to dryness and then pumpedunder high vacuum for 4 h, obtaining the crude(S)-(+)-2-amino-3-hydroxy-3-methylbutanic acid ester hydrochloride 129(619 mg, 90% yield) as white semi-solid.

130: To a stirred mixture of diacetylene acid 6 (200 mg, 0.76 mmol,prepared as in Example 1) and 129 (300 mg, 0.91 mmol, 1.20 equiv) inanhydrous DMF (5 mL) is added EDC.HCl (204 mg 1.07 mmol, 1.20 equiv),HOBt (145 mg, 1.87 mmol, 1.20 equiv) at room temperature. The mixture iscooled with an ice-bath, and diisopropylethylamine (1.06 mL, 7.12 mmol,8.0 equiv) is added. The whole reaction mixture is stirred under argonat 0° C. for 1 h, then allowed to warm to ambient temperature with thestirring is continued for additional 20 hours. The resulting yellowsolution is condensed to dryness with a rotavapor, and the residue istreated with water (50 mL). The mixture is extracted with EtOAc (3×50mL). The combined extracts are washed with water (30 mL), brine (30 mL)and dried over anhydrous Na₂SO₄. Evaporation of the solvent affords thecrude product, which is purified by flash chromatography (eluting with0-6% MeOH in DCM) to afford 130 (240 mg, 80% yield) as red solid. ¹H NMR(300 MHz, CD₃OD) δ 1.32 (s, 3H), 1.36 (s, 3H), 3.76 (s, 3H), 4.64 (s,1H), 6.61 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.58 (d, J=8.7 Hz,2H), 7.83 (d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 26.11, 26.41,51.48, 61.60, 70.83, 71.38, 76.78, 79.01, 84.67, 108.30, 114.24, 126.14,127.54, 132.16, 133.86, 150.21, 168.08, 177.11; MS (ESI, positive): m/z391 [M+H⁺].

CPD-037,(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N,3′-dihydroxy-3′-methylbutanamide:72.0% yield; ¹H NMR (300 MHz, CD₃OD) δ 1.27 (s, 3H), 1.33 (s, 3H), 4.50(s, 1H), 6.61 (d, J=8.7 Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.58 (d, J=8.4Hz, 2H), 7.85 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 25.78, 26.07,58.80, 70.74, 71.54, 76.68, 78.95, 84.60, 108.28, 114.21, 126.09,127.55, 132.12, 133.82, 150.24, 167.83, 168.07; HRMS: calculated forC₂₂H₂₁N₃O₄H⁺ 392.1610. found 392.1607 [M+H]⁺.

Example 28

(i) 2-nitropropane, glyoxylic acid, KOH, 35-45° C., 3 h, 50%. (ii) MeI,C_(S2)CO₃, 0° C., 1 h, then room temperature 12 h, 92%. (iii) Zn, AcOH,0° C., 2 h then room temperature, 16 h, 68%. (iv) (Boc)₂O, DIEA, THF,room temperature 16 h, 88%. (v) H₂, Pd/C, room temperature, 2 h, 90%.(vi) EDC.HCl, HOBt, DIEA, DMF, 6, 0° C., 1 h, then room temperature 14h, 79%. (vii) TFA, DCM, 0° C., 2 h, then room temperature, 10 h, 90%.(viii) Hydroxylamine hydrochloride, 25% NaOMe/MeOH, THF, 0° C., 2 h,then room temperature, 68%.

(2S)-3-methyl-3-nitro-2-{[(1′S)-1′-phenylethyl]amino}butanoic acid(132): The 2-nitropropane (18.5 mL, 0.206 mmol, 1.02 equiv) and water(200 mL) are placed under argon in a 500 mL flask with a stir bar withgood stirring, the potassium hydroxide (13.60 g, 0.24 mmol, and 1.20equiv) is added all at once. The flask is placed in a regulated oil bathheated to 45° C. The (S)-(−)-α-methybenzylamine 131 (25 g, 0.206 mmol,1.02 equiv) is added very quickly (very fast CO₂ absorption). Thereaction mixture is maintained at 44-46° C. and stirred swiftly as theglyoxylic acid (50% aq, 18.60 g, 0.202 mmol) is added slowly dropwise(60 min, slowest for the last one-third) via a syringe. The reactionmixture became cloudy, then clear, and when the solid began formingagain the addition is slowed down. After completion of the addition, thereaction is stirred for an additional 3 h under argon at 35° C., andstirred swiftly as 3M aq hydrochloric acid (152 mL, 0.46 mmol) is addeddropwise (over 30 min). The resulting thick off-white suspension isstirred for overnight (12 h) at room temperature. The cooled suspensionis filtered with suction filtration, and the filter cake is rinsed withdiluted aqueous HCl (0.2M, 0.5 L), water (0.5 L) and diethyl ether(0.125 L). The solid in the filter cake is dried by suction, and thendried under high vacuum for 3 h at 50° C. to get a slightly off-whitepower (27 g, 50% yield).

Purification of 3-methyl-3-nitro-(2(S)-(1(S)-phenylethyl-amino))-butyricacid 132. 3M HCl (63 mL), water (0.72 L) and acetic acid (88 ml) isplaced in an Erlenmyer flask and stirred well as it as immersed in a 60°C. bath and warmed to 40-50° C. (internal). When the solution is up tothe temperature, dissolved3-methyl-3-nitro-(2(s)-(1(s)-phenylethyl-amino))-butyric acid in thestirred warm DMSO solution (50° C., dry, 40 mL) and added 25 mL ofacetic acid to form a clear solution, then added the warm DMSO solutionto the Erlenmeyer at an even dropwise rat. The suspension is thenfiltered through paper by suction and ethyl ether (125 mL). The filtercake is then suction to compact “dryness” over 30 min. The solids thentransferred to room temperature and dried under full vacuum for 12 hours(85% yield).

Second purification of3-methyl-3-nitro-(2(S)-(1(S)-phenylethyl-amino))-butyric acid 131(Procedure is similar to the first precipitation above). A solution ofdiluted aq hydrochloric acid (3.0M, 40 mL), water (500 mL) and aceticacid (80 mL) is placed in a 1 L Erlenmeyer flask and stirred well as itis immersed in a 45-60° C. bath and warmed to 40° C. (internal). Anotherflask, to a solution of the3-methyl-3-nitro-(2(s)-(1(s)-phenylethyl-amino))-butyric acid (5.10 g)in anhydrous DMSO (40 mL) is added acetic acid. The mixture is thenwarmed to 50° C. and added dropwise to the Erlenmeyer flask. Uponcomplete addition, the suspension is stirred and placed in a 0° C. bathto cool room temperature. The suspension is then filtered through paperby suction and rinsed with dilute aq hydrochloric acid (0.2M, 500 mL),water (1 L), isopropanol (40 mL) and diethyl ether (125 mL). The filtercake is then suctioned to compact “dryness” over 30 min. The filtered isthen transferred to room temperature vacuum and dried under full vacuumfor 14 hours. After that, the solids is dried at 50° C. under highvacuum for 3 hours to yield 131 as white powder (5.00 g, 98%). ¹H NMR(300 MHz, DMSO-d₆) δ 1.21 (d, J=6.3 Hz, 3H), 1.43 (s, 3H), 1.45 (s, 3H),3.62 (q, J=12.6 Hz, 1H), 7.17-7.31 (m, 5H); ¹³C NMR (75 MHz, DMSO-d₆) δ22.48, 24.05, 25.60, 57.14, 65.50, 98.69, 127.62, 127.81, 128.91,144.85, 173.06; MS (ESI, positive): m/z 267 [M+H⁺].

Methyl (2S)-3-methyl-3-nitro-2-{[(1′S)-1′-phenylethyl]amino}butanoate(133): In an oven-dried 100 mL flask with a stir bar is charged with 131(3.00 g, 11.3 mmol) and cesium carbonate (3.85 g, 11.82 mmol, 1.05equiv) under argon with rapid string. Dimethylformamide (10 mL) is addedrapidly and stirred for 10 min, with aid of sonication for 5 min. Afterthe reaction mixture is cooled to 0° C., iodomethane (0.81 g, 13.00mmol, 1.15 equiv) is added dropwise over 15 min. The reaction mixture isstirred under argon and at 0° C. for 1 h then is allowed to warm toambient temperature with stirring is continued for 12 h. The reaction iswashed with EtOAc and water into a separatory funnel containing EtOAc(100 mL), water (20 mL) and 3.0 M aq hydrochloric acid. The organiclayer is separated. And the aqueous layer is adjusted pH to 7-8 andextracted with EtOAc (2×100 mL). The combined organic phases are washedwith 3% Li₂SO₄ (3×30 mL), half-saturated aq NaHCO₃ (30 mL) and brine (30mL) and dried over anhydrous Na₂SO₄. The solvent is concentrated to giveamber oil (2.93 g, 93% yield). ¹H NMR (300 MHz, CDCl₃) δ 1.33 (d, J=6.6Hz, 3H), 1.49 (s, 3H), 1.54 (s, 3H), 2.06 (s, 1H), 3.60 (m, 1H), 3.75(s, 3H), 7.21-7.35 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 22.39, 24.02,25.12, 52.55, 57.39, 65.20, 89.33, 127.43, 127.75, 128.64, 143.67,172.67; MS (ESI, positive): m/z 281 [M+H⁺].

Methyl (2S)-3-amino-3-methyl-2-{[(1S)-1′-phenylethyl]amino}butanoate(134): 133 (2.83 g, 10.0 mmol) is dissolved in anhydrous THF (30 mL) andglacial acetic acid (45 mL) along with activated powdered molecularsieves 4A (3.4 g), and stirred mildly for 3 h under argon. The flask isthen immersed in 0° C. bath and stirred well for 20 min. To the coldreaction mixture is added zinc dust (5.85 g, 90.0 mmol, 10.0 equiv). Themixture reaction is stirred at 0° C. for 2 h, and then allowed warm toambient temperature with stirring continued for 16 h. The mixture isthen diluted with THF (40 mL) and filtered through a celite pad withadditional THF (100 mL) washing. The solution is rotary evaporated toyield a slightly yellow oily solid. This material is dissolved in 3:1chloroform/isopropanol (100 mL) and 0.25 EDTA solutions at pH 10.5-11(60 mL). Additional 4M NaOH solutions are added in portions to reachpH=10.5-11.0. The funnel contents are thoroughly shaken, and the aqueousphase separated. The organic phase is then washed with 0.25 EDTApH=10.5-11.0 (50 mL), brine (40 mL), dried (Na₂SO₄), filtered andevaporated under reduced pressure, followed with additional heptane(3×40 mL) and evaporation to yield a light-amber oil, which is purifiedby CombiFlash (eluting with MeOH in DCM 0-7%) to afford 134 as colorlessoil (1.763 g, 68.8% yield). ¹H NMR (300 MHz, CDCl₃) δ 1.00 (s, 1H), 1.05(s, 1H), 1.32 (d, J=6.6 Hz, 3H), 2.74 (s, 1H), 3.56 (q, J=13.2 1H), 3.71(s, 3H), 7.21-7.30 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 25.68, 27.34,27.90, 51.55, 51.81, 57.25, 68.54, 127.32, 128.58, 145.02, 176.05; MS(ESI, positive): m/z 251 [M+H⁺].

Methyl(2S)-3-{[(tert-butoxy)carbonyl]amino}-3-methyl-2-{[(1′S)-1′-phenylethyl]amino}butanoate(135): 134 (1.70 g, 6.8 mmol) is dissolved in anhydrous THF (20 mL)under argon, and diisopropylethylamine (1.30 mL, 7.5 mmol, 1.10 equiv)is added to this solution. tert-Butylpyrocarbonate (1.78 g, 8.2 mmol,1.20 equiv) is added. After stirring at room temperature for 16 h, thereaction mixture is dissolved in EtOAc (100 mL), and washed with watercontaining 1 eq HCl (0.3 M HCl, 20 mL), half saturated NaHCO₃ solution,14% NH₄OH (30 mL), brine (50 mL), dried (Na₂SO₄), filtered andcontracted under reduced pressure to yield the BOC-diamino-esterresidue, which is purified by CombiFlash (eluting with EtOAc in DCM0-5%) to afford it as viscous oil (2.10 g, 88% yield). ¹H NMR (300 MHz,CDCl₃) δ 1.27-1.37 (m, 18H), 1.99 (br s, 1H), 3.16 (br s, 1H), 3.55 (q,J=20.1 Hz, 1H), 3.73 (s, 3H), 4.93 (br s, 1H), 7.22-7.30 (m, 5H); ¹³CNMR (75 MHz, CDCl₃) δ 23.78, 24.17, 25.41, 28.59, 51.89, 54.37, 57.36,66.07, 127.259, 127.47, 128.70, 144.72, 175.15.

Methyl (2S)-2-amino-3-{[(tert-butoxy)carbonyl]amino}-3-methyl butanoate(136): 135 (0.50 g, 1.4 mmol) is dissolved in anhydrous THF (10 mL) in50 mL flask and placed under argon. Palladium hydroxide catalyst (0.18g, 20 wt %) is rapidly weight and added to the flask. The flask is thenfilled with hydrogen and refilled. (−101 kpa). After 2 h, LC/MS showedthe reaction is completed. The mixture is filtered through a celite pad,and the filtrate is condensed to dryness. The residue is purified byCombiFlash (eluting with 0-5% MeOH in DCM) to afford 34 as white solid(330 mg, 95% yield). ¹H NMR (300 MHz, CDCl₃) δ 1.30 (s, 3H), 1.37 (s,3H), 1.39 (s, 9H), 3.26 (br s, 2H), 3.71 (s, 3H), 3.87 (s, 1H), 4.95 (s,1H); ¹³C NMR (75 MHz, CDCl₃) δ 24.15, 24.23, 28.55, 52.28, 54.77, 60.55,79.77, 155.26, 173.41.

Methyl(2S)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3′-{[(tert-butoxy)carbonyl]amino}-3-methylbutanoate(137). Following the procedure of 125a. 79.5% yield; ¹H NMR (300 MHz,CD₃OD) δ 1.45 (m, 15H), 3.73 (s, 3H), 4.78 (d, J=6.9 Hz, 1H), 6.61 (d,J=8.1 Hz, 2H), 7.24 (d, J=8.4 Hz, 2H), 7.58 (d, J=8.1 Hz, 1H), 7.85 (d,J=8.1 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 24.00, 26.13, 27.66, 51.56,53.90, 62.09, 70.92, 76.86, 79.09, 79.48, 84.71, 108.32, 114.25, 126.14,127.40, 132.22, 133.62, 133.88, 150.17, 157.30, 167.46, 170.89; MS (ESI,positive): m/z 490 [M+H⁺].

Methyl(2S)-3-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-methylbutanoate(138). Following the procedure of 126a. 90.6% yield; ¹H NMR (300 MHz,CD₃OD) δ 1.21 (s, 3H), 1.25 (s, 3H), 3.77 (s, 3H), 4.64 (s, 1H), 6.62(d, J=8.7 Hz, 2H), 7.24 (d, J=8.7 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.83(d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 26.22, 26.71, 51.49, 52.00,61.67, 70.72, 76.66, 78.95, 84.60, 108.25, 114.20, 126.08, 127.66,132.07, 133.82, 150.26, 168.39, 171.48; MS (ESI, positive): m/z 390[M+H⁺].

CPD-040,(2S)-3-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxy-3-methylbutanamide:Following the procedure of 127. 68.4% yield; ¹H NMR (300 MHz, CD₃OD) δ1.28 (s, 3H), 1.30 (s, 3H), 4.52 (s, 1H), 6.62 (d, J=8.4 Hz, 2H), 7.24(d, J=8.4 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.87 (d, J=8.1 Hz, 2H); ¹³CNMR (75 MHz, CD₃OD) δ 25.21, 25.83, 53.36. 57.58, 70.72, 76.73, 78.93,84.65, 108.26, 114.20, 126.17, 127.67, 132.07, 133.71, 133.81, 150.25,167.53, 168.08; HRMS: calculated for C₂₃H₂₂N₃O₃H⁺ 391.1770. found391.1767 [M+H]⁺.

Example 29

(i) (TMS)CHN₂, MeOH, benzene, 0° C. to room temperature, 1 h, 87%. (ii)(trimethylsily)acetylene, PdCl₂(PPh₃)₂, CuI, DIEA, THF, 70° C., 14 h,95%. (iii) K₂CO₃, MeOH, room temperature, 40 min, 84%. (iv)4-ethylnylaniline, Cu(OAc)₂, pyridine, MeOH, room temperature, 20 h. (v)3N NaOH, MeOH, reflux, 40 min, 31% (from 142). (vi) EDC. HCl, HOBt,DIEA, DMF, 13, 0° C., 1 h, then room temperature, 36 h, 74%. (vii)hydroxylamine hydrochloride, 25% NaOMe/MeOH, THF, 0° C., 2 h, then roomtemperature, 16 h, 40%.

5-Bromopyridine-2-carboxylic acid (140): To an ice-cold solution of 139(3.00 g, 15.0 mmol) dissolved in anhydrous MeOH (20 mL) and benzene (20mL) is added dropwise (TMS)CHN₂ (2.5 ml, 5.0 mmol, 2.0 equiv), then isallowed to warm to ambient temperature with stirring is continued underargon for 1 h. The reaction is monitored by LC/MS and TLC. The resultingsolution is condensed to dryness with a rotavapor, and the residue ispurified by CombiFlash (eluting with 0-10% EtOAc in hexane) to give 140as with solid (2.79 g, 87% yield). ¹H NMR (300 MHz, CDCl₃) δ 3.93 (s,3H), 7.56 (d, J=9.3 Hz, 1H), 8.10 (d, J=10.5 Hz, 1H), 8.93 (s, 1H); ¹³CNMR (300 MHz, CDCl₃) δ 52.88, 125.52, 128.28, 139.40, 147.03, 151.62,165.23; MS (ESI, positive): m/z 490 [M+H⁺].

Methyl 5-[2-(trimethylsilyl)ethynyl]pyridine-2-carboxylate (141): To anoven-dried round bottom flask equipped with a condenser and magneticstir bar is added 140 (2.00 g, 9.30 mmol), bis(triphenylphosphine)palladium (II) dichloride (0.197 g, 0.28 mmol, 0.03 equiv) and copper(I) iodide (0.053 g, 0.28 mmol, 0.03 equiv). The vessel is then sealedwith a rubber septum under argon, and then anhydrous THF (20 mL) anddiisopropylethylamine (20 mL) is added. Finally,(trimethylsily)acetylene (1.80 mL, 13.0 mmol, 1.40 equiv) is added andthe reaction mixture is heated to 70° C. in an oil bath for 14 h. Theresulting yellow suspension is filtered through a celite pad, and thefiltrate is condensed to dryness with a rotavapor, and the residue istreated with water (100 mL), extracted with EtOAc (3×100 mL). Thecombined extracts are washed with water (100 mL), brine (100 mL) anddried over anhydrous Na₂SO₄. The crude product is purified by flashchromatography (eluting with 0-10% EtOAc in hexane) to afford 141 (2.06g, 95% yield) as white solid. It changed to brown solid in 10 min.(Caution: prevent from exposure to light!). ¹H NMR (300 MHz, CDCl₃) δ0.25 (s, 9H), 3.92 (s, 3H), 7.49 (d, J=8.7 Hz, 1H), 8.21 (d, J=10.5 Hz,1H), 9.12 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 0.20, 52.72, 98.65, 103.22,125.00, 126.96, 137.36, 146.77, 151.19, 165.44; MS (ESI, positive): m/z224 [M+H⁺].

Methyl 5-ethynylpyridine-2-carboxylate (142): 141 (2.00 g, 8.58 mmol) isdissolved in anhydrous MeOH (20 mL) at room temperature, and potassiumcarbonate (0.024 g, 0.17 mmol, 0.02 equiv) is added. The mixture isstirred for 40 min under argon at room temperature. Then the mixturereaction is evaporated in vacuum to afford the crude product, which ispurified by flash chromatography (eluting with 0-10% MeOH in DCM) toafford 142 (1.61 g, 84% yield) as white solid. ¹H NMR (300 MHz, CDCl₃) δ3.30 (s, 1H), 3.92 (s, 3H), 7.52 (d, J=9.3 Hz, 1H), 8.23 (d, J=10.5 Hz,1H), 9.13 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 52.79, 80.23, 82.43,125.49, 127.20, 137.47, 146.07, 151.24, 165.31; MS (ESI, positive): m/z162 [M+H⁺].

Sodium 5-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]pyridine-2-carboxylate(144): Copper (II) acetate (1.36 g, 7.46 mmol, 2.0 equiv) is added atroom temperature under stream of argon to a stirred solution of 142(0.60 g, 3.73 mmol) and 4-ethylnylbenzenamine (2.18 g 18.63 mmol, 5.0equiv) dissolved in anhydrous pyridine (10 mL) and MeOH (10 mL). Thereaction mixture is stirred at room temperature for 20 h. The resultingsuspension is filtered, and the solid is washed with EtOAc (3×50 mL).The solid is dried under high vacuum for 12 h to afford as an orangepowder, and then used for next step directly. 4N NaOH (10 mL) is addedto a stirred solution of the crude methyl ester (600 mg) in MeOH (50 mL)at room temperature. Then reaction solution is heated to reflux for 40min under argon. The reaction mixture turned clear. After all thestarting material has been consumed monitored by TLC, the reactionmixture is cooled to room temperature, and the solvents are removed byevaporation under reduced pressure. The yellow solid is washed by water(3×50 mL), EtOAc (3×50 mL) to give a yellow solid (320 mg, 31% yield,for two steps), which is used for next step without future purification.¹H NMR (300 MHz, CD₃OD) δ 6.62 (d, J=8.4 Hz, 2H), 7.26 (d, J=8.7 Hz,2H), 7.59 (d, J=9.0 Hz, 1H), 8.27 (d, J=10.2 Hz, 1H), 9.01 (s, 1H); ¹³CNMR (75 MHz, CD₃OD) δ 70.50, 75.996, 78.48, 85.59, 107.59, 114.17,127.44, 133.09, 134.06, 137.62, 142.94, 150.69, 170.58; MS (ESI,positive): m/z 263 [M+H⁺].

Methyl(2S,3R)-2-({5′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]pyridin-2′-yl}formamido)-3-hydroxybutanoate(145): Following the procedure of 125a. 74.5% yield; ¹H NMR (300 MHz,CD₃OD) δ 1.25 (d, J=6.3 Hz, 3H), 3.78 (s, 3H), 4.37-4.41 (m, 1H), 4.70(m, 1H), 6.62 (d, J=8.7 Hz, 2H), 7.28 (d, J=8.7 Hz, 2H), 7.69 (d, J=9.0Hz, 1H), 8.26 (d, J=10.2 Hz, 1H), 8.99 (s, 1H); ¹³C NMR (75 MHz, CD₃OD)δ 19.24, 51.77, 58.95, 67.23, 70.40, 77.10, 78.18, 86.45, 107.30,114.13, 127.66, 129.13, 134.16, 136.21, 144.82, 148.89, 150.79, 166.52,171.18; MS (ESI, positive): m/z 378 [M+H⁺].

CPD-041,(2S,3R)-2-({5-[4-(4-aminophenyl)buta-1,3-diyn-1-yl]pyridin-2-yl}formamido)-N,3-dihydroxybutanamide:Following the procedure of 127. 40.0% yield; ¹H NMR (300 MHz, CDCl₃) δ1.24 (d, J=6.3 Hz, 3H), 4.18-4.22 (m, 1H), 4.43 (d, J=5.4 Hz 1H), 6.62(d, J=8.7 Hz, 2H), 7.28 (d, J=8.7 Hz, 2H), 7.68 (d, J=9.0 Hz, 1H), 8.27(d, J=10.5 Hz, 1H), 8.99 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 19.13,58.05, 67.13, 70.38, 77.06, 78.17, 86.42, 107.28, 114.12, 127.59,129.15, 134.15, 136.22, 144.73, 148.96, 150.81, 166.15, 168.19; HRMS:calculated for C₂₀H₁₈N₄O₄ 378.1328. found 378.1328 M⁺.

Example 30

(i) L-threonine methyl ester, TEA, DCM, 0° C., 1 h, 91%. (ii)PdCl₂(PPh₃)₂, CuI, TEA, THF, room temperature, 12 h, 87%. (iii) K₂CO₃,MeOH, room temperature, 40 min, 88%. (iv) Cu(OAc)₂, pyrindine, MeOH,room temperature, 24 h, 58%. (v) hydroxylamine hydrochloride, NaOMe,THF, MeOH, 0° C., 2 h, then room temperature, 18 h, 56%.

Methyl (2S,3R)-3-hydroxy-2-[(4-iodobenzene)sulfonamido]butanoate (147):To an ice-cold solution of pipsylchloride (5.00 g, 16.5 mmol) andL-threonine methyl ester hydrochloride (4.20 g, 24.7 mmol, 1.5 equiv)dissolved in anhydrous DCM (50 mL), is added dropwise triethylamine (6.8mL, 29.6 mmol, 3.0 equiv). After 1 h, TLC showed the reaction iscompleted. The reaction mixture is diluted with DCM (150 mL), and washedwith 1 N HCl (30 mL), brine (30 mL) and dried over anhydrous Na₂SO₄. Thecrude product is purified by CombiFlash (eluting with 0-70% EtOAc inhexane) to give 147 as white solid (6.00 g, 91% yield). ¹H NMR (300 MHz,CDCl₃) δ 1.22 (d, J=6.3 Hz, 3H), 2.26 (d, J=5.4 Hz, 1H), 3.54 (s, 3H),3.83 (d, J=6.5 Hz, 1H), 4.17-4.22 (m, 1H), 5.71 (d, J=9.3 Hz, 1H), 7.52(d, J=6.9 Hz, 2H), 7.85 (d, J=9.9 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ20.13, 52.99, 61.14, 68.53, 100.46, 128.81, 138.48, 139.75, 170.82; MS(ESI, positive): m/z 400 [M+H⁺].

Methyl(2S,3R)-3-hydroxy-2-({4′-[2′-(trimethylsily)ethynyl]benzene}sulfonamido)butanoate(148): 86.6% yield; ¹H NMR (300 MHz, CDCl₃) δ 0.25 (s, 9H), 1.24 (d,J=6.3 Hz, 3H), 2.64 (d, J=5.7 Hz, 1H), 3.51 (s, 3H), 3.82 (d J=4.9 Hz,1H), 4.15-4.20 (m, 1H), 5.91 (d, J=9.0 Hz, 1H), 7.54 (d, J=8.4 Hz, 2H),7.76 (d, J=8.1 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 0.02, 20.06, 52.94,61.22, 68.52, 98.82, 103.312, 127.27, 128.14, 132.53, 139.44, 170.87; MS(ESI, positive): m/z 370 [M+H⁺].

Methyl (2S,3R)-2-[(4′-ethynylbenzene)sulfonamido]-3-hydroxybutanoate(149): 88.2% yield; ¹H NMR (300 MHz, CDCl₃) δ 1.27 (d, J=7.2 Hz, 3H),2.39 (d, J=5.1 Hz, 1H), 3.26 (s, 1H), 3.53 (s, 3H), 3.85 (d, J=6.3 Hz,1H), 4.17-4.21 (m, 1H), 5.78 (d, J=8.4 Hz, 1H), 7.59 (d, J=7.8 Hz, 2H),7.80 (d, J=7.8 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 20.10, 52.94, 61.18,68.54, 81.05, 82.16, 127.16, 127.38, 132.80, 139.97, 170.84; MS (ESI,positive): m/z 298 [M+H⁺].

Methyl (2S,3R)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′diyn-1-yl]benzene}sulfonamido)-3-hydroxybutanoate (150): 58% yield; ¹HNMR (300 MHz, CDCl₃) δ 1.26 (d, J=6.3 Hz, 3H), 2.48 (br s, 1H), 3.52 (s,3H), 3.84 (s, J=6.3 Hz, 1H), 3.99 (br s, 2H), 4.15-4.19 (m, 1H), 5.82(d, J=7.8 Hz, 1H), 6.59 (d, J=7.8 Hz, 2H), 7.33 (d, J=7.8 Hz, 2H), 7.57(d, J=7.8 Hz, 2H), 7.77 (d, J=7.8 Hz); ¹³C NMR (75 MHz, CDCl₃) δ 20.10,52.96, 61.21, 68.52, 71.83, 78.47, 79.07, 85.34, 110.09, 114.89, 127.40,132.87, 134.50, 139.55, 148.25, 170.86; MS (ESI, positive): m/z 413[M+H⁺].

CPD-039,(2S,3R)-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]benzene}sulfonamido)-N,3-dihydroxybutanamide:56.4% yield; ¹H NMR (300 MHz, CD₃OD) δ 1.06 (d, J=6.3 Hz, 3H), 3.56 (d,J=5.1 Hz, 1H), 3.89-3.93 (m, 1H), 6.62 (d, J=8.7 Hz, 2H), 7.25 (d, J=9.0Hz, 2H), 7.61 (d, J=8.7 Hz, 2H), 7.83 (d, J=8.7 Hz, 2H); ¹³C NMR (75MHz, CD₃OD) δ 18.47, 60.54, 67.80, 70.62, 77.32, 78.48, 85.09, 108.06,114.21, 126.94, 127.15, 132.48, 133.89, 140.59, 150.36, 167.50; HRMS:calculated for C₂₀H₁₉N₃O₅SH⁺ 414.1124. found 414.1117 [M+H]⁺.

Example 31

(i) CAN, CH₃CN, NaNO₂, 0° C. to room temperature, 16 h, 42%. (ii) MsCl,TEA, DCM, 40° C., 4 h, 77%. (iii) 6-Brominidole, basic Al, 60° C., 5 h,70%. (iv) Zn, AcOH, 4A, 0° C., 2 h, then room temperature, 15 h, 92%.(v) (Boc)₂O, DIEA, THF, room temperature, 16 h, 94%. (vi) PdCl₂(PPh₃)₂,CuI, TEA, 70° C., 16 h, 88%. (vii) K₂CO₃, MeOH, room temperature, 15 h,85%. (viii) Cu(OAc)₂, pyridine/MeOH, 4-ethynylbenzenamine, roomtemperature, 24 h, 50%. (ix) TFA, DCM, 0° C., 2 h, and then roomtemperature 14 h, 72%. (x) hydroxylamine hydrochloride, NaOMe, THF,MeOH, 0° C., 2 h, then room temperature, 48 h, 26%.

Methyl 2-hydroxy-3-nitrobutanoate (152): To a stirred solution of methyl(2E)-but-2-enoate (1.60 g, 16.4 mmol) in anhydrous CH₃CN (80 mL) areadded CAN (26.30 g, 48.0 mmol, 3.0 equiv) and NaNO₂ (1.13 g, 48.0 mmol,3.0 equiv) at 0° C. under argon. The reaction mixture is vigorouslystirred at room temperature for 18 h. The resulting yellow suspension iscondensed to dryness with a rotavapor, and the residue is treated withwater (100 mL). The mixture is extracted with EtOAc (3×70 mL). Thecombined extracts are washed with saturated NaHCO₃ (50 mL), brine (50mL) and dried (anhydrous Na₂SO₄). The crude product is purified byCombiFlash (eluting with 10-30% EtOAc in hexane) to give 152 (1.10 g,42% yield) as colorless liquid. ¹H NMR (300 MHz, CDCl₃) δ 1.20 (d, J=6.0Hz, 3H), 3.84 (br s, 1H), 3.85 (br s, 3H), 5.47-5.16 (m, 2H); ¹³C NMR(75 MHz, CDCl₃) δ 11.81, 11.93, 53.82, 53.96, 87.05, 87.11, 87.77,87.82, 163.14 163.23; MS (ESI, positive): m/z 186 [M+Na]⁺.

Methyl (2Z)-3-nitrobut-2-enoate (153): To a stirred solution of nitroalcohol 152 (2.50 g, 15.3 mmol) in anhydrous CH₂Cl₂ (20 mL) are addedMeSO₂C1 (3.19 mL, 45.9 mmol, 3.0 equiv), triethylamine (6.38 mL, 45.9mmol, 3.0 equiv) at 40° C. in under argon for 4 h. After the reaction iscompleted (monitored by LC/MS), the mixture is poured into ice water andextracted with CH₂Cl₂ (3×70 mL). The combined organic layers are washedwith water (50 mL), brine (50 mL) and dried (anhydrous Na₂SO₄).Evaporation of the solvent (200 torr, 30° C.) gives the crude product,which is purified by CombiFlash (eluting with 0-7% EtOAc in hexane) toafford 153 (1.70 g, 77% yield) as green liquid. ¹H NMR (300 MHz, CDCl₃)δ 2.54 (s, 3H), 3.79 (s, 3H), 7.01 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ14.11, 52.71, 121.07, 160.30, 164.75; MS (ESI, positive): m/z 146[M+H⁺].

Methyl 2-(6′-bromo-1′H-indol-3′-yl)-3-nitrobutanoate (154): To a mixtureof 6-brominidole (1.00 g, 5.10 mmol) and nitroalkene 153 (1.70 g, 11.72mmol, 1.4 equiv) is added activated basic alumina (6.12 g) at roomtemperature under argon. The reaction mixture is warm to 60° C. for 5 h.The result solid is directly loaded into silica gel column and purifiedby CombiFlash (eluting with 10-30% EtOAc in hexane) to afford 154 (1.20g, 70% yield) as brown foam. ¹H NMR (300 MHz, CDCl₃) δ 1.41 (d, J=7.2Hz, 2H), 1.72 (d, J=6.6 Hz, 1H), 3.66 (s, 2H), 3.71 (s, 1H), 4.46 (q,J=23.4 Hz, 1H), 5.28-5.34 (m, 1H), 7.13 (d, J=2.7 Hz, 1H), 7.21-7.27 (m,1H), 7.43-7.53 (m, 2H), 8.62 (d, J=34.2 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃)δ 18.42, 47.03, 47.71, 53.01, 83.42, 85.03, 108.08, 108.52, 114.78.114.97, 116.37, 116.63, 120.25, 123.82, 124.01, 124.70, 125.02, 137.06,137.32, 171.05, 172.13.

Methyl 3-amino-2-(6-bromo-1H-indol-3-yl)butanoate (155): Following theprocedure of 134: 92% yield; ¹H NMR (300 MHz, CDCl₃) δ 1.02 (d, J=6.3Hz, 2H), 1.20 (d, J=4.8 Hz, 1H), 1.51 (br s, 2H), 3.68 (s, 2H), 3.68 (s,1H), 7.14-7.26 (m, 2H), 7.47-7.59 (m, 2H), 8.94 (d, J=33.3 Hz, 1H); ¹³CNMR (75 MHz, CDCl₃) δ 21.79, 22.12, 49.48, 49.90, 52.00, 52.16, 52.32,111.02, 112.14, 114.47, 115.97, 120.67, 120.83, 123.26, 123.38, 123.63,124.27, 125.81, 126.17, 137.18, 174.16, 174.43.

Methyl2-(6′-bromo-1′H-indol-3′-yl)-3′-{[(tert-butoxy)carbonyl]amino}butanoate(156): Following the procedure of 135.94% yield; ¹H NMR (300 MHz, CDCl₃)δ 1.18 (q, J=20.1 Hz, 3H), 1.35 (d, J=33.3 Hz, 9H), 3.69 (d, J=4.8 Hz,3H), 4.06 (d, J=6.0 Hz, 1H), 4.30-4.37 (m, 1H), 4.69 (br s, 1H), 5.04(d, J=9.0 Hz, 1H), 7.18 (t, J=21.0 Hz, 2H), 7.49 (t, J=18.3 Hz, 2H),8.87 (d, J=12.6 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 19.43, 28.57, 48.18,49.16, 52.29, 79.73, 110.57, 114.53, 115.82, 120.42, 123.21, 124.27,126.10, 137.02, 155.55, 173.69.

Methyl3-{[(tert-butoxy)carbonyl]amino}-2-{6′-[2′-(trimethylsilyl)ethynyl]-1′H-indol-3′-yl}butanoate(157): Following the procedure of 141.88% yield; ¹H NMR (300 MHz, CDCl₃)δ 0.25 (s, 9H), 1.18 (m, 3H), 1.37 (d, J=19.2 Hz, 9H), 3.66 (d, J=3.0Hz, 3H), 4.07 (d, J=2.7 Hz, 1H), 4.29-4.35 (m, 1H), 5.05 (d, J=9.3 Hz,1H), 7.19-7.26 (m, 2H), 7.49-7.55 (m, 2H), 9.10 (d, J=7.2 Hz, 1H); ¹³CNMR (75 MHz, CDCl₃) δ 0.37, 19.26, 28.52, 48.15, 49.14, 52.24, 79.69,92.47, 107.09, 110.44, 115.65, 116.38, 118.93, 123.83, 125.50, 125.69,127.51, 135.68, 155.57, 173.36, 173.77; MS (ESI, positive): m/z 451[M+H⁺].

Methyl3-{[(tert-butoxy)carbonyl]amino}-2-(6′-ethynyl-1′H-indol-3′-yl)butanoate(158): Following the procedure of 142. 85.0% yield; ¹H NMR (300 MHz,CDCl₃) δ 1.17 (q, J=27.6 Hz, 3H), 1.37 (d, J=20.4 Hz, 9H), 3.04 (s, 1H),3.66 (d, J=3.6 Hz, 3H), 4.01 (d, J=7.2 Hz, 1H), 4.30-4.36 (m, 1H), 5.09(d, J=9.3 Hz, 1H), 7.23 (t, J=19.8 Hz, 2H), 7.49 (s, 1H), 7.55 (t,J=18.3 Hz, 1H), 9.22 (d, J=11.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ19.32, 28.50, 48.25, 52.26, 75.95, 79.71, 85.45, 110.44, 115.25, 115.89,119.08, 123.80, 125.62, 125.79, 127.65, 135.70, 155.63, 173.38, 173.77;MS (ESI, positive): m/z 335 [M+H⁺].

Methyl2-{6′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]-1′H-indol-3′-yl}-3′-{[(tert-butoxy)carbonyl]amino}butanoate(159): Following the procedure of 143. 50.3% yield; ¹H NMR (300 MHz,CDCl₃) δ 1.18 (q, J=21.0 Hz, 3H), 1.38 (d, J=18.0 Hz, 9H), 3.69 (d,J=3.3 Hz, 3H), 3.91 (br s, 2H), 4.10 (d, J=5.1 Hz, 1H), 4.29-4.34 (m,1H), 5.00 (d, J=9.3 Hz, 1H), 6.58 (d, J=7.8 Hz, 2H), 7.24-7.27 (m, 2H),7.33 (d, J=7.8 Hz, 2H), 7.53 (s, 1H), 7.58 (t, J=11.1 Hz, 1H), 8.80 (d,J=11.7 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 19.35, 28.52, 48.07, 49.16,52.32, 72.70, 73.41, 79.74, 82.55, 82.81, 110.87, 111.07, 114.92,115.34, 116.15, 119.24, 124.26, 125.81, 127.89, 134.24, 135.62, 147.72,155.72, 155.72, 155.53, 173.26, 173.67; MS (ESI, positive): m/z 472[M+H⁺].

Methyl3-amino-2-{6′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]-1′H-indol-3′-yl}butanoate(160): Following the procedure of 126c. 72.6% yield; ¹H NMR (300 MHz,CDCl₃) δ 1.02 (d, J=6.3 Hz, 2H), 1.19 (d, J=6.0 Hz, 1H), 1.61 (br s, 2Hz), 3.66 (d, J=6.6 Hz, 3H), 6.58 (d, J=8.4 Hz, 2H), 7.27-7.25 (m, 2H),7.32 (d, J=6.9 Hz, 2H), 7.52 (d, J=4.2 Hz, 1H), 7.63 (q, J=20.7 Hz, 1H),8.77 (s, 0.6H), 8.88 (s, 0.4H); ¹³C NMR (75 MHz, CDCl₃) δ 21.77, 22.08,49.57, 49.99, 51.91, 52.17, 72.68, 73.47, 82.57, 82.70, 111.07, 111.40,112.53, 114.90, 115.50, 119.46, 119.60, 124.30, 124.35, 125.10, 125.74,127.52, 127.90, 134.25, 135.78, 147.71, 174.14, 174.42; MS (ESI,positive): m/z 765 [2M+Na]⁺.

CPD-042,3-amino-2-{6′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]-1′H-indol-3′-yl}-N-hydroxybutanamide:Following the procedure of 127.26% yield; ¹H NMR (300 MHz, CD₃OD) δ 1.28(d, J=6.0 Hz, 2H), 1.39 (d, J=6.3 Hz, 1H), 3.86-3.95 (m, 2H), 6.62 (d,J=8.4 Hz, 2H), 7.17-7.18 (m, 1H), 7.23 (d, J=8.7 Hz, 2H), 7.48 (d, J=6.3Hz, 1H), 7.44 (s, 0.33H), 7.51 (s, 0.67H), 7.57 (s, 1H), 7.64 (d, J=8.4Hz, 0.33H), 7.76 (d, J=8.4 Hz, 0.67H); ¹³C NMR (75 MHz, CD₃OD) δ 16.84,29.56, 49.53. 71.37, 72.79, 81.59, 82.27, 107.89, 109.22, 112.14,114.32, 115.88, 118.60, 119.08, 123.44, 126.84, 127.36, 127.54, 133.55,136.48, 149.71, 169.59; HRMS: calculated for O₂₂H₂₀N₄O₂ 372.1586. found372.1584 M⁺.

Example 32

CPD-015,(2S)-2-({4′-[4′-(3′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-(1′H-imidazol-4′-yl)propanamide

Followed the procedure of CPD-012: Methyl(2S)-2-({4-[4-(3-aminophenyl)buta-1,3-diyn-1-yl]phenyl}formamido)-3-(1H-imidazol-4-yl)propanoate.19.4% yield; ¹H NMR (300 MHz, CD₃OD) δ 3.12 (q, 2H, J=20.7 Hz), 3.71 (s,3H), 4.84 (q, 1H, J=14.4 Hz), 6.73-6.76 (m, 1H), 6.83-6.84 (m, 2H,),7.07 (t, J=16.2 Hz, 1H), 7.50-7.58 (m, 3H), 7.77 (q, J=14.7 Hz 3H) 7.87(s, 1H); ¹³C NMR (75 MHz, CD₃OD) δ 28.75, 51.75, 53.60, 71.92, 75.82,78.29, 79.59, 80.13, 83.34, 116.76, 118.19, 121.81, 125.41, 127.54,129.23, 131.93, 132.31, 133.86, 134.19, 148.17, 167.92, 172.28; MS (ESI,positive): m/z 413 [M+H]⁺.

CPD-015,(2S)-2-({4′-[4′-(3′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-(1′H-imidazol-4′-yl)propanamide:75.0% yield; ¹H NMR (300 MHz, CD₃OD) δ 3.12 (q, J=18.6 Hz 2H), 4.21 (d,J=6.9 Hz, 1H), 4.74 (t, J=13.8 Hz, 1H), 6.73-6.82 (m, 1H), 6.82-6.84 (m,2H), 6.92 (br s, 1H), 7.08 (t, J=15.6 Hz, 1H,) 7.55-7.62 (m, 3H),7.69-7.72 (m, 1H), 7.78 (t, J=15.6 Hz, 1H); ¹³C NMR (75 MHz, CD₃OD) δ29.42, 52.22, 67.95, 71.82, 75.73, 79.53, 83.30, 116.74, 118.16, 121.72,125.35, 127.61, 128.70, 129.19, 131.25, 131.85, 132.23, 134.26, 148.23,167.72. 169.29; HRMS: calculated for C₂₃H₁₈N₅O₃H⁺ 414.1566. found414.1571 [M+H]⁺.

Example 33

CPD-016,(2S)-2-({4′-[4′-(2′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3′-(1′H-imidazol-4′-yl)propanamid

Followed the procedure of CPD-013: Methyl(2S)-2-({4′-[4′-(2′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-(1H-imidazol-4-yl)propanoate.25.8% yield; ¹H NMR (300 MHz, CD₃OD) δ 3.14-3.22 (m, 2H), 3.17 (s, 3H),4.86 (q, J=8.7 Hz, 1H), 6.59 (t, J=15.9 Hz, 1H), 6.74 (d, J=8.7 Hz, 1H),6.90 (br s, 1H), 7.12 (t, J=13.8 Hz, 1H), 7.25 (d, J=9.3 Hz, 1H),7.53-7.60 (m, 3H), 7.79 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ28.73, 51.70, 53.60, 73.62, 75.88, 77.79, 78.29, 80.23, 81.01, 104.99,114.52, 117.03, 125.54, 127.53, 130.88, 132.16, 132.81, 134.12, 135.26,151.15, 167.91, 172.25; MS (ESI, positive): m/z 413 [M+H]⁺.

CPD-016,(2S)-2-({4′-[4′-(2′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3′-(1′H-imidazol-4′-yl)propanamide:51.0% yield, 60% pure; ¹H NMR (300 MHz, CD₃OD) δ 3.09-3.15 (m, 2H), 4.74(t, J=13.8 Hz, 1H), 6.59 (t, J=13.8 Hz, 1H), 6.74 (d, J=8.1 Hz, 1H),6.92 (br s, 1H), 7.128 (t, J=14.1 Hz, 1H), 7.25 (d, J=6.3 Hz, 1H),7.55-7.62 (m, 3H), 7.69-7.81 (m, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 29.44,52.17, 67.95, 75.82, 77.75, 80.19, 80.10, 104.98, 114.52, 117.01,125.49, 127.60, 128.70, 130.87, 131.24, 132.11, 132.80, 134.15, 151.17,167.73, 169.24; HRMS: calculated for C₂₃H₁₈N₅O₃H⁺ 414.1566. found414.1565 [M+H]⁺.

Example 34

To a solution of 4-iodobenzylaldehyde (2.00, 8.6 mmol, 1.00 equiv) andmorpholine (0.94 g, 10.8 mmol, 1.25 equiv) in anhydrous THF (30 mL) isadded NaBH(OAc)₃ (2.76 g, 12.04 mmol, 1.40 equiv) at 0° C. under argon.The reaction mixture is then warmed to room temperature and stirred for18 h. The solvent is concentrated to dryness. The residue is dilutedwith sat. Na₂CO₃ (50 mL). And the mixture solution is extracted withEtOAc (3×80 mL). The combined extracts are washed with water (30 mL),brine (30 mL), and dried over anhydrous Na₂SO₄. Evaporation of thesolvent affords the crude product, which is purified by CombiFlash(eluting with 0-15% MeOH in DCM) to afford 161 (2.28 mg, 87% yield) aswhite solid.

To an oven-dried round bottom flask equipped with water cooled westcondenser and magnetic stir bar are added the compound 161 (1.03 g, 3.41mmol, 1.00 equiv), bis(triphenylphosphine) palladium (II) dichloride (29mg, 0.041 mmol, 0.01 equiv) and copper (I) iodide (15 mg, 0.08 mmol,0.02 equiv.). The vessel is then sealed with a rubber septum under argonand are added anhydrous THF (30 mL) and TEA (0.72 mL, 5.12 mmol, 1.5equiv). Finally, compound 3 (0.60 g, 3.75 mmol, 1.1 equiv) is added. Thereaction mixture is stirred at room temperature for 22 h. The resultingdark solution is condensed to dryness with a rotavapor, and the residueis treated with water (50 mL), extracted with EtOAc (3×80 mL). Thecombined extracts are washed with water (50 mL) and brine (anhydrousNa₂SO₄). The crude products are purified by flash chromatography(eluting with 0-50% EtOAc in hexane) to afford 162 (0.91 g, 80%) yellowsolid.

To a solution of methyl ester 162 (335 mg, 1.0 mmol, 1.00 equiv) inmethanol (8 mL) is added a solution of LiOH in water (42 mg, 1.05 mmol,1.05 equiv, 4 ml of water The reaction mixture is stirred at reflux for4 h under argon. Then the solution is cooled to room temperature andconcentrated to dryness. The residue is diluted with water (30 mL). And1 N HCl is added to pH to 4. The suspension solution is then filtered.The white solid is washed with water (30 ml), then dried under highvacuum to give compound 163 (300 mg, 93%), which is going to next stepwithout further purification.

To a solution of acid 163 (100 mg, 0.31 mmol) in anhydrous DMF (5 mL) isadded difluoro amine 75 mg, 0.34 mmol, 1.1 equiv), EDC.HCl (72 mg, 0.37mmol, 1.2 equiv), HOBt (51 mg, 0.34 mmol, 1.2 equiv) at room temperatureunder argon. The mixture is cooled to 0° C., DIEA (0.28 mL, 1.56 mmol,5.00 equiv) is added. The reaction mixture is stirred at 0° C. for 2hours, then is allowed to warm to room temperature for 14 hours. Theyellow solution is then concentrated to dryness. The residue is treatedwith water (30 mL), extracted with EtOAc (3×50 mL). The combinedextracts are washed with water (30 mL), brine (30 mL), and dried(anhydrous Na₂SO₄). The crude product is purified by CombiFlash (elutingwith MeOH in DCM 0-1.5%) to give 164 (120 mg, 79% yield) as yellowsolid.

To an ice-cold solution of 164 (100 mg, 0.21 mmol) dissolved inanhydrous THF (1 mL) and MeOH (1 mL) is added hydroxylaminehydrochloride (43 mg, 0.63 mmol, 3.0 equiv) followed by 25% sodiummethoxide in methanol solution (0.24 mL, 1.05 mmol, 5.0 equiv). Thereaction mixture is stirred under argon and at 0° C. for 2 h, thenallowed to warm to ambient temperature with the stirring is continuedovernight (14 h). The resulting yellow suspension is condensed todryness with a rotavapor, and the residue is treated water (20 mL) andsaturated NH₄Cl (2 mL), extracted with EtOAc (3×80 mL). The combinedextracts are washed with water (30 mL), brine (30 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent affords the crude product,which is purified by CombiFlash (eluting with 0-15% MeOH in DCM) toafford CPD-069 (60 mg, 60% yield) as yellow solid.

Example 35

To an isopropylmagnesium bromide in 2-methyl THF (2.90 M) (10.7 mL, 31.2mmol, 4.00 equiv) is added TMS ethynheyl (4.41 mL, 31.2 mmol, 4.00equiv) at 0° C. Then the reaction mixture is warmed to room temperatureand stirred under argon for 2 h. Then a solution of compound 166 (2.50g, 7.78 mmol, 1.00 equiv) in THF (8 mL) is added. The reaction mixtureis stirred at room temperature for 2 h. It is quenched by addedsat.NH₄Cl (pH to 7). The mixture is extracted with EtOAc (3×100 mL). Thecombined extracts are washed with water (80 mL), brine (80 mL), anddried over anhydrous Na₂SO₄. Evaporation of the solvent affords thecrude product, which is purified by CombiFlash (eluting with 0-15% MeOHin DCM) to afford 167 (2.20 g, 70% yield) as white foam. ¹H NMR (300MHz, CDCl₃) δ 0.12 (s, 9H), 0.81 (s, 3H), 3.09 (s, 1H), 3.92 (s, 6H),4.12 (d, J=10.2 Hz, 1H), 4.90 (s, 1H), 5.13 (dd, J₁=21.0 Hz, J₂=12.3 Hz,2H), 5.45 (d, J=10.5 Hz, 1H), 7.32-7.36 (m, 5H); ¹³C NMR (75 MHz, CDCl₃)δ −0.27, 14.25, 30.65, 57.62, 62.11, 66.91, 72.74, 72.89, 89.99, 102.66,108.31, 127.98, 128.06, 128.43, 136.53. 156.43; LC/MS m/s [M+H]⁺ 420.2

Compound 167 (0.80 g, 1.91 mmol) is dissolved in anhydrous DCM (40 mL)under argon and cooled to −78° C. in flask I. Oxalyl chloride (0.39 mL,3.05 mmol, 1.6 equiv) is added to anhydrous DCM (40 mL) in a separateflask II under argon and cooled to −78° C. Anhydrous DMSO (0.48 mL, 6.30mmol, 3.30 equiv) is added to the oxalyl chloride solution (flask II),and the mixture stirred at −78° C. for 15 min. The alcohol solution istransferred by syringe at −78° C. to the flask II over a period of 20min. The resulting cloudy white mixture is stirred for 2 h at −78° C.DIPEA (1.65 mL, 9.55 mmol, 5.0 equiv) is added and the solution isstirred for 30 min at −78° C. and 10 min at 0° C. Ice-cold DCM (100 mL)is added, and the solution is washed with ice-cold 3% NH₄Cl (3×50 mL),brine (100 mL), dried (anhydrous Na₂SO₄). The crude product is purifiedby CombiFlash (eluting with 0-50% EtOAc in hexane) to give compound 168(0.62 g, 80% yield) as white foam. ¹H NMR (300 MHz, CDCl₃) δ 0.01 (s,9H), 0.58 (s, 3H) 3.69 (s, 6H), 4.45 (d, J=9.3 Hz, 1H), 4.89 (s, 2H),5.40 (d, J=9.0 Hz, 1H), 7.04-7.13 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ−0.84, 14.21, 30.80, 63.88, 67.17, 72.93, 101.23, 102.11, 106.88,128.12, 128.47, 136.16, 155.72, 181.35; LC/MS m/s [M+H]⁺ 418.1

Compound 168 (140 mg, 0.33 mmol) is dissolved in anhydrous THF (5 mL)under argon. A solution of methyl magnesium bromide in THF (1.4 M, 1.2mL, 1.65 mmol, 5.0 equiv) is added quickly by syringe at −78 C andstirred vigorously. After 2 h, the reaction mixture is quenched by sat.NH₄Cl (pH=7) and is stirred for an additional 15 min. The mixture isextracted with EtOAc (3×50 mL). The combined organic layers are washedwith brine (50 mL), dried (anhydrous Na₂SO₄). The crude product ispurified by CombiFlash (eluting with 0-50% EtOAc in hexane) to give 169(0.1 g, 74% yield) as white solid. ¹H NMR (300 MHz, CDCl₃) δ 0.16 (s,9H), 0.81 (s, 3H), 1.47 (s, 3H), 3.72 (s, 1H), 3.90 (s, 6H), 4.05 (d,J=10.5 Hz, 1H), 5.13 (s, 2H), 5.27 (d, J=9.6 Hz, 1H), 7.27-7.35 (m, 5H);¹³C NMR (75 MHz, CDCl₃) δ −0.03, 14.30, 27.38, 30.57, 60.23, 66.92,68.45, 72.40, 88.53, 107.31, 108.83, 127.97, 128.02, 128.46, 136.50,156.55; LC/MS m/s [M+H]⁺ 434.2

To a solution of compound 169 (50 mg, 0.115 mmol, 1.0 equiv) in THF (5mL) is added TBAF (30.0 mg, 0.115 mmol, 1.0 equiv) at 0° C. under argon.The reaction mixture is stirred at 0° C. for 5 min. Then it isconcentrated to dryness. The crude product is purified by CombiFlash(eluting with 0-50% EtOAc in hexane) to give 170 (38 mg, 90% yield) aswhite solid. ¹H NMR (300 MHz, CDCl₃) δ 0.81 (s, 3H), 1.50 (s, 3H), 2.48(s, 1H), 3.81 (s, 1H), 3.92 (s, br, 6H), 4.07 (d, J=11.1 Hz, 1H), 5.19(dd, J₁=18.6 Hz, J₂=12.3 Hz, 2H), 5.29 (d, J=10.5 Hz, 1H), 7.28-7.35 (m,5H); ¹³C NMR (75 MHz, CDCl₃) δ; LC/MS m/s [M+H]⁺ 362.2

To a solution of 170 (410 mg, 1.14 mmol, 1.00 equiv) and benzyl azide(151 mg, 1.14 mmol, 1.00 equiv) in a cosolvent t-BuOH/H₂O (1:1) (4 mL)is added a solution of sodium ascorbate (22.6 mg, 0.114 mmol, 0.1 equiv)in 0.5 mL of water and a solution of CuSO₄ (14.23 mg, 0.057 mmol, 0.05equiv) in 0.5 mL of water. The reaction mixture is stirred at roomtemperature under argon for 24 h. Evaporation of the solvents affordsthe crude product, which is purified by CombiFlash (eluting with MeOH inDCM 0-5%) to give 171 (520 mg, 92%) as white foam. ¹H NMR (300 MHz,CDCl₃) δ 0.71 (s, 3H), 1.62 (s, 3H), 1.81 (s, 1H), 3.07 (s, 1H), 3.15(s, 1H), 3.43 (s, br, 4H), 4.02 (s, 2H), 4.16 (s, 1H), 4.60 (d, J=9.3Hz, 1H), 5.10 (s, 2H), 5.46 (s, 2H), 5.92 (d, J=9.0 Hz, 1H), 7.23-7.45(m, 10H); ¹³C NMR (75 MHz, CDCl₃) δ 16.85, 26.09, 40.27, 54.33, 61.79,67.00, 67.27, 67.41, 68.10, 77.81, 121.02, 128.15, 128.19, 128.30,128.56, 128.93, 129.20, 134.13, 135.92, 151.70, 156.59, 170.97; LC/MSm/s [M+H]⁺ 513.2

To a solution of 171 (336 mg, 0.656 mmol) in anhydrous MeOH (10 mL) isadded 10% Pd/C (30 mg). The reaction mixture is stirred under a balloonof hydrogen. After 1 h, LC/MS showed that the Cbz group is deprotected.Then 1 mL of 4 M HCl in dioxane is added. The reaction mixture isstirred for another 18 h. The resulting solution is filtered through apad of celite and washed with MeOH (20 mL). The filtrate is concentratedto dryness to afford the 172 as white solid, which is going to next stepwithout the further purification. ¹H NMR (300 MHz, CD₃OD) δ 0.83 (s,3H), 1.91 (s, 3H), 3.37-3.42 (m, 4H), 4.11 (dd, J₁=75.6 Hz, J₂=10.8 Hz,2H), 4.51 (s, 1H), 8.39 (s, 1H); ¹³C NMR (75 MHz, CD₃OD) δ 15.56, 26.08,40.35, 61.44, 64.00, 68.64, 69.40, 125.68, 146.41, 165.99; LC/MS m/s[M+H]⁺ 289.2

To a stirred mixture of 172 (210 mg, 0.582 mml, 1.05 equiv) and acid 6(144 mg, 0.554 mmol, 1.00 equiv, prepared as in Example 1) in anhydrousDMF (5 mL) is added N-ethyl-N′-(3-dimethylaminopropyl)carbodiimidehydrochloride (EDC hydrochloride) (149 mg 0.776 mmol, 1.40 equiv),1-hydroxybenzotriazole (HOBt) (105 mg, 0.776 mmol, 1.40 equiv) at roomtemperature. The mixture is cooled with an ice-bath, anddiisopropylethylamine (DIEA) (0.99 mL, 5.44 mmol, 10.0 equiv) is added.The whole reaction mixture is stirred under argon and at 0° C. for 1 h,then allowed to warm to temperature with the stirring is continued foradditional 36 h. The resulting yellow solution is condensed to drynesswith a rotavapor, and the residue is treated with water (50 mL),extracted with EtOAc (3×50 mL). The combined extracts are washed withbrine (50 mL), and dried over anhydrous Na₂SO₄. Evaporation of thesolvent affords the crude product, which is purified by CombiFlash(eluting with 0-10% MeOH in DCM) to afford 173 (130 mg, 44% yield) asyellow solid. LC/MS m/s [M+H]⁺ 532.2

CPD-072: compound 173 (110 mg, 0.21 mmol) is taken into 2.0 mL of MeOH.50% aq hydroxylamine (0.20 mL, 3.0 mmol, 30 equiv) is added and followedby potassium cyanide (10.0 mg, 0.10 mmol, 1.5 equiv) at room temperatureunder argon. The reaction mixture is stirred room temperature for 20 h.Then the yellow solution is concentrated to dryness. The residue istreated water (5 mL), washed with EtOAc (10 mL). The precipitate is thenwashed with milliQ water (3×30 mL), dried under high vacuum to giveCPD-072 (55.0 mg, 66% yield) as yellow solid. LC/MS m/s [M+H]⁺ 445.2

Example 36

To a solution of benzyl chloroformate (20.0 g, 0.117 mol, 1.00 equiv) inanhydrous acetone (300 mL) is added sodium azide (11.4 g, 0.176 mol, 1.5equiv). Then a solution of PPh₃ (30.74 g, 0.117 mol, 1.00 equiv) inanhydrous DCM (100 mL) is dropwise added in 1.5 h at 0° C. under argon.The reaction mixture is stirred at 0° C. for additional 30 min. Then thewhite suspension is filtered and washed with DCM (100 mL). The filtrateis concentrated to dryness to afford the crude product, which ispurified by crystallization from EtOAc and hexanes to give compound 174(29.27 g, 60%) as white solid. ¹H NMR (300 MHz, CDCl₃) δ 5.06 (s, 2H),7.23 (m, 4H), 7.40-7.46 (m, 6H), 7.51-7.56 (m, 3H), 7.740-7.76 (m, 7H);¹³C NMR (75 MHz, CDCl₃) δ 67.32, 127.34, 127.41, 128.06, 128.11, 128.53,128.61, 128.76, 132.31, 132.35, 133.00, 133.13, 137.82, 161.65;

175: To a solution of compound 70b (3.30 g, 14.22 mmol, 1.00 equiv) inanhydrous benzene (60 mL) is added iminophosphorane 174 (5.85 g, 14.22mmol, 1.00 equiv). Then the reaction mixture is stirred at reflux for 40h. The yellow solution is cooled to room temperature. Evaporation of thesolvent is affords the crude product, which is purified by CombiFlash(eluting with EtOAc in hexanes 0-50%) to give the compound 175 (4.1 g,80%) as white solid. ¹H NMR (300 MHz, CDCl₃) δ 2.42 (s, 3H), 5.15 (s,2H), 5.70 (s, 1H), 7.06 (t, J=109.4 Hz, 1H), 7.32-7.39 (m, 7H), 7.59(j=8.1 Hz, 2H), 9.96 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 21.49, 67.78,105.04, 108.27, 109.26, (109.14, 109.26, 109.38), 111.48, 125.09,128.32, 128.49, 128.60, 130.46, 135.35, 139.46, (139.65, 139.96,140.28), 142.78, 152.36; LC/MS m/s [M+H]⁺ 366.2

To a solution of 175 (2.00 g, 5.48 mmol, 1.00 equiv) in anhydrousDiethyl ether (300 mL) and DCM (80 mL) is added Cu₂O (0.568 g, 3.97mmol, 0.10 equiv) at −20° C. under argon. The reaction mixture is thendropwise added methyl isocyanoacetate (7.82 g, 79.44 mmol, 2.00 equiv).The reaction mixture is stirred at −20° C. for 3 hours, then is allowedto warm to room temperature for 40 hours. The mixture solution isconcentrated to dryness. The crude product is purified by CombiFlash(eluting with EtOAc in hexane 0-60%) to give the 176 (6.6 g, less polarone) as white solid. ¹H NMR (300 MHz, CDCl₃) δ 2.41 (s, 3H), 3.59 (dd,J₁=117.9 Hz, J₂=13.8 Hz, 2H), 3.88 (s, 3H), 5.30 (dd, J₁=30.9 Hz,J₂=12.0 Hz, 2H), 5.27 (s, 1H), 6.45 (t, J=114.0 Hz, 1H), 7.31-7.54 (m,9H), 7.73 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 21.39, 53.11, 55.19,(67.43, 67.83, 68.23), 69.07, 70.92, 112.57, 123.89, 128.35, 128.72,130.12, 134.64, 140.69, 141.89, 149.32, 149.99, 169.29; LC/MS m/s [M+H]⁺465.2

To a solution of 176 (4.83 g, 10.41 mmol, 1.00 equiv) in CHCl₃ (100 mL)is added neutral Aluminum oxide (10.61 g, 20.82 mmol, 10.00 equiv) andmilliQ water (0.37 g, 20.82 mmol, 2.00 equiv). The reaction mixture isstirred at room temperature under argon for 3 days. Evaporation of thesolvent is afford the crude product, which is purified by CombiFlash(eluting with MeOH in DCM 0-2%) to give 177 (4.0 g, 80%) as white solid.The compound 177 (4.0 g) is crystallized from EtOAc/Hexanes to giveoptical pure compound (3.0 g, 60%). LC/MS m/s [M+H]⁺ 483.2

To a solution of 177 (2.5 g, 5.19 g mmol, 100 equiv) in acetone (60 mL)is added sodium iodide (1.87 g, 12.45 mmol, 2.4 equiv) at 0° C. underargon. A solution of trifluoroacetatic anhydride (1.19 mL in 2 mLacetone) is added dropwise in 8 min. The reaction mixture is stirred at0° C. for 30 min, then is quenched by ice cold water (30 mL). Themixture is extracted with EtOAc (3×80 mL). The combined organic layersare washed with sat. Na₂S₂O₃ (3×40 mL), water (30 mL), brine (30 mL) anddried (anhydrous Na₂SO₄). The crude product is purified by CombiFlash(eluting with MeOH in DCM 0-5%) to give 178 (2.1 g, 86%) as colorlessoil. ¹H NMR (300 MHz, CDCl₃) δ 2.30 (s, 3H), 3.65 (dd, J₁=55.2 Hz,J₂=14.1 Hz, 2H), 3.65 (s, 3H), 3.71 (s, 1H), 4.99 (dd, J₁=26.4 Hz,J₂=12.3 Hz, 2H), 5.37 (d, J=9.9 Hz, 1H), 6.08 (s, 1H), 6.42 (t, J=111.0Hz, 1H), 7.10 (d, J=8.1 Hz, 2H), 7.26-7.37 (m, 7H), 8.21 (s, 1H); ¹³CNMR (75 MHz, CDCl₃) δ 21.06, 36.83, 52.29, 53.01, (60.92, 61.21, 61.49),67.29, (110.76, 114.07, 117.37), 127.92, 127.98, 128.32, 128.39, 128.57,130.01, 130.15, 131.44, 131.67, 131.98, 135.70, 137.72, 155.42, 160.99,168.97; LC/MS m/s [M+H]⁺ 467.2

To a solution of 178 (500 mg, 1.1 mmol, 1.00 equiv) in methanol (5 mL)is added 3M HCl in MeOH (2 mL). The reaction mixture is stirred at roomtemperature for 18 hours. Then the mixture is concentrated to dryness toafford 179 as white solid, which is going to next step withoutpurification. ¹H NMR (300 MHz, CDCl₃) δ 2.24 (s, 3H), 3.67 (s, 3H),3.61-3.87 (m, 2H), 5.03 (s, 2H), 5.05 (s, 1H), 6.20 (s, 1H), 6.56 (t,J=108.9 Hz, 1H), 7.03 (d, J=7.2 Hz, 2H), 7.24-7.37 (m, 7 h), 9.34 (s,br, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 21.00, 35.50, 53.71, 54.73, (60.84,61.12, 61.40), 67.61, 105.01, (110.74, 114.08, 117.40), 128.13, 128.43,129.95, 130.77, 131.37, 135.73, 137.47, 135.35, 166.09; LC/MS m/s [M+H]⁺439.1.

To a solution of 179 (150 mg, 0.32 mmol, 1.00 equiv) in anhydrous THF (8mL) is added TEA (0.089 mL, 0.64 mmol, 2.00 equiv) at 0° C., then(Boc)₂O (76 mg, 0.35 mmol, 1.10 equiv) is added. The reaction mixture isstirred at 0° C. for 30 min. Then it is allowed to warm to roomtemperature for 14 h. The resulting solution is concentrated to dryness.The residue is diluted with water (30 mL). The mixture solution isextracted with EtOAc (3×50 mL). The combined organic layers are washedwith water (30 mL), brine (30 mL) and dried over (anhydrous Na₂SO₄).Evaporation of the solvent is affords the crude product, which ispurified by CombiFlash (eluting with EtOAc in Hexanes 0-25%) to give 180(0.167 g, 97%) as colorless oil. ¹H NMR (300 MHz, CDCl₃) δ 1.45 (s, 9H),2.30 (s, 3H), 3.67 (dd, J₁=84.6 Hz, J₂=13.8 Hz, 2H), 3.69 (s, 2H), 4.96(dd, J₁=27.6 Hz, J₂=2.3 Hz, 2H), 4.96 (s, 1H), 5.76 (d, J=9.3 Hz, 1H),6.45 (t, J=111.0 hz, 1H), 7.09 (d, J=7.5 Hz, 2H) 7.29-7.38 (m, 7H); ¹³CNMR (75 MHz, CDCl₃) δ 28.22, 36.35, 52.87, 55.20, 60.37, (61.44, 61.71,61.99), 67.03, 80.67, 105.00, (111.25, 114.56, 117.88), 127.88, 128.21,128.51, 129.87, 137.80, 135.83, 137.45, 155.01, 155.30, 170.17; LC/MSm/s [M+H]⁺ 539.2

To a solution of 180 (150 mg, 0.28 mmol, 1.00 equiv) in acetate buffer(pH 5.2) and MeOH (1:2, 15 mL) is added Raney Ni (suspension inmethanol, 5 mL) followed by addition of sodium hyphophite monohydrate(0.35 g in milliQ water 1 mL) immediately. The reaction mixture isstirred at room temperature for 3 hours under argon. The mixture isfiltered through a celite pad and washed with MeOH (50 ml). The filtrateis concentrated to dryness. The residue is treated with water (30 mL),extracted with EtOAc (3×80 mL). The combined organic layers are washedwith water (30 mL), 10% NaHCO₃ (2×30 mL), brine (30 mL), and dried(anhydrous Na₂SO₄). The crude product is purified by CombiFlash (elutingwith MeOH in DCM 0-10%) to give 181 (66 mg, 85%) as colorless oil. ¹HNMR (300 MHz, CDCl₃) δ 1.15 (s, 3H), 1/41 (s, 9H), 1.48 (br, 2H), 3.74(s, 3H), 4.32 (d, J=8.1 Hz, 1H), 5.57 (d, J=8.4 Hz, 1H), 5.67 (t,J=113.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 28.17, 52.35, (56.19, 56.48,56.77), 57.02, 80.39, (113.22, 116.49, 119.76), 155.43, 171.67; LC/MSm/s

[M+H]⁺ 283.2

To a solution of 181 (300 mg, 1.06 mmol, 1.00 equiv) in anhydrousdioxane (4 mL) is added 4 M HCl in dioxane (8 mL). The reaction mixtureis stirred at room temperature for 14 h. Evaporation of the solvent isaffords the 182, which is going to next step without furtherpurification. LC/MS m/s [M+H]⁺ 183.1

To a solution of 182 (96 mg, 0.37 mmol, 1.00 equiv) in anhydrous DMF (5mL) is added DIEA (0.340 mL, 1.98 mmol, 5.00 equiv). The mixture iscooled to 0° C. Compound 184 (172 mg, 0.42 mmol, 1.10 equiv) is added.The reaction mixture is stirred at 0° C. for 2 hours, and then isallowed to warm to room temperature for 14 hours. The yellow solution isthen concentrated to dryness. The residue is treated with water (30 mL),extracted with EtOAc (3×30 mL). The combined extracts are washed withwater (30 mL), brine (30 mL), and dried (anhydrous Na₂SO₄). The crudeproduct is purified by CombiFlash (eluting with MeOH in DCM 0-5%) togive 183 (65 mg, 83%) as a yellow solid. ¹H NMR (300 MHz, CDCl₃) δ 1.26(s, 3H), 1.68 (s, br, 2H), 3.80 (s, 3H), 3.96 (s, br, 2H), 4.80 (d,J=7.8 Hz, 1H), 5.73 (t, J=113.1 Hz, 1H), 6.58 (d, J=9.0 Hz, 2H), 7.24(d, J=8.1 Hz, 1H), 7.32 (d, J=8.7 Hz, 2H), 7.56 (d, J=8.4 Hz, 2H), 7.76(d, J=8.7 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 19.46, 52.67, 55.87,(56.31, 56.58, 56.86), 71.75, 77.25, 79.63, 84.45, 105.00, 110.09,(113.20, 116.47, 119.75), 114.59, 126.23, 127.20, 132.50, 132.97,134.19, 147.88, 165.51, 170.61; LC/MS m/s [M+H]⁺ 426.2

To an ice-cold solution of 184 (50 mg, 0.12 mmol, 1.00 equiv) dissolvedin anhydrous MeOH (2 mL) is added KCN (10 mg, 0.15 mmol, 1.27 equiv).The mixture is the cooled to 0° C., and 2 mL of 50% NH₂OH aq is added.The reaction mixture is stirred at 0° C. for 4 h, then allowed to warmto ambient temperature with the stirring is continued overnight (14 h).The resulting yellow solvent is condensed to dryness with a rotavapor,and the residue is treated with water (20 mL), and extracted with EtOAc(3×50 mL). The combined extracts are washed with water (30 mL), brine(30 mL), and dried over anhydrous Na₂SO₄. Evaporation of the solventaffords the crude product, which is purified by CombiFlash (eluting with0-10% MeOH in DCM) to give CPD-079 (39.2 mg, 80%) as a yellow solid. ¹HNMR (300 MHz, CD₃OD) δ 1.26 (s, 3H), 4.72 (s, 1H), 5.77 (t, J=112.5 Hz,1H), 6.61 (d, J=8.4 Hz, 1H), 7.24 (d, J=8.4 Hz, 2H), 7.56 (d, J=8.1 Hz,2H), 7.84 (d, J=8.1 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD) δ 17.81, 53.31,56.56, 70.55, 76.51, 78.76, 84.41, 108.10, 114.02, 125.93, 127.41,131.86, 133.60, 143.96, 149.33, 149.95, 166.29, 167.57; LC/MS m/s [M+H]⁺427.3

Example 37

To a solution of starting material methyl 185 (20 mg, 47.1 pmol, 1.00equiv) in anhydrous THF (1 mL) is added TEA (20 μL, 141.1 pmol, 3.00equiv) at room temperature under argon. The mixture is cooled to 0° C.;Acetyl chloride (7 μL, 98.8 pmol, 2.10 equiv) is added. The reactionmixture is stirred at 0° C. for 1 h, then allowed to warm to ambienttemperature with the stirring is continued overnight (20 h). Theresulting yellow suspension is condensed to dryness with a rotavapor,and the residue is treated water (20 mL), extracted with EtOAc (3×50mL). The combined extracts are ished with water (30 mL), brine (30 mL),and dried over anhydrous Na₂SO₄. Evaporation of the solvent afforded thecrude product, which is purified by CombiFlash (eluting with 0-7% MeOHin DCM) to afford 186 (19.7 mg, 83%) as off yellow solid. ¹H NMR (300MHz, CDCl₃) δ 1.58 (s, 3H), 2.05 (s, 3H), 2.17 (s, 3H), 3.75 (s, 3H),5.09 (d, J=8.7 Hz, 1H), 5.92 (s, 1H), 6.60 (d, J=8.4 Hz, 2H), 7.46-7.53(m, 4H), 7.59 (d, J=8.1 Hz, 2H), 7.65 (s, 1H), 7.86 (d, J=8.4 Hz, 2H),9.07 (d, J=9.0 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 17.64, 23.55, 24.66,52.74, 53.42 57.55, (59.57, 59.86, 60.19), 73.32, 80.45, 82.75, 108.65,111.94, 115.23, 116.79, 119.36, 125.72, 127.33, 132.68, 133.13, 133.49,139.06, 166.23, 168.49, 169.31, 172.90; LC/MS m/s [M+H]⁺ 510.2

To an ice-cold solution of 186 (18 mg, 35.4 pmol, 1.00 equiv) dissolvedin MeOH (1 mL) is added KCN (5 mg, 75 pmol, 2.0 equiv). The mixture isthe cooled to 0° C., 2 mL of 50% NH₂OH aq is added. The reaction mixtureis stirred at 0° C. for 4 h, then allowed to warm to ambient temperaturewith the stirring is continued overnight (20 h). The resulting yellowsolvent is condensed to dryness with a rotavapor, and the residue istreated water (20 mL), extracted with EtOAc (3×50 mL). The combinedextracts are ished with water (30 mL), brine (30 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent afforded the crude product,which is purified by CombiFlash (eluting with 0-10% MeOH in DCM) toafford CPD-082,N-((2S,3S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-acetamidophenyl)buta-1,3-diynyl)benzamide,(8 mg, 44%) as a yellow solid. ¹H NMR (300 MHz, CD₃OD) δ 1.48 (s, 3H),2.02 (s, 3H), 2.14 (s, 3H), 6.75 (t, J=113.4 Hz, 1H), 7.49 (d, J=8.4 Hz,2H), 7.60-7.65 (m, 4H), 7.89 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CD₃OD)δ 15.40, 21.56, 22.53, 31.33, 55.56, 72.16, 75.60, 79.56, 82.26, 105.00,112.48, 115.75, 119.27, 125.41, 127.26, 132.19, 132.87, 133.50, 140.03,165.42, 166.56, 170.35, 174.35; LC/MS m/s [M+H]⁺ 511.3.

Example 38

To a solution of 187 (65 mg, 0.18 mmol, 1.00 equiv) in anhydrous THF (8mL) is added 2, 3, 4, 5, 6-pentafluorophenol (92 mg, 0.54 mmol, 3.00equiv). Then the mixture is cooled to 0° C. DCC (40 mg, 0.198 mmol, 1.1equiv) and DMAP (6.5 mg, 0.054 mmol, 0.3 equiv) are added. The reactionmixture is stirred at 0° C. for 4 h, then allowed to warm to ambienttemperature with the stirring is continued overnight (20 h). Theresulting suspension is filtered and ished with 20 mL of EtOAc. Thefiltrate is condensed to dryness with a rotavapor, and the residue istreated water (20 mL), extracted with EtOAc (3×30 mL). The combinedextracts are ished with water (30 mL), brine (30 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent afforded the crude product,which is purified by CombiFlash (eluting with 0-2% MeOH in DCM) toafford 188 (77 mg, 81%) as a yellow solid. ¹H NMR (300 MHz, CDCl₃) δ;2.43-2.46 (m, 4H), 3.51 (s, 2H), 3.70-3.73 (m, 4H), 7.33 (d, J=8.4 Hz,2H), 7.50 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 24.93, 33.94,53.61, 63.04, 66.94, 73.27, 78.15, 79.85, 83.87, 119.96, 126.79, 128.54,129.20, 130.61, 132.57, 132.73, 139.99, 161.87; LC/MS m/s [M+H]⁺ 511.1.

To a solution of 190 (33 mg, 0.131 mmol, 1.00 equiv) in anhydrous DMF (2mL) is added DIEA (0.23 mL, 1.31 mmol, 10.00 equiv) is added. Themixture is cooled to 0° C. Compound 188 (70 mg, 0.14 mmol, 1.08 equiv)is added. The reaction mixture is stirred at 0° C. for 2 hours, and thenis allowed to warm to room temperature for 14 hours. The yellow solutionis then concentrated to dryness. The residue is treated with water (30mL), extracted with EtOAc (3×30 mL). The combined extracts are ishedwith water (30 mL), brine (30 mL), and dried (anhydrous Na₂SO₄). Thecrude product is purified by CombiFlash (eluting with MeOH in DCM 0-5%)to give 189 (50 mg, 75%) as a yellow solid. ¹H NMR (300 MHz, CDCl₃) δ1.26 (s, 3H), 2.41-2.44 (m, 4H), 3.49 (s, 2H), 3.68-3.71 (m, 4H), 3.80(s, 3H), 4.80 (d, J=7.8 Hz, 1H), 5.73 (t, J=112.8 Hz, 1H), 7.24 (d,J=8.1 Hz, 1H), 7.31 (d, J=8.1 Hz, 2H), 7.46 (d, J=8.4 Hz, 2H), 7.58 (d,J=8.4 Hz, 2H), 7.78 (d, J=8.4 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 19.47,52.65, 53.61, 55.85, (55.88, 56.56, 56.86), 63.05, 66.96, 73.42, 76.56,80.26, 82.96, 116.46, 120.13, 125.72, 127.26, 129.15, 132.51, 132.65,133.39, 139.84, 166.39, 170.61; LC/MS m/s [M+H]⁺ 510.3.

To an ice-cold solution of 189 (40 mg, 0.078 mmol, 1.00 equiv) dissolvedin anhydrous MeOH (1 mL) is added KCN (10 mg, 0.15 mmol, 2.0 equiv). Themixture is the cooled to 0° C., 2 mL of 50% NH₂OH aq is added. Thereaction mixture is stirred at 0° C. for 4 h, then allowed to warm toambient temperature with the stirring is continued overnight (14 h). Theresulting yellow solvent is condensed to dryness with a rotavapor, andthe residue is treated water (20 mL), extracted with EtOAc (3×50 mL).The combined extracts are ished with water (30 mL), brine (30 mL), anddried over anhydrous Na₂SO₄. Evaporation of the solvent afforded thecrude product, which is purified by CombiFlash (eluting with 0-10% MeOHin DCM) to afford CPD-084,(2S,3S)-3-amino-4,4-difluoro-3-methyl-2-(4-((4-(morpholinomethyl)phenyl)buta-1,3-diynyl)benzamido)butanoicacid, (30 mg, 75%) as a yellow solid. LC/MS m/s [M+H]⁺ 512.3.

Example 39

To a solution of 191 (60 mg, 0.217 mmol, 1.00 equiv) in anhydrous THF (8mL) is added 2, 3, 4, 5, 6-pentafluorophenol (112 mg, 0.652 mmol, 3.00equiv). Then the mixture is cooled to 0° C. DCC (49 mg, 0.239 mmol, 1.1equiv) and DMAP (8 mg, 0.065 mmol, 0.3 equiv) are added. The reactionmixture is stirred at 0° C. for 4 h, then allowed to warm to ambienttemperature with the stirring is continued overnight (20 h). Theresulting suspension is filtered and ished with 20 mL of EtOAc. Thefiltrate is condensed to dryness with a rotavapor, and the residue istreated water (20 mL), extracted with EtOAc (3×30 mL). The combinedextracts are ished with water (30 mL), brine (30 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent afforded the crude product,which is purified by CombiFlash (eluting with 0-2% MeOH in DCM) toafford 192 (75 mg, 81%) as a yellow solid. LC/MS m/s [M+H]⁺ 442.1.

To a solution of 194 (33 mg, 0.131 mmol, 1.00 equiv) in anhydrous DMF (2mL) is added DIEA (0.23 mL, 1.31 mmol, 10.00 equiv) is added. Themixture is cooled to 0° C. Compound 192 (65 mg, 0.157 mmol, 1.08 equiv)is added. The reaction mixture is stirred at 0° C. for 2 hours, and thenis allowed to warm to room temperature for 14 hours. The yellow solutionis then concentrated to dryness. The residue is treated with water (30mL), extracted with EtOAc (3×30 mL). The combined extracts are ishedwith water (30 mL), brine (30 mL), and dried (anhydrous Na₂SO₄). Thecrude product is purified by CombiFlash (eluting with MeOH in DCM 0-5%)to give 193 as a yellow solid. LC/MS m/s [M+H]⁺ 441.3.

To an ice-cold solution of 193 (0.078 mmol, 1.00 equiv) dissolved inMeOH (1 mL) is added KCN (0.15 mmol, 2.0 equiv). The mixture is thecooled to 0° C., 2 mL of 50% NH₂OH aq is added. The reaction mixture isstirred at 0° C. for 4 h, then allowed to warm to ambient temperaturewith the stirring is continued overnight (14 h). The resulting yellowsolvent is condensed to dryness with a rotavapor, and the residue istreated water (20 mL), extracted with EtOAc (3×50 mL). The combinedextracts are ished with water (30 mL), brine (30 mL), and dried overanhydrous Na₂SO₄. Evaporation of the solvent afforded the crude product,which is purified by CombiFlash (eluting with 0-10% MeOH in DCM) toafford CPD-086,(2S,3S)-3-amino-4,4-difluoro-2-(4-((4-(hydroxymethyl)phenyl)buta-1,3-diynyl)benzamido)-3-methylbutanoicacid, as a yellow solid. LC/MS m/s [M+H]⁺ 442.1.

Examples 40-274

The following compounds can be prepared essentially according to theprocedures set forth above, with modifications where necessary of thestarting materials to provide the desired product.

Ex. No. Structure Name 40

N-(1-(hydroxyamino)-3-(naphthalen-2-yl)- 1-oxopropan-2-yl)-4-(phenylethynyl)benzamide 41

(S)-N-(1-(hydroxyamino)-3-(naphthalene-2-sulfonamido)-1-oxopropan-2-yl)-4- (phenylethynyl)benzamide 42

4-((4-aminophenyl)buta-1,3-diynyl)-N- ((2S,3R)-1-hydrazinyl-3-hydroxy-1-oxobutan-2-yl)benzamide (CPD-045) 43

(2S,3R)-2-(4-((4-aminophenyl)buta-1,3-diynyl)benzamido)-3-hydroxybutanoic acid (CPD-046) 44

N-((2S,3R)-1-amino-3-hydroxy-1- oxobutan-2-yl)-4-((4-aminophenyl)buta-1,3-diynyl)benzamide (CPD-047) 45

(S)-4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-3-isopropyl-2-oxopyrrolidin-3- yl)benzamide (CPD-048) 46

4-((4-aminophenyl)buta-1,3-diynyl)-N-((1R,2S)-1-hydroxy-3-(hydroxyamino)-1- (4-hydroxyphenyl)-3-oxopropan-2-yl)benzamide (CPD-049) 47

4-((4-aminophenyl)buta-1,3-diynyl)-N-((1S,2S)-1-hydroxy-3-(hydroxyamino)-1- (4-hydroxyphenyl)-3-oxopropan-2-yl)benzamide (CPD-050) 48

4-((4-aminophenyl)buta-1,3-diynyl)-N-((2S)-3-hydroxy-1-(hydroxyamino)-3-(4- hydroxyphenyl)-1-oxobutan-2-yl)benzamide (CPD-051) 49

4-((4-aminophenyl)buta-1,3-diynyl)-N-((3R)-3-hydroxy-1-(hydroxyamino)-3-(4- hydroxyphenyl)-1-oxobutan-2-yl)benzamide (CPD-052) 50

4-((4-aminophenyl)buta-1,3-diynyl)-N- ((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2- yl)benzamide (CPD-056) 51

4-((4-aminophenyl)buta-1,3-diynyl)-N-((2S,3S)-4,4,4-trifluoro-3-hydroxy-1- (hydroxyamino)-1-oxobutan-2-yl)benzamide (CPD-057) 52

4-((4-aminophenyl)buta-1,3-diynyl)-N- ((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide (CPD-058) 53

4-(3-(4-aminophenoxy)prop-1-ynyl)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (CPD-059)54

(R)-4-(3-(4-aminophenoxy)prop-1-ynyl)- N-(1-hydroxy-2-oxopyrrolidin-3-yl)benzamide (CPD-060) 55

4-((4-aminophenyl)buta-1,3-diynyl)-N- ((2S,3S)-4-fluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide (CPD-061) 56

4-((4-aminophenyl)buta-1,3-diynyl)-N-((2S,3S)-3-hydroxy-1-(hydroxyamino)-3-(4-(hydroxymethyl)phenyl)-1-oxobutan-2- yl)benzamide (CPD-062) 57

4-(3-(4-aminophenyl)prop-2-ynyloxy)-N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1- oxobutan-2-yl)benzamide (CPD-063)58

(R)-tert-butyl 4-((4-(1-hydroxy-2-oxoazetidin-3-ylcarbamoyl)phenyl)buta- 1,3-diynyl)phenylcarbamate(CPD-064) 59

(S)-N-(3-amino-1-(hydroxyamino)-3- methyl-1-oxobutan-2-yl)-4-((2-aminophenyl)buta-1,3-diynyl)benzamide (CPD-065) 60

(S)-4-((2-aminophenyl)buta-1,3-diynyl)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1- oxobutan-2-yl)benzamide(CPD-066) 61

4-((2-aminophenyl)buta-1,3-diynyl)-N- ((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide (CPD-067) 62

N-((2S,3S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide (CPD-069) 63

(R)-4-((4-aminophenyl)buta-1,3-diynyl)-N- (3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)benzamide (CPD-070) 64

(R)-4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-2-oxoazetidin-3-yl)benzamide (CPD-071) 65

4-((4-aminophenyl)buta-1,3-diynyl)-N-((3R)-3-hydroxy-1-(hydroxyamino)-1-oxo-3-(1H-1,2,3-triazol-4-yl)butan-2- yl)benzamide (CPD-072) 66

N-((3S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-aminophenyl)buta-1,3- diynyl)benzamide (CPD-079) 67

N-((2S,3S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4- (morpholinomethyl)phenyl)ethynyl)benzamide (CPD-080) 68

N-((2S,3S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminophenyl)buta-1,3- diynyl)benzamide (CPD-081) 69

4-((4-aminophenyl)buta-1,3-diynyl)-N-((2S,3S)-4,4,4-trifluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide (CPD-083) 70

(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′- diynyl]benzamido}-3-[(4′-hydroxymethyl)phen-1′-yl]-1,3- dihydroxybutanamide 71

(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′- diynyl]benzamido}-3-[(4′-aminomethyl)phen-1′-yl]-1,3- dihydroxybutanamide 72

(2S,3R)-3-amino-2-{4′-[(4″- aminophenyl)buta-1′,3′-diynyl]benzamido}-3-fluoromethyl-1,3- dihydroxybutanamide 73

(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]phenyl-4′-piperizine-4′- carboxamido}-1,3-dihydroxybutanamide 74

(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-[(2′-amino)imidazol- 5′-yl]-1,3-dihydroxybutanamide75

(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-(imidazol-5′-yl]-1,3- dihydroxybutanamide 76

(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-(triazol-5′-yl]-1,3- dihydroxybutanamide 77

(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-(triazol-1′-yl]-1,3- dihydroxybutanamide 78

(2S,3R)-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-(3′-amminium- triazol-1′-yl]-1,3-dihydroxybutanamide79

1-hydroxy-3-{N-[(4″-aminophenyl)buta- 1′,3′-diynyl]benzyl}-2-pyrrolidone80

1-hydroxy-3-{4′-[(4″-aminophenyl)prop-2-ynyloxy]benzamido}-2-pyrrolidone 81

1-hydroxy-3-{4′-[(4″-aminophenyl)buta- 1′,3′-diynyl]benzamido}-2-lactam82

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-fluorophenyl)buta-1,3- diynyl)benzamide 83

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-fluorophenyl)buta-1,3-diynyl)benzamide 84

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-fluorophenyl)buta-1,3- diynyl)benzamide 85

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-fluorophenyl)buta-1,3-diynyl)benzamide 86

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)-4-((4-fluorophenyl)buta-1,3-diynyl)benzamide 87

4-((4-chlorophenyl)buta-1,3-diynyl)-N- ((2S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 88

4-((4-chlorophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 89

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-chlorophenyl)buta-1,3- diynyl)benzamide 90

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-chlorophenyl)buta-1,3-diynyl)benzamide 91

4-((4-chlorophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 92

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3- diynyl)benzamide 93

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3- diynyl)benzamide 94

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3- diynyl)benzamide 95

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3- diynyl)benzamide 96

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3- diynyl)benzamide 97

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3- diynyl)benzamide 98

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3-diynyl)benzamide 99

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3- diynyl)benzamide 100

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-hydroxyphenyl)buta-1,3-diynyl)benzamide 101

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3- diynyl)benzamide 102

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-methoxyphenyl)buta-1,3- diynyl)benzamide 103

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4- methoxyphenyl)buta-1,3-diynyl)benzamide 104

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-methoxyphenyl)buta-1,3- diynyl)benzamide 105

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-methoxyphenyl)buta-1,3-diynyl)benzamide 106

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-methoxyphenyl)buta-1,3- diynyl)benzamide 107

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3- diynyl)benzamide 108

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4- (dimethylamino)phenyl)buta-1,3-diynyl)benzamide 109

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3- diynyl)benzamide 110

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3- diynyl)benzamide 111

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3- diynyl)benzamide 112

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3- diynyl)benzamide 113

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3- diynyl)benzamide 114

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3- diynyl)benzamide 115

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3- diynyl)benzamide 116

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3- diynyl)benzamide 117

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-ureidophenyl)buta-1,3- diynyl)benzamide 118

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-ureidophenyl)buta-1,3-diynyl)benzamide 119

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-ureidophenyl)buta-1,3- diynyl)benzamide 120

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-ureidophenyl)buta-1,3-diynyl)benzamide 121

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)-4-((4-ureidophenyl)buta-1,3-diynyl)benzamide 122

4-((4-acetamidophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 123

4-((4-acetamidophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 124

4-((4-acetamidophenyl)buta-1,3-diynyl)- N-((2S)-3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 125

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-acetamidophenyl)buta-1,3- diynyl)benzamide 126

4-((4-acetamidophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 127

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta- 1,3-diynyl)benzamide 128

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta-1,3- diynyl)benzamide 129

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta- 1,3-diynyl)benzamide 130

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta- 1,3-diynyl)benzamide 131

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta- 1,3-diynyl)benzamide 132

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3- diynyl)benzamide 133

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4- (hydroxymethyl)phenyl)buta-1,3-diynyl)benzamide 134

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3- diynyl)benzamide 135

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3- diynyl)benzamide 136

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3- diynyl)benzamide 137

4-((4-((2S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid 138

4-((4-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2- ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid 139

4-((4-((2S)-3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid 140

4-((4-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid 141

4-((4-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan- 2-ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid 142

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-formylphenyl)buta-1,3- diynyl)benzamide 143

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-formylphenyl)buta-1,3-diynyl)benzamide 144

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-formylphenyl)buta-1,3- diynyl)benzamide 145

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-formylphenyl)buta-1,3-diynyl)benzamide 146

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)-4-((4-formylphenyl)buta-1,3-diynyl)benzamide 147

4-((4-carbamoylphenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 148

4-((4-carbamoylphenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 149

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-carbamoylphenyl)buta-1,3- diynyl)benzamide 150

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-carbamoylphenyl)buta-1,3- diynyl)benzamide 151

4-((4-carbamoylphenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 152

4-((4-(aminomethyl)phenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 153

4-((4-(aminomethyl)phenyl)buta-1,3- diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1- oxobutan-2-yl)benzamide 154

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(aminomethyl)phenyl)buta-1,3- diynyl)benzamide 155

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(aminomethyl)phenyl)buta-1,3- diynyl)benzamide 156

4-((4-(aminomethyl)phenyl)buta-1,3- diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3- methylureido)-1-oxobutan-2-yl)benzamide157

4-((4-cyanophenyl)buta-1,3-diynyl)-N- ((2S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 158

4-((4-cyanophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 159

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-cyanophenyl)buta-1,3- diynyl)benzamide 160

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-cyanophenyl)buta-1,3-diynyl)benzamide 161

4-((4-cyanophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 162

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4- ((dimethylamino)methyl)phenyl)buta-1,3- diynyl)benzamide 163

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-((dimethylamino)methyl)phenyl)buta-1,3- diynyl)benzamide 164

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4- ((dimethylamino)methyl)phenyl)buta-1,3- diynyl)benzamide 165

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-((dimethylamino)methyl)phenyl)buta-1,3- diynyl)benzamide 166

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)-4-((4-((dimethylamino)methyl)phenyl)buta-1,3- diynyl)benzamide 167

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3- diynyl)benzamide 168

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4- (ureidomethyl)phenyl)buta-1,3-diynyl)benzamide 169

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3- diynyl)benzamide 170

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3- diynyl)benzamide 171

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3- diynyl)benzamide 172

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta- 1,3-diynyl)benzamide 173

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta-1,3- diynyl)benzamide 174

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta- 1,3-diynyl)benzamide 175

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta- 1,3-diynyl)benzamide 176

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta- 1,3-diynyl)benzamide 177

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(pyrrolidin-1- ylmethyl)phenyl)buta-1,3- diynyl)benzamide 178

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(pyrrolidin-1-ylmethyl)phenyl)buta-1,3- diynyl)benzamide 179

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(pyrrolidin-1- ylmethyl)phenyl)buta-1,3- diynyl)benzamide 180

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-(pyrrolidin-1-ylmethyl)phenyl)buta-1,3- diynyl)benzamide 181

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)-4-((4-(pyrrolidin-1-ylmethyl)phenyl)buta-1,3- diynyl)benzamide 182

4-((4-((1H-imidazol-1- yl)methyl)phenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 183

4-((4-((1H-imidazol-1- yl)methyl)phenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide 184

4-((4-((1H-imidazol-1- yl)methyl)phenyl)buta-1,3-diynyl)-N-((2S)-3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 185

4-((4-((1H-imidazol-1- yl)methyl)phenyl)buta-1,3-diynyl)-N-((2S)-3-acetamido-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 186

4-((4-((1H-imidazol-1- yl)methyl)phenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3- (3-methylureido)-1-oxobutan-2-yl)benzamide 187

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-2-ylbuta-1,3- diynyl)benzamide 188

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(thiophen-2-ylbuta-1,3-diynyl)benzamide 189

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-2-ylbuta-1,3- diynyl)benzamide 190

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-(thiophen-2-ylbuta-1,3-diynyl)benzamide 191

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)-4-(thiophen-2-ylbuta-1,3-diynyl)benzamide 192

4-((5-aminothiophen-2-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 193

4-((5-aminothiophen-2-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 194

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((5-aminothiophen-2-yl)buta-1,3- diynyl)benzamide 195

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((5-aminothiophen-2-yl)buta-1,3- diynyl)benzamide 196

4-((5-aminothiophen-2-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 197

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((l-methyl-1H-imidazol-4-yl)buta- 1,3-diynyl)benzamide 198

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-imidazol-4-yl)buta-1,3- diynyl)benzamide 199

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-imidazol-4-yl)buta- 1,3-diynyl)benzamide 200

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-imidazol-4-yl)buta- 1,3-diynyl)benzamide 201

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((1-methyl-1H-imidazol-4-yl)buta- 1,3-diynyl)benzamide 202

4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N- ((2S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 203

4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 204

4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N- ((2S)-3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 205

4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N-((2S)-3-acetamido-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 206

4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 207

4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 208

4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 209

4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 210

4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 211

4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 212

4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N- ((2S)-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 213

4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 214

4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N- ((2S)-3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)benzamide 215

4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N-((2S)-3-acetamido-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 216

4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 217

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((l-methyl-1H-pyrazol-4-yl)buta-1,3- diynyl)benzamide 218

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-pyrazol-4-yl)buta-1,3- diynyl)benzamide 219

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-pyrazol-4-yl)buta-1,3- diynyl)benzamide 220

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((l-methyl-1H-pyrazol-4-yl)buta-1,3- diynyl)benzamide 221

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((1-methyl-1H-pyrazol-4-yl)buta-1,3- diynyl)benzamide 222

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide 223

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide 224

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide 225

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide 226

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide 227

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide 228

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide 229

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide 230

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide 231

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide 232

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide 233

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide 234

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide 235

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide 236

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide 237

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide 238

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide 239

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide 240

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide 241

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide 242

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide 243

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide 244

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide 245

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide 246

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide 247

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide 248

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide 249

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide 250

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide 251

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide 252

4-((2-aminothiazol-5-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide 253

4-((2-aminothiazol-5-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 254

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminothiazol-5-yl)buta-1,3- diynyl)benzamide 255

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminothiazol-5-yl)buta-1,3- diynyl)benzamide 256

4-((2-aminothiazol-5-yl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 257

4-((2-aminophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3- methoxy-3-methyl-1-oxobutan-2-yl)benzamide 258

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminophenyl)buta-1,3- diynyl)benzamide 259

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((2-aminophenyl)buta-1,3-diynyl)benzamide 260

4-((2-aminophenyl)buta-1,3-diynyl)-N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)benzamide 261

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3- diynyl)benzamide 262

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3-diynyl)benzamide 263

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3- diynyl)benzamide 264

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((2-hydroxyphenyl)buta-1,3-diynyl)benzamide 265

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3- diynyl)benzamide 266

N-((2S)-4,4-difluoro-3-hydroxy-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3- diynyl)benzamide 267

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3-diynyl)benzamide 268

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3- diynyl)benzamide 269

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((2-methoxyphenyl)buta-1,3-diynyl)benzamide 270

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3- diynyl)benzamide 271

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide 272

N-((2S)-3-amino-4,4-difluoro-1- (hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4- (morpholinomethyl)phenyl)ethynyl)benzamide 273

N-((2S)-3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2- yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide 274

N-((2S)-4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2- yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide

Example 275 Biological Examples Protein Purification

Plasmids encoding wild-type E. coli LpxC, P. aeruginosa LpxC (residues1-299) with a C40S mutation, and A. aeolicus LpxC lacking the eightC-terminal amino acids and containing a C181A mutation (1-274) areprepared following established procedures. An E. coli LpxC constructlacking the C-terminal five amino acids (1-300) is prepared by using theQuikChange site-directed mutagenesis kit (Stratagene) from thefull-length E. coli LpxC gene. LpxC proteins are overexpressed inBL21(DE3)STAR cells (Invitrogen) grown in LB media and purified usinganion-exchange (Q-Sepharose Fast Flow, Amersham) and size exclusion(Sephacryl S-200 HR, Amersham) chromatography. Purified proteins areconcentrated and buffer-exchanged into 25 mM HEPES, pH 7.0, with 100 mMKCl and 0.1 mM ZnSO₄. For the EcLpxC proteins, 2 mM dithiothreitol isadded to all the purification buffers. All proteins samples forenzymatic assay and crystallography are stored at −80° C.

Enzymatic Inhibition Assay

UDP-3-O—[(R)-3-hydroxymyristoyl]-N-acetylglucosamine and[α-³²P]UDP-3-O-[(R)-3-hydroxymyristoyl]-N-acetylglucosamine are preparedas previously described. Assays of LpxC activity are performed at 30° C.in 25 mM sodium phosphate, pH 7.4, 1 mg/mL bovine serum albumin, 100 mMKCl and 2 mM DTT, in the presence of 5 μM substrate and 0.2 nM EcLpxC,unless noted otherwise. 10% DMSO is included and held constant in assaymixtures. Initial velocities are calculated from the linear portion ofreaction progress curves (<10% conversion of substrate to product).

K_(M) and V_(max) values are determined by varying the substrateconcentration from 0.5 to 50 μM. Data is analyzed using an Eadie-Hofsteeplot and by a nonlinear curve-fitting program (KaleidaGraph, SynergySoftware); the resultant values are nearly identical within experimentalerrors. To determine a K, value, the compound concentrations are variedfrom 12.5 pM to 15 nM, or from 0.8 pM to 51 nM. Fractional activity(u_(i)/u₀) versus the compound concentration is plotted and fitted tocalculate a K_(i) ^(app) value using the Morrison equation:

$\frac{v_{i}}{v_{0}} = {1 - \frac{\left( {\lbrack E\rbrack_{T} + \lbrack I\rbrack_{T} + K_{I}^{app}} \right) - \sqrt{\left( {\lbrack E\rbrack_{T} + \lbrack I\rbrack_{T} + K_{I}^{app}} \right)^{2} - {{4\lbrack E\rbrack}_{T}\lbrack I\rbrack}_{T}}}{{2\lbrack E\rbrack}_{T}}}$

where u_(i) is the initial velocity of the reaction in the presence ofthe inhibitor, u₀ is the initial velocity of the reaction in the absenceof the inhibitor, [E]_(T) is the total enzyme concentration, and [I]_(T)is the total inhibitor concentration. A K_(I) value is calculated using:K_(I)=K_(I) ^(app)/(1+[S]/K_(M)), where [S] is the substrateconcentration. All measurements are done in triplicates.Construction of E. coli W3110PA

P. aeruginosa lpxC is used to replace E. coli chromosomal lpxC. A linearPCR product containing the P. aeruginosa ORF with flanking sequencescontaining 33 bps of DNA complementary to the upstream 5′ region of E.coli lpxC and 45 bps of DNA complementary to the downstream 3′ region ofE. coli lpxC, is amplified from a plasmid carrying P. aeruginosa lpxCusing primers pa-LpxC-5′ (5′-TCG GTT GGA TAG GTA ATT TGG CGA GAT AAT ACGATG ATC AAA CAA CGC ACC TTG AAG AAC ATC-3′) and pa-LpxC-3′ (5′-GTG CCAGAT TTG CCA GTC GAA TTT TAT ACG ACA GTA TAA ATG TCG CTA CAC TGC CGC CGCC-3′). This PCR product is gel purified and then electroporated into E.coli DY330 cells, which carry λ-red recombinases, using a Bio-Rad GenePulser II set to 2.5 kV, 25 μF, and 400Ω. While DY330 cannot survive onthe LB/agar plate supplemented with 15 μg/mL of the compound ofdisclosure, cells wherein E. coli lpxC replaced with P. aeruginosa lpxCcan survive on this media. Transformants are therefore selected directlyusing the compound of disclosure without introducing a closely linkedresistance cassette for a different antibiotic marker. Genomic DNA fromresistant colonies is isolated, and the region around lpxC amplifiedwith primers 300-up-lpxC (5′-ACA AAC GTC CTG AAA TCA CTC TGG TG-3′) and300-down-lpxC (5′-TCC CTA ATA AGA GAT GCG GCC AGA A-3′), and sequencedwith primers paLpxC-361-5′ (5′-GAG CAG GAA GCT GCC AA-3′) andpaLpxC-581-3′ (5′-GTA CTC GAT GTC GCG CA-3′). One clone in which PalpxChad replaced chromosomal EclpxC is selected and grown at 30° C. Thisstrain is used to generate P1 vir lysate, which is used transducechromosomal PalpxC into the chromosome of E. coli W3110. Transducedcells are plated on LB/agar containing 15 μg/mL of the compound ofdisclosure and 10 mM sodium citrate. The resulting colonies are purified3 times on this media. Genomic DNA from resistant colonies is isolated,and the region around lpxC is amplified with the primers 300-up-lpxC and300-down-lpxC, and sequenced with paLpxC-361-5′ and paLpxC-581-3′. Thecolony that harbored the P. aeruginosa lpxC knock-in is named asW3110PA.

Minimum Inhibitory Concentration (MIC)

MICs are determined according to the NCCLS protocol using 96-wellplates. Briefly, diluted bacterial cells (10⁶ cells/mL) are added intoeach well of the 96-well plates containing LB medium with 5% DMSO andvarious concentrations of the compound of disclosure. After incubationof the plates for 22 hours at 37° C.,[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide solution(MTT) is added (final concentration, 0.2 mg/mL) and incubated at 37° C.for another 3 hrs. MIC is determined as the lowest concentration of anantibiotic that prevented color change (yellow to purple).

The antibiotic activities of several exemplary compounds useful in themethods of the disclosure are evaluated by measurements of minimuminhibitory concentrations (MICs) using wild-type E. coli (W3110), P.aeruginosa (PAO1), and modified E. coli strains with the native lpxCgene replaced by that of R. leguminosarum (W3110RL) or P. aeruginosa(W3110PA).

Compounds disclosed herein have MIC values generally ranging from about0.01 μg/ml to about 400 μg/ml.

MIC value key for values listed in Table 1:

A: <1 μg/mL

B: 1-10 μg/mL

C: 11-50 μg/mL

D: 51-100 μg/mL

E: >100 μg/mL.

TABLE 1 P. E. coli E. coli aeruginosa E. coli Compound W3110 W3110RL(PAO1) W3110PA

B E E E

A E B A

C E E E

A E A A CPD-007 B E B B CPD-009 A B A A CPD-011 A B A A CPD-012 A B A ACPD-013 A C B A CPD-014 A E B B CPD-015 A E B D CPD-016 B E E D CPD-017C E E E CPD-018 B E C D CPD-019 D E E E CPD-020 A B C B CPD-021 B E B CCPD-022 A D B A CPD-023 A C D B CPD-024 A E D C CPD-025 B E D E CPD-026B E E E CPD-027 A C B B CPD-028 A E E E CPD-029 B E E E CPD-030 C E E ECPD-031 C E E E CPD-032 C D C C CPD-033 B E C B CPD-034 C D C D CPD-035A C A B CPD-036 B E A B CPD-037 A B A A CPD-038 A D A B CPD-039 B E D DCPD-040 A B A A CPD-041 A C B B CPD-042 B D D D CPD-043 A D D D CPD-044A D D D CPD-045 B D D D CPD-046 B D D D CPD-047 B D D D CPD-048 B D D DCPD-049 B D C D CPD-050 A C B A CPD-051 A D A A CPD-052 A D B B CPD-053A D A A CPD-054 B D C C CPD-055 B D C C CPD-056 A B A A CPD-057 A D A ACPD-058 A A A A CPD-059 B D C C CPD-060 B D C C CPD-061 A D B B CPD-062A D B A CPD-069 A B CPD-071 B D CPD-072 A A CPD-079 A A CPD-080 A A

The antibiotic activities of several exemplary compounds useful in themethods of the disclosure are evaluated by measurements of minimuminhibitory concentrations (MICs) using two N. gonorrhoeae strains: FA19(a drug-sensitive strain) and 35/02 (drug-resistant strain.) FA19 is anisolate from uncomplicated infection and was lyophilized in 1962. 35/02displays intermediate-level resistance to extended spectrumcephalosporins such as ceftriaxone (MIC=0.12 μg/ml) and cefixime(MIC=0.28 μg/ml) and high-level resistance to penicillin (MIC=6 μg/ml).The strain is being sequenced to elucidate the mechanisms involved inhigh-level chromosomally mediated resistance.

Compounds disclosed herein have MIC values generally ranging from about0.01 μg/ml to about 10 μg/ml.

MIC value key for values listed in Table 2:

A: <0.1 μg/mL

B: 0.1-1 μg/mL

C: 2-4 μg/mL

D: 5-7 μg/mL

E: 8 μg/mL

TABLE 2 N. gonorrhoeae Compound FA 19 35/02

E E CPD-011 C D CPD-013 B C CPD-040 C D CPD-065 B C CPD-066 B C CPD-067A B

Disk Diffusion Assay

An assay was performed on two strains of Acinetobacter Baumannii:antibiotic susceptible strain (Sus. A.b. Isolate), andmultidrug-resistant strains (MDR A.b. Isolate). 2 μg of compound isadded per disc, which is 6 mm in diameter. Activity is measured as thediameter (in mm) of the growth inhibition. The results are summarized inTable 3, where A is no detectable inhibition, B is 6-10 mm, C is 11-15mm, D is ≧16.

TABLE 3 Compound Sus. A.b. Isolate MDR A.b. Isolate CPD-011 A A CPD-012A A CPD-013 A A CPD-037 C B CPD-040 B B CPD-051 A A CPD-058 C C CPD-067B B Ciprofloxacin D A Carbenicillin A A Chloramphenicol B A Imipenem D ACeftriaxone A A Tetracycline B A Polymyxin B B B

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be incorporated within the spirit and purview of this application andscope of the appended claims. All publications, patents, and patentapplications cited herein are hereby incorporated herein by referencefor all purposes.

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein Q, Y, D, and X independently represent CH or nitrogen, provided that at least two of Q, Y, D, and X are CH; each R is independently hydrogen, or C₁-C₆ alkyl, or two R groups form ═O; R₁ is —C(R₅)═C(R₄)(R₅), —C≡C—R₄, aryl optionally substituted with R₆, heteroaryl optionally substituted with R₆, or heterocyclyl optionally substituted with R₆; R₂ is —CH(R₉)(R₁₀), or heterocyclyl optionally substituted with one or more R₁₀; R₃ is hydrogen or C₁-C₆ alkyl; or R₂ and R₃ together with the nitrogen to which they are attached form heterocyclyl ring optionally substituted with one or more R₁₀; R₄ is C₁-C₆ alkyl optionally substituted with R₇, aryl optionally substituted with R₈, heteroaryl optionally substituted with R₈, or heterocyclyl optionally substituted with R₈; each R₅ is independently hydrogen, or C₁-C₆ alkyl; each R₆ is independently selected from the group consisting of halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy; each R₇ is independently selected from the group consisting of halogen, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy; each R₈ is independently selected from the group consisting of halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl), —CH₂—NH(C₁-C₆ alkyl), —CH₂—N(C₁-C₆ alkyl)₂, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH, —CONH—NH₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —NHC(═NH)NH₂, —NH—S(O)₀₋₂—(C₁-C₆ alkyl), —NH—S(O)₀₋₂-aryl, —NH—S(O)₀₋₂-heteroaryl, aryl(C₁-C₆ alkyl), heteroaryl(C₁-C₆ alkyl), heterocyclyl(C₁-C₆ alkyl), —CH₂—NHCONH₂, —CH₂—NHCONH(C₁-C₆ alkyl), and —CH₂—OCO(C₁-C₆ alkyl); R₉ is hydrogen, C₁-C₆ alkyl, aryl, aryl(C₁-C₆ alkyl), heteroaryl, heteroaryl(C₁-C₆ alkyl), heterocyclyl, or heterocyclyl(C₁-C₆ alkyl), wherein each alkyl, aryl, heteroaryl, or heterocyclyl moiety is optionally substituted with one or more R₁₁; R₁₀ is independently selected from the group consisting of halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, oxo, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH, —CONH—NH₂, —CO₂H, and —CO₂(C₁-C₆ alkyl); each R₁₁ is independently selected from the group consisting of halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl), oxo, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl), —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH, —CONH—NH₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —NHC(═NH)NH₂, —NH—S(O)₀₋₂—(C₁-C₆ alkyl), —NH—S(O)₀₋₂-aryl, and —NH—S(O)₀₋₂-heteroaryl; provided that when R₁ is phenylethaynyl, aminophenylethynyl, or pyridinylethynyl, two R groups form oxo, and R₃ is hydrogen, then R₂ is not 3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl, 3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl), 3-amino-1-(hydroxyamino)-1-oxopropan-2-yl, 3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl).
 2. A compound according to claim 1, wherein two R groups form ═O.
 3. A compound according to claim 1, wherein R₁ is —C≡C—R₄.
 4. A compound according to claim 3 wherein R₁ is —C≡C—R₄, wherein R₄ is aryl optionally substituted with R₈, or heteroaryl optionally substituted with R₈.
 5. A compound according to claim 4, wherein R₄ is aryl optionally substituted with R₈, where R₈ is selected from the group consisting of halogen, —NO₂, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy.
 6. A compound according to claim 5, wherein the compound is of formula:


7. A compound according to claim 1, wherein R₈ is selected from the group consisting of is halogen, —NO₂, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl), —CH₂—NH(C₁-C₆ alkyl), —CH₂—N(C₁-C₆ alkyl)₂, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —COH, —CO₂H, —CO₂(C₁-C₆ alkyl), —OCO(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkoxy), —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —NH—S(O)₀₋₂—(C₁-C₆ alkyl), —NH—S(O)₀₋₂-aryl, —NH—S(O)₀₋₂-heteroaryl, aryl(C₁-C₆ alkyl), heteroaryl(C₁-C₆ alkyl), heterocyclyl(C₁-C₆ alkyl), —CH₂—NHCONH₂, —CH₂—NHCONH(C₁-C₆ alkyl), and —CH₂—OCO(C₁-C₆ alkyl).
 8. A compound according to claim 7, wherein R₈ is selected from the group consisting of is halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, hydroxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl), —CH₂—NH(C₁-C₆ alkyl), —CH₂—N(C₁-C₆ alkyl)₂, —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —COH, —CO₂H, —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —NH—S(O)₀₋₂—(C₁-C₆ alkyl), heteroaryl(C₁-C₆ alkyl), heterocyclyl(C₁-C₆ alkyl), —CH₂—NHCONH₂, and —CH₂—NHCONH(C₁-C₆ alkyl).
 9. A compound according to claim 8, wherein R₈ is selected from the group consisting of is halogen, —CN, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, —CONH₂, —COH, —CO₂H, —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), and —NH—S(O)₀₋₂—(C₁-C₆ alkyl). 10-31. (canceled)
 32. A compound according to claim 1, wherein R₂ is of formula:

R₂₄ is selected from the group consisting of hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl), hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), amino(C₁-C₆ alkyl), —NHCO(C₁-C₆ alkyl), —NHCONH₂, —NHCONH(C₁-C₆ alkyl), —OCO(C₁-C₆ alkyl), and —NHCO(C₁-C₆ alkoxy); R₂₅ is selected from the group consisting of hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ haloalkyl, —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)₂, —OH, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, —SH, —S(C₁-C₆ alkyl), hydroxy(C₁-C₆ alkyl), alkoxy(C₁-C₆ alkyl), and amino(C₁-C₆ alkyl); R₂₆ is C₁-C₆ haloalkyl; and R₁₀ is —CONH₂, —CON(C₁-C₆ alkyl), —CON(C₁-C₆ alkyl)₂, —CONH—OH, —CONH—NH₂, —CO₂H, or —CO₂(C₁-C₆ alkyl).
 33. (canceled)
 34. A compound according to claim 33, wherein R₂₆ is —CH₂F, —CHF₂, or —CF₃.
 35. (canceled)
 36. A compound according to claim 32, wherein R₂₅ is hydrogen, halogen, C₁-C₆ alkyl, or C₁-C₆ haloalkyl. 37-40. (canceled)
 41. A compound according to claim 32, wherein R₂₅ is methyl, and R₂₆ is —CHF₂.
 42. A compound according to claim 32, wherein R₂₅ is hydrogen, and R₂₆ is —CHF₂. 43-48. (canceled)
 49. A compound according to claim 32, wherein R₁₀ is —CONH—OH, —CONH—NH₂, or —CO₂H.
 50. A compound according to claim 49, wherein R₁₀ is —CONH—OH.
 51. A compound according to claim 32, wherein R₃ is hydrogen.
 52. A compound according to claim 1, which is: 4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-2-oxopyrrolidin-3-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-2-oxopyrrolidin-3-yl)benzamide; 4-(3-(4-aminophenoxy)prop-1-ynyl)-N-(1-hydroxy-2-oxopyrrolidin-3-yl)benzamide; 4-(5-(dimethylamino)penta-1,3-diynyl)-N-(3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide; N-(3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-(phenylbuta-1,3-diynyl)benzamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide; 2-{4′-[(3″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide; 2-{4′-[(2″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide; 2-{4′-[[(2″-amino)pyridin-5″-yl]buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide; 2-{4′-[[(2″-amino)pyrimidin-5″-yl]buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide; 2-{4′-[(pyridin-3″-yl]buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-1,3-dihydroxybutanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-(1′H-imidazol-4′-yl)propanamide; tert-butyl 4-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-4-(hydroxycarbamoyl)butanoate; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxypropanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-methylbutanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxy-3-methylpentanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxyacetamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-phenylpropanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxy-4-methylpentanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N,3-dihydroxypropanamide; 2-({4′-(4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxy-4-(methylsulfanyl)butanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-(1′H-indol-3′-yl)propanamide; tert-butyl N-[5-({4-[4-(4-aminophenyl)buta-1,3-diyn-1-yl]phenyl}formamido)-5-(hydroxycarbamoyl)phentyl]carbamate; 1-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}carbonyl)-N-hydroxypyrrolidine-2-carboxamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3′-(4′-hydroxyphenyl)propanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-5′-carbamimidamido-N-hydroxypentanamide; 4-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-4-(hydroxycarbamoyl)butanoic acid; 3-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-3-(hydroxycarbamoyl)propane acid; 3-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxypropanamide; 6-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxyhexanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N,3′-dihydroxy-3′-methylbutanamide; 3-amino-2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1-yl]phenyl}formamido)-N-hydroxy-3-methylbutanamide; 2-({5-[4-(4-aminophenyl)buta-1,3-diyn-1-yl]pyridin-2-yl}formamido)-N,3-dihydroxybutanamide; 2-({4′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]benzene}sulfonamido)-N,3-dihydroxybutanamide; 3-amino-2-{6′-[4′-(4′-aminophenyl)buta-1′,3′-diyn-1′-yl]-1′H-indol-3′-yl}-N-hydroxybutanamide; 2-({4′-[4′-(3′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3-(1′H-imidazol-4′-yl)propanamide; 2-({4′-[4′-(2′-aminophenyl)buta-1′,3′-diyn-1′-yl]phenyl}formamido)-N-hydroxy-3′-(1′H-imidazol-4′-yl)propanamid; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-acetamidophenyl)buta-1,3-diynyl)benzamide; 3-amino-4,4-difluoro-3-methyl-2-(4-((4-(morpholinomethyl)phenyl)buta-1,3-diynyl)benzamido)butanoic acid; 3-amino-4,4-difluoro-2-(4-((4-(hydroxymethyl)phenyl)buta-1,3-diynyl)benzamido)-3-methylbutanoic acid; N-(1-(hydroxyamino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl)-4-(phenylethynyl)benzamide; N-(1-(hydroxyamino)-3-(naphthalene-2-sulfonamido)-1-oxopropan-2-yl)-4-(phenylethynyl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydrazinyl-3-hydroxy-1-oxobutan-2-yl)benzamide; 2-(4-((4-aminophenyl)buta-1,3-diynyl)benzamido)-3-hydroxybutanoic acid; N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-4-((4-aminophenyl)buta-1,3-diynyl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-3-isopropyl-2-oxopyrrolidin-3-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-3-(hydroxyamino)-1-(4-hydroxyphenyl)-3-oxopropan-2-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-3-(hydroxyamino)-1-(4-hydroxyphenyl)-3-oxopropan-2-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(3-hydroxy-1-(hydroxyamino)-3-(4-hydroxyphenyl)-1-oxobutan-2-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(3-hydroxy-1-(hydroxyamino)-3-(4-hydroxyphenyl)-1-oxobutan-2-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(4,4,4-trifluoro-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-(3-(4-aminophenoxy)prop-1-ynyl)-N-(3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide; 4-(3-(4-aminophenoxy)prop-1-ynyl)-N-(1-hydroxy-2-oxopyrrolidin-3-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(4-fluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(3-hydroxy-1-(hydroxyamino)-3-(4-(hydroxymethyl)phenyl)-1-oxobutan-2-yl)benzamide; 4-(3-(4-aminophenyl)prop-2-ynyloxy)-N-(3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)benzamide; tert-butyl 4-((4-(1-hydroxy-2-oxoazetidin-3-ylcarbamoyl)phenyl)buta-1,3-diynyl)phenylcarbamate; N-(3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(2-aminophenyl)buta-1,3-diynyl)benzamide; 4-((2-aminophenyl)buta-1,3-diynyl)-N-(3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((2-aminophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(1-hydroxy-2-oxoazetidin-3-yl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(3-hydroxy-1-(hydroxyamino)-1-oxo-3-(1H-1,2,3-triazol-4-yl)butan-2-yl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-aminophenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminophenyl)buta-1,3-diynyl)benzamide; 4-((4-aminophenyl)buta-1,3-diynyl)-N-(4,4,4-trifluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-[(4′-hydroxymethyl)phen-1′-yl]-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-[(4′-aminomethyl)phen-1′-yl]-1,3-dihydroxybutanamide; 3-amino-2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-fluoromethyl-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]phenyl-4′-piperizine-4′-carboxamido}-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-[(2′-amino)imidazol-5′-yl]-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-(imidazol-5′-yl]-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-(triazol-5′-yl]-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-(triazol-1′-yl]-1,3-dihydroxybutanamide; 2-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-3-(3′-ammonium-triazol-1′-yl]-1,3-dihydroxybutanamide; 1-hydroxy-3-{N-[(4″-aminophenyl)buta-1′,3′-diynyl]benzyl}-2-pyrrolidone; 1-hydroxy-3-{4′-[(4″-aminophenyl)prop-2-ynyloxy]benzamido}-2-pyrrolidone; 1-hydroxy-3-{4′-[(4″-aminophenyl)buta-1′,3′-diynyl]benzamido}-2-lactam; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-fluorophenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-fluorophenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-fluorophenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-fluorophenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-fluorophenyl)buta-1,3-diynyl)benzamide; 4-((4-chlorophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-chlorophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-chlorophenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-chlorophenyl)buta-1,3-diynyl)benzamide; 4-((4-chlorophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(trifluoromethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(dimethylamino)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(3-methylureido)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-ureidophenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-ureidophenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-ureidophenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-ureidophenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-ureidophenyl)buta-1,3-diynyl)benzamide; 4-((4-acetamidophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-acetamidophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-acetamidophenyl)buta-1,3-diynyl)-N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-acetamidophenyl)buta-1,3-diynyl)benzamide; 4-((4-acetamidophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(methylsulfonamido)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(hydroxymethyl)phenyl)buta-1,3-diynyl)benzamide; 4-((4-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid; 4-((4-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid; 4-((4-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid; 4-((4-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid; 4-((4-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-ylcarbamoyl)phenyl)buta-1,3-diynyl)benzoic acid; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-formylphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-formylphenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-formylphenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-formylphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-formylphenyl)buta-1,3-diynyl)benzamide; 4-((4-carbamoylphenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-carbamoylphenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-carbamoylphenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-carbamoylphenyl)buta-1,3-diynyl)benzamide; 4-((4-carbamoylphenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; 4-((4-(aminomethyl)phenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-(aminomethyl)phenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(aminomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(aminomethyl)phenyl)buta-1,3-diynyl)benzamide; 4-((4-(aminomethyl)phenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; 4-((4-cyanophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-cyanophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-cyanophenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-cyanophenyl)buta-1,3-diynyl)benzamide; 4-((4-cyanophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-((dimethylamino)methyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-((dimethylamino)methyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-((dimethylamino)methyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-((dimethylamino)methyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-((dimethylamino)methyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(ureidomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(pyrrolidin-1-ylmethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(pyrrolidin-1-ylmethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(pyrrolidin-1-ylmethyl)phenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(pyrrolidin-1-ylmethyl)phenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(pyrrolidin-1-ylmethyl)phenyl)buta-1,3-diynyl)benzamide; 4-((4-((1H-imidazol-1-yl)methyl)phenyl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-((1H-imidazol-1-yl)methyl)phenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-((1H-imidazol-1-yl)methyl)phenyl)buta-1,3-diynyl)-N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-((1H-imidazol-1-yl)methyl)phenyl)buta-1,3-diynyl)-N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((4-((1H-imidazol-1-yl)methyl)phenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-2-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(thiophen-2-ylbuta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-2-ylbuta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-2-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(thiophen-2-ylbuta-1,3-diynyl)benzamide; 4-((5-aminothiophen-2-yl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((5-aminothiophen-2-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((5-aminothiophen-2-yl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((5-aminothiophen-2-yl)buta-1,3-diynyl)benzamide; 4-((5-aminothiophen-2-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-imidazol-4-yl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-imidazol-4-yl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-imidazol-4-yl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1 H-imidazol-4-yl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((1-methyl-1H-imidazol-4-yl)buta-1,3-diynyl)benzamide; 4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; 4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((1H-imidazol-4-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; 4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; 4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((1H-1,2,3-triazol-4-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; 4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; 4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((2H-tetrazol-5-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((1-methyl-1 H-pyrazol-4-yl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((1-methyl-1H-pyrazol-4-yl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(isoxazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(oxazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(isothiazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(thiazol-5-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(thiophen-3-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-(furan-3-ylbuta-1,3-diynyl)benzamide; 4-((2-aminothiazol-5-yl)buta-1,3-diynyl)-N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)benzamide; 4-((2-aminothiazol-5-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminothiazol-5-yl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminothiazol-5-yl)buta-1,3-diynyl)benzamide; 4-((2-aminothiazol-5-yl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; 4-((2-aminophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminophenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-aminophenyl)buta-1,3-diynyl)benzamide; 4-((2-aminophenyl)buta-1,3-diynyl)-N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((2-hydroxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((2-methoxyphenyl)buta-1,3-diynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methoxy-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide; N-(3-amino-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide; N-(3-acetamido-4,4-difluoro-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide; N-(4,4-difluoro-1-(hydroxyamino)-3-methyl-3-(3-methylureido)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide; or a pharmaceutically acceptable salt thereof.
 53. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, solvent, adjuvant or diluent.
 54. A method of treating Gram-negative bacterial infections, the method comprising administering to a subject in need of such treatment an effective amount of one or more compounds according to claim
 1. 55-58. (canceled) 